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1. INTRODUCTION 
Particle design techniques are widely used to modify the physico-chemical and 
biopharmaceutical properties of active pharmaceutical ingredients (APIs) (Maghsoodi et al., 
2008). Particle engineering techniques that control the crystal size distribution and morphology 
and make use of different additives can offer improvements as concerns the solubility, rate of 
dissolution and permeability of poorly water-soluble drugs and can open up new, alternative 
administration routes (Pomázi et al., 2011, Ghosh et al., 2012, Maggi et al., 2013). 
The various size reduction techniques include bottom-up approaches, where micro- or 
nanoparticles are built up from dissolved drug molecules, and top-down methods, where the 
raw material is subsequently broken down by using milling methods until micro- or nanosized 
particles are produced (Ambrus et al., 2009). Milling belongs among the disintegration 
procedures. Dry and wet milling can be distinguished. Microparticles may be produced by dry 
or wet milling, with or without the use of excipients. For the preparation of nanoparticles (in 
either dry or wet milling), the usage of additives is required, because the processes are 
controlled by surface forces and, if the particles are not stabilized, they may coagulate because 
of the high particle mobility (Paltonen and Hirvonen, 2010). For wet milling, additives are 
essential, independently of the preparation of micro- or nanoparticles. Through wet milling, the 
preparation of pre-dispersions is possible, while intermediate solid-state products (powders) 
can be prepared by means of drying, and the development of liquid or semi-solid formulations 
(sprays and gels) is feasible directly from pre-dispersions. 
Intranasal administration is a possible route for the delivery of drugs to reach the 
systemic circulation (Prommer and Thompson, 2011). It offers certain advantages, including 
rapid absorption, avoidance of the hepatic first-pass metabolism and gastrointestinal side-
effects, and painless application, with sterility not a requirement (Meng et al., 2014). In the case 
of intranasally administered formulations containing a suspended drug, particle size (PS) 
distribution (PSD) is a determining factor. In order to achieve a systemic effect, intranasal 
compounds can be mixed with different additives so as to ensure a longer residence time, better 
mucoadhesion (Horvát et al., 2009) and increased permeability (Chunga et al., 2010). 
Pharmaceutical formulations delivered intranasally may be liquid (spray) (Baumann et al., 
2012), gel (Osth et al., 2002) or powder forms. 
It is a major challenge in pharmaceutical technology to find organic solvent-free, cost-
effective, time-saving PS reduction techniques which are suitable for preparation of the 
products (pre-dispersions) of the same quality, built into the process of production of 
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pharmaceutical formulations. This thesis reports the development of two wet milling techniques 
with the aim of decreasing the PSs of poorly water-soluble drugs to the micro or nano range (in 
the presence of polymer as aggregation inhibitor). 
 
2. THEORETICAL BACKGROUND 
2.1. Milling techniques 
Milling is a technique commonly applied to produce micro- or nanosized drug crystals in order 
to increase the dissolution rate and absorption, and hence the bioavailability of poorly-soluble 
materials. According to the Noyes–Whitney equation, reduction of the PSs of drug crystals 
increases the specific surface area (SSA), which can improve the rate of dissolution of a drug 
(Noyes and Whitney, 1897). There are many different types of milling techniques; dry and wet 
milling can be distinguished. 
 
2.1.1. Dry milling 
Dry milling is carried out at low moisture contents of the drug. A number of dry milling 
possibilities are known; the survey of these in Table 1 is non-exhaustive. Techniques for dry 
milling are usually used for micronization (Boudriche et al., 2014). In this case, the Rittinger 
theory describes the PS reduction produced relative to the energy (E) input of milling: the new 
surface area generated is directly proportional to the E required for the PS reduction. As the 
surface area of a quantity of particles of uniform diameter x is proportional to 1/x, the E required 
for PS reduction is therefore also proportional: 
E1-2= CVR 


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
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where E1-2 is the specific energy, and CVR is a constant characteristic of the material 
(Temmerman et al., 2013). In general, additives are not required for micronization (Liu et al., 
2014). Nanonization can be achieved on the use of an additive and a long milling time, but in 
this case changes may occur in the physico-chemical structure of the drug. The dry milling 
process has both advantages and disadvantages (Table 2). 
 
 
 
 
Table 1 Dry milling techniques (Sushant and Archana, 2013) 
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Milling techniques Milling device PS (µm) 
Cutting machine Cutter mill 100-80 000 
Milling based on compression Roller mill 50-10 000 
Ball milling Planetary ball mill 1-2 000 
 
Table 2 Advantages and disadvantages of dry milling (Manfredini & Schianchi, web reference 1) 
Advantages Disadvantages 
Total recovery of production wastes Dust production 
Minor consumption of water Adhesion 
Practical to run and service Electrostatic charge 
Elimination of the additional costs needed for the 
appropriate management of slurries 
 
Stability of the API  
 
Ball milling 
Ball milling is usually used for the dry micronization of drugs, in order to enhance their 
rates of dissolution. Apart from its comminution function, ball milling also serves as an 
intensive mixing technique capable of producing co-ground drug–excipient mixtures (Loh et 
al., 2015). Furthermore, the preparation of nanosized particles is also possible through ball 
milling. Our research group has reported results on dry nanonization through the application of 
a planetary ball mill in the presence of additives with a long milling time (2 h). The presence 
of additives and the increase of their amount reduced the collision energy required for the 
nanonization of meloxicam (MEL) (Table 3) (Kürti et al., 2011, Kürti et al., 2013). 
 
Table 3 Milling energetic map of the experiments performed 
Cumulative collision energy transferred (kJ/g) in the cases of different MEL to additive ratios 
Rotation speed (rpm) Collision frequency (1/s) No additive 1:0.5 1:1 1:2 
200 240 8.56   5.71   4.28   2.85 
300 360 28.89 19.27 14.45   9.63 
400 480 68.50 45.67 34.25 22.83 
 
The ball mill consists of a chamber filled with balls constructed from ceramic, agate, 
silicon nitride, zirconia (ZrO2), etc. The drug to be milled is put into the chamber, which is 
made to rotate, vibrate or perform planetary motion. The movements of the chamber result in 
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the balls cascading or moving in a pattern, colliding with each other and with the inner walls of 
the chamber. The reduction in PS of the drug particles results from the impact they receive from 
the balls and attractive forces arising from the movement of the balls relative to each other. The 
quantities of the balls and drugs to be milled are the determining factor as concerns the 
effectiveness of the milling. The total volume of the chamber is usually one-third filled by balls 
and one-third by drug materials (Figure 1). In the case of a rotating chamber, rotation is usually 
carried out at 55-75% of the critical speed at which the balls adhere to the walls of the milling 
chamber as a result of the centrifugal force. The critical speed may be estimated via the 
following equation: 
critical speed = 42.3/√D (King, web reference 2) 
where D is the diameter of the milling chamber (Juhnke et al., 2012). 
 
 
Figure 1 Schematic view of the ball mill (W. Cao, web reference 3) 
 
2.1.2. Wet milling 
In many cases, wet milling is required to reach the expected PS of a drug. In the wet milling 
procedure, a sufficiently concentrated dispersion of drug particles in an aqueous or non-aqueous 
liquid medium is treated. Some wet milling opportunities are presented in Table 4. Wet milling 
is applicable for micronization (Pomázi et al., 2013), but is usually used for nanonization (Hou 
et al., 2007, Bujňáková et al., 2015). For wet milling, the usage of additives is required to 
prevent the aggregation of the milled drug particles and to inhibit particle growth (ripening) 
during milling/storage (Niwa et al., 2011). Drug suspensions produced by wet milling can be 
transferred into the related drug products, such as capsules, granules, tablets, injectables, sprays 
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and gels (Wang et al., 2013, Junyaprasert and Morakul, 2015). Table 5 lists some advantages 
and disadvantages of wet milling (Swarbrick, 2013). Certain scaling-up techniques are detailed 
below. 
 
Table 4 Wet milling techniques (Fan et al., 2009, Pomázi et al., 2013, Swarbrick, 2013, Pawar et al., 
2014) 
Milling techniques Milling device PS (µm) 
”Rotor/stator” 
  milling 
Colloid mill 
Toothed high-shear inline mixers 
Cone mill 
1-50 
Milling based on cavitation High-pressure homogeniztaion 1-20 
Pearl milling Pearl mill 0.02-200 
 
Table 5 Advantages and disadvantages of wet milling 
Advantages Disadvantages 
Increased mill capacity Increased wear of the grinding medium 
Lower energy consumption Drying stage after milling 
Closed system (without dust production) Hazards of corrosion 
Easier handling of materials Extra water needs 
Intermediate product Stability of API 
 
Acoustic cavitation 
During the sonication process, the ultrasound waves that form in the liquid media result in 
alternating high-pressure and low-pressure cycles, with rates depending on the frequency. In 
the low-pressure cycle, the high-intensity ultrasound waves evolve small gas- or vapour-filled 
bubbles (cavities) in the liquid. When the bubbles reach a volume at which they can no longer 
absorb energy, they collapse violently during a high-pressure cycle. This phenomenon is called 
ultrasonic cavitation (Figure 2). It has been proven that, when ultrasound technology is applied 
in the frequency range 20–100 kHz, the implosion of vacuum bubbles can induce a PS reduction 
(Suslick, 1998). The use of ultrasound is a common technique to promote chemical reactions 
(Patil et al., 2013). As regards pharmaceutics, power ultrasound can be applied for 
emulsification and to investigate the sedimentation of emulsions and suspensions (Benes et al., 
1998, Behrend and Schubert, 2000). Supercritical, solvent diffusion (Hatkar and Gogate, 2012) 
and melt emulsification are well-known bottom-up methods in the field of sonocrystallization 
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for solving problems of drug solubility (Ambrus et al., 2012). The application of ultrasound can 
readily be scaled up; as an example, sonification is successfully applied at an industrial level 
for the preparation of metal nanoparticles (Li et al., 2013). The disintegration of drug particles 
(top-down approach) has not been widely investigated so far with the aim of improving the 
properties of drugs, and acoustic cavitation is therefore a new possibility for controlling the 
crystal size distribution and morphology of drugs, primarily with the intent of PS reduction 
(Patil and Pandit, 2007, Raman and Abbas, 2008). It has the ability to erode and break down 
particles and to increase the SSA of crystals (Sandilya and Kannan, 2010). 
 
 
Figure 2 Schematic illustration of acoustic cavitation (Electrowave Ultrasonics Corporation, web 
reference 4) 
 
Ultrasonic liquid processing is influenced by a number of parameters (amplitude, pressure, 
temperature and concentrations of compounds). The effect of the process may be determined 
as a function of the E per processed volume (Vp): 
effect = f (E/Vp) 
where E is the product of the power output (P) and the exposure time (t): 
E [Ws] = P [W] * t [s] 
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Additionally, the value of P per surface area of the sonotrode of an ultrasonic unit depends on 
the parameters as described by Hielscher (web reference 5). There are two sonication routes for 
wet grinding to achieve a PS reduction: the static method, which means that a sample at rest is 
sonicated, and the dynamic method, which allows continuous circulation of the sample by 
means of a pump during the sonication. These two methods are appropriate for the PS reduction 
of materials with different physico-chemical properties (Bartos et al., 2014). The production of 
intermediates (as pre-dispersions) and powder products (after drying) is carried out by applying 
a short-term ultrasound E input. 
 
Media milling 
Wet stirred media milling has proven to be a robust process for the production of nanoparticle 
suspensions of poorly water-soluble drugs (Afolabi et al., 2014). In this method the 
nanosuspensions are produced through the use of high-shear media mills or pearl mills (Figure 
3). Media mills consist of a milling chamber, a milling shaft and a recirculation chamber. Media 
milling is a continuous process wherein the drug suspension is pumped through the milling 
chamber to effect PS reduction of the suspended material. The milling chamber is charged with 
the milling media, dispersant medium, drug and stabilizer, and the milling media or pearls are 
then rotated at a very high shear rate. The milling medium consists of glass, zirconium oxide or 
highly cross-linked polystyrene resin (Patravale et al., 2004). The physical characteristics of the 
resulting nanocrystals depend on the number of milling pearls, the amounts of drug and 
stabilizer, and the milling time, speed and temperature (Chen et al., 2011). 
 
 
Figure 3 Schematic representation of the pearl milling process (Loh et al., 2015) 
2.1.3. Combination milling techniques 
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To overcome the limitations of the conventional PS reduction technologies for poorly-soluble 
drugs, new combinational methods have been developed for the production of ultrafine 
suspensions. Combinative technologies are a relatively new approach to improve the 
effectiveness of PS reduction and to reduce the process times. In general, they can be described 
as a combination of a bottom-up process (the building-up of particles) (Blagden et al., 2007, 
Bund and Pandit, 2007, Bakar et al., 2009) followed by a top-down technology (disintegration) 
(Salazar et al., 2012, Möschwitzer, 2013, Vivek et al., 2014). This method involves two steps 
of PS reduction. There is also a possibility for the combination of dry and wet milling in one 
step, but literature data relating to the application of this combined method are lacking. Retsch 
GmbH has made a recommendation for the combination of planetary ball milling, as dry 
milling, and pearl milling, as wet milling (Retsch®, web reference 6). 
 
2.2. The role of additives in wet milling 
In dry nanonization, and wet micronization and nanonization, the application of additives is 
required in order to retain the individuality of the particles. Micro- and nanoparticles with high 
SSA and high free E are controlled by surface forces and, if the particles are not stabilized, they 
may coagulate because of the high particle mobility (Friedrich et al., 2006). Stabilizers are 
added to compensate the extra free E of the newly created surfaces, thereby preventing the 
aggregation of milled drug particles and inhibiting particle growth (ripening) during 
milling/storage (Bilgili and Afolabi, 2012). The degree of compensation required is related to 
the interactions between the drugs and stabilizers. For effective stabilization and a reasonable 
processing time, strong and fairly fast adsorption is necessary, with full coverage and slow 
desorption. If the amount of the stabilizer is too low, particles tend to aggregate, while 
concentrations that are too high promote Ostwald ripening (Peltonen and Hirvonen, 2010). 
The choice of stabilizer is specific for each drug candidate and each formulation 
procedure. Polymers and surfactants are commonly used as stabilizers to impart physical 
stability to the suspensions produced by the wet milling of poorly water-soluble drugs, which 
singly or in combination help to minimize the agglomeration of suspended particles via 
electrostatic and steric mechanisms. In these processes, aqueous suspensions containing drug 
particles and dissolved stabilizers (polymer and/or surfactant) are treated. Different additives 
are used to stabilize these particles: poly(vinylpyrrolidone) (PVP), PoloxamerR (Poloxamer 188 
= poly(ethylene)–poly(propylene glycol), polysorbate (Tween 80R = poly(oxyethylenesorbitan 
monooleate)), SolutolR (Solutol HS 15 = poly(ethylene glycol 15-hydroxystearate)), PVA 
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(poly(vinyl alcohol)), etc. (Paltonen and Hirvonen, 2010). Some of them are listed in Table 6. 
The application of additives allows the preparation of stable pre-dispersions with optimum drug 
PS, which can be used for the development of further pharmaceutical formulations. 
 
Table 6 Stabilizers (Friedrich et al., 2006, Ghosh et al., 2011) 
Name Feature 
PVP K-25 protective layer-forming polymer 
Poloxamer 188 non-ionic surfactant 
Tween 80 emulsifier and solubilizer 
Solutol HS 15 non-ionic solubilizer 
PVA protective layer-forming polymer 
 
2.3. Formulation of nasal dosage forms 
Intranasal administration is a potential way to deliver drugs into the systemic circulation as an 
alternative route for some therapeutic agents (Fortuna et al., 2014). The development of nasal 
formulations has opened up new areas of indication and many delivery problems can be solved. 
The main reasons for this are the high permeability, wide absorption area, and porous and thin 
endothelial basement membrane of the nasal epithelium. Pharmaceutical formulations delivered 
intranasally may be powder (Kaye et al., 2009), gel (Osth et al., 2002) or liquid (drops and 
sprays) (Baumann et al., 2012) forms. The advantages of a nasal spray include the ease of use 
for the patients and the possibility of self-administration without the assistance of a physician 
(Marttin et al., 2000). In the case of spray formulations, drugs in dissolved form can achieve 
the fastest therapeutic effect, and they have to be in dissolved form for the absorption of drugs 
(dissolution of drug on the mucosa in the case of suspensions) (Sosnik et al., 2014). However, 
low aqueous solubility is a common characteristic in current biopharmaceutics, and over 40% 
of new chemical entities exhibit poor solubility (Beig et al., 2012). Difficulties are therefore 
liable to occur in the event of the preparation of drug solution-containing formulations. This 
problem may be solved through the preparation of a pre-dispersion of a poorly-soluble drug 
with a suitable technique so as to reach the optimum PS for high bioavailability and, following 
this, the development of a liquid formulation. 
For the preparation of intranasal formulations in order to achieve a systemic effect, 
intranasal compounds can be mixed with different additives in order to ensure the pH 
(compliance with the nasal cavity), viscosity (Furubayashi et al., 2007), a longer residence time, 
better mucoadhesion (Horvát et al., 2009), increased permeability (Chunga et al., 2010), and in 
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some cases controlled release of a drug. Because of the rapid mucociliary clearance in the nasal 
cavity, viscous, mucoadhesive formulations are needed in order to prolong the contact time 
with the nasal mucosa, thereby enhancing the delivery of the drugs (Hasçiçek et al., 2003). 
Different agents are used to increase the viscosity (cellulose derivates) and the mucoadhesive 
strength (carbomers, chitosans, lectins, thiomers, alginate poly(ethylene glycol acrylate) or 
Poloxamer) in the intranasal formulation (Pathak, 2011, Anand et al., 2012). One of the most 
important biocompatible, mucoadhesive agents is sodium hyaluronate (HA). This natural 
anionic polysaccharide has excellent mucoadhesive capacity (Liao et al., 2005), high 
biocompatibility and low immunogenicity (Ding et al., 2012). Besides its mucoadhesive 
properties, it may enhance the absorption of drugs and proteins via the mucosal tissues (Lim et 
al., 2000). To ensure controlled drug delivery, responsive polymers (α-cyclodextrins, acrylic 
acid, hydroxyethyl acrylate, PVP, and PVA) may be used, which regulate the release of drugs 
(Bajpai et al., 2008). 
The solubility, the rate of dissolution and the permeability of drugs are of great importance 
(Zelkó and Süvegh, 2005), and reduction of the PS to the micro or nano range is therefore the 
strategy of first choice with the aim of increasing the bioavailability of poorly-soluble drugs 
(Sinha et al., 2013, Anarjan et al., 2015). Nanoparticles are controlled by surface forces and, if 
the particles are not stabilized, they may coagulate because of the high particle mobility. 
Different additives are used to stabilize these particles: polysorbate, hydroxypropyl 
methylcellulose, Poloxamer, PVP, etc. (Paltonen and Hirvonen, 2010). PVA is frequently used 
as a stabilizer, coating the particles and promoting their separation from each other. 
 
 
 
 
 
 
 
3. AIMS 
The aim of my research work was to investigate new possibilities in the field of wet milling 
techniques through study of the PS reduction effect. Via the preparation of pre-dispersions, 
different organic solvent-free wet milling techniques were compared (sonication and combined 
wet milling) and the process parameters affecting the PS and their influence on the physico-
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chemical and biopharmaceutical properties of drugs were determined. Poorly water-soluble, 
crystalline, non-steroidal anti-inflammatory model drugs (NSAIDs) (MEL and ibuprofen-IBU) 
were chosen for PS reduction investigations. Intranasal formulations as sprays containing 
suspended drugs were developed from selected drug pre-dispersions and investigated. 
 
The main steps in the experiments were as follows: 
i. The use of acoustic cavitation, an organic solvent-free, static wet milling 
technique, as a new approach for PS reduction (preliminary studies with IBU 
and MEL). 
ii. Comparisons of the PS reduction effects of static and dynamic sonication as 
process intensification through use of a factorial design (MEL). 
iii. Application of a combination of planetary ball and pearl milling for the 
production of pre-dispersions of micronized and nanonized MEL. 
iv. The development and investigation of intranasal formulations directly from the 
pre-dispersions containing micro- or nanonized MEL. 
v. Creation of a proposal for the production of an innovative intranasal dosage form 
for pain management through controlled drug delivery. 
 
4. MATERIALS AND METHODS 
4.1. Materials 
MEL was obtained from EGIS Ltd. (Budapest, Hungary), and IBU from Aldrich Chemie 
(Deisenhofen, Germany) (Table 7). 
The milling additives: PVP K-25 was purchased from ISP Customer Service GmBH (Köln, 
Germany), Poloxamer and Solutol from BASF (Ludwigshafen, Germany) and Tween from 
Hungaropharma (Budapest, Hungary). PVA 4-98 (Mw ~ 27,000) and HA (Mw = 1,400 kDa) 
were gifts from Gedeon Richter Plc. (Budapest, Hungary) (Table 8). Mucin (porcine gastric 
mucin type II) was from Sigma Aldrich (Sigma Aldrich Co. LLC, St. Louis MO, US). 
Table 7 Properties of the active agents 
 Meloxicam (MEL) Ibuprofen (IBU) 
Chemical 
structure 
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Chemical name 
4-hydroxy-2-methyl-N-(5-methyl-
2-thiazolyl)-2H-1,2-benzothiazine-
3-carboxamide-1,1-dioxide 
2-(4-(2-
methylpropyl)phenyl)propanoic acid 
Physical 
properties 
a yellow powder 
poor solubility in water 
a white crystalline powder 
poor solubility in water 
Applications 
a NSAID, a selective COX-2 
inhibitor 
a NSAID, a non-selective inhibitor of 
COX 
 
Table 8 Milling additives and the mucoadhesive agent 
 Chemical structure Synonyms Physical 
properties 
PVP 
 
Povidone 
Kollidon 
white-to-yellow-
white powder 
soluble in water and 
polar solvents 
amorphous 
hygroscopic 
Poloxamer 
 
Lutrol 
Pluronic 
white or almost 
white, waxy 
powder, microbeads 
or flakes 
very soluble in 
water and in alcohol 
Tween 
 
Polysorbate viscouse yellow 
liquid 
soluble in water, 
ethanol, methanol, 
ethyl acetate 
Solutol 
 
Kolliphor 
Macrogol(15)-
hydroxystearate 
Yellowish white 
paste  
soluble in water, 
ethanol and 2-
propanol 
PVA 
 
Mowiol a white powder 
soluble in water, 
slightly soluble in 
ethanol 
semi-crystalline 
HA 
 
 white powder 
soulble in water, in 
alcohol-water 
mixture 
 
4.2. Methods 
4.2.1. Preparation of formulations 
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4.2.1.1. Preliminary experiments of static sonication for PS reduction of IBU and MEL 
A high-power ultrasound device (Hielscher UP 200 S Ultrasonic processor, Germany) 
operating at 200 W was applied as the E input in the sample preparation. The samples were 
sonicated at room temperature without cooling or by using an ice bath with a standardized 
temperature at around 18 °C. A range of ultrasonic amplitudes were tested in order to determine 
the optimum amplitude for 10, 20 or 30 min during the procedures (Table 9) (Figure 4). During 
the content optimization, different additives were applied. The effects of the concentrations of 
IBU and MEL on the PS decrease were also studied (Table 10) (Bartos et al., 2014). 
 
Table 9 Parameters applied during the sonication of IBU and MEL 
Temperature (°C) room temperature, ice cooling 
Amplitude (%) 30, 50, 70 
Time (min) 10, 20, 30 
 
Table 10 Applied additives; concentrations of IBU and MEL and their additives 
Additives PVP, Poloxamer, Tween, Solutol 
Concentration (m/v (%)*) 1, 0.25 (IBU and MEL) 
0.5, 0.25 (additive) 
*m/v (%): mass/volume percentage concentration 
 
 
Figure 4 Scheme of PS reduction by static sonication (A) and double-walled flow cell for 
dynamic sonication (B) 
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4.2.1.2. Preparation of sonicated formulations for the comparison of static and dynamic 
sonication for reduction of the PS of MEL 
MEL was chosen as a model drug for the comparison of static and dynamic sonication. In each 
sample, 0.5% of PVP was dissolved in an appropriate volume of water (Table 11). A high-
power ultrasound device (200 W) was applied in the sample preparation. In the case of static 
sonication, samples at rest were treated. In the case of dynamic sonication, the samples were 
circulated continuously with a peristaltic pump (Heidolph PD 5006 Pump drive) in a double-
walled flow cell (Flow Cell GD14 K) during the sonication (Figure 4). The temperature was set 
with a thermostat in both cases (Julabo, Germany). Through the use of different sonotrode 
positions, the immersed surface area of the ultrasonic horn could be changed (Bartos et al., 
2015A). 
 
Design of experiments for comparative studies of static and dynamic sonications 
Six parameters were screened in the static sonication experiments, using a two-level fractional 
factorial design of resolution III. Here, the main effects are not confounded with each other, 
whereas they are confounded with two-factor interactions. This design is typically used for the 
rapid identification of the main effects governing the behavior of a multi-parameter system. 
High and low values for each parameter were set on the basis of our prior experience with 
similar tasks (reported in Table 11). Dynamic sonication experiments were run by screening 
five parameters, using the same experimental design type. High and low parameter values for 
the dynamic sonication experiments are presented in Table 11. All the experiments were run as 
triplicates. 
Table 11 The applied sonication parameters 
 Static sonication Dynamic sonication 
Volume (ml) 25; 100 100 
Position* 0.25; 0.75 0.25 
Pump speed (rpm) - 50; 100 
Concentration of 
MEL (mg/ml) 
2; 18 2; 18 
Temperature (ºC) 0; 36 0; 36 
Amplitude (%) 30; 70 30; 70 
Time (min) 10; 30 10; 30 
*Position 0.25: the sonotrode was immersed to 25% of the total depth of the liquid 
  Position 0.75: the sonotrode was immersed to 75% of the total depth of the liquid 
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Adiabatic experiments were carried out to reveal the transmission efficiency of ultrasound E in 
the liquid (Figure 5). An appropriate volume of MEL-free 0.5 w/v (%) (weight/volume 
percentage concentration) PVP solution was used. Temperature was measured every 5 min up 
to 30 min during the sonication processing. The highest temperature rise (90 ºC) was observed 
in the small sample volume (25 ml) within 5 min. The dynamic and static methods were 
compared by using the following fixed parameters: 100 ml sample volume and 0.25 sonotrode 
position. In the case of static sonication, because of the higher E input, the temperature increase 
was higher after 10 min. When the dynamic method was used, the temperature increase was 
lower, due to the circulation in the vessel. 
 
 
Figure 5 Results of the adiabatic investigations for an appropriate volume of MEL-free 
0.5 w/v (%) PVP solution 
 
4.2.1.3. Preparation of pre-dispersions with a combination of planetary ball and pearl milling 
for PS reduction 
A wet milling technique (a combination of planetary ball and pearl milling) was employed. 
0.5 g of PVA was dissolved in 17.5 ml of water, and the resulting solution was used as a 
dispersant medium in which 2.0 g of MEL was suspended. The resulting suspensions (10% 
drug content, 2.5% additive content) were wet-milled at 400 rpm in the milling chamber (50 ml) 
of a planetary ball mill (Retsch PM 100 MA, Retsch GmbH, Germany). The milling balls were 
0.3 mm ZrO2 beads. The effects of different pearl weights on the PS reduction were 
investigated. 10, 20, 50 and 150 g of beads were applied and milling was carried out without 
pearls as a benchmark. The milled suspensions were separated with a sieve with 150 µm mesh 
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size. Suspension sampling was carried out at milling times of 10, 20, 30, 40, 50, 60, 70, 80 and 
90 (end of milling) min to perform the PS analysis (PSA). 
 
4.2.1.4. Preparation of pre-dispersions for the development of an intranasal formulation 
On the basis of preliminary experiments, a modified wet milling technique was employed to 
prepare the pre-dispersions. 0.5 g of PVA was dissolved in 17.5 ml of phosphate buffer solution 
(PBS) (pH 5.6, the pH of the nasal mucosa) and the resulting solution was used as a dispersant 
medium in which 2.0 g of MEL was suspended. The suspension was wet-milled in the planetary 
mill at 400 rpm for 10 or 50 min, using ZrO2 beads (Table 12). The milled suspensions were 
separated from the beads by sieving. 
 
Table 12 Pre-dispersions of MEL suspended in a dispersant medium containing PVA and PBS 
Abbreviation in the text Rotation speed 
(rpm) 
Milling chamber volume 
(ml) 
Milling time 
(min) 
raw MEL pre-dispersion - - 0 
micro MEL pre-
dispersion* 
400 50 10 
nano MEL pre-
dispersion** 
400 50 50 
*micro MEL: micronized MEL, prepared by a combined technique 
**nano MEL: nanonized MEL, prepared by a combined technique 
 
4.2.1.5. Preparation of intranasal formulations 
The intranasal formulations were prepared directly from the pre-dispersions. 3.0 ml of each pre-
dispersion was diluted with PBS (pH 5.6) in order to reach a concentration of 1 mg/ml MEL, 
and 0.15 g of HA was added; the final formulation therefore contained 5 mg/ml HA. The 
formulations were stored at 8 ºC in a refrigerator for 24 h. The intranasal viscous liquid 
formulations containing suspended MEL (referred to below as nasal sprays) were prepared and 
characterized according to an investigational protocol (Figure 6). 
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Figure 6 Protocol of the development and characterization of nasal sprays containing MEL 
 
4.2.2. Physical-chemical investigations of solid-state products 
Pre-dispersions prepared with different wet milling techniques were dried in order to obtain 
solid products for physical-chemical investigations. 
 
4.2.2.1. Particle size analysis (PSA)  
The volume-based PSD of drug in the samples was measured by laser diffraction (Mastersizer 
2000) (Malvern Instruments Ltd, Worcestershire, UK) A dynamic laser light scattering method 
was used. Distilled water was applied as dispersant and the obscuration was in the range of 11-
16 % for all measurements. In all cases, the volume-weighted PSD values as D10, D50 and D90 
were evaluated (n = 3). The specific surface area (SSA) was derived from the PSD data. The 
assumption was made that all the particles measured were spherical. 
 
4.2.2.2. Scanning electron microscopy (SEM) 
After drying of the samples, the shape and surface characteristics of the samples were visualized 
by using SEM (Hitachi S4700, Hitachi Scientific Ltd., Tokyo, Japan). The samples were 
sputter-coated with gold–palladium under an argon atmosphere, using a gold sputter module in 
a high-vacuum evaporator, and the samples were examined at 15 kV and 10 μA. The air 
pressure was 1.3-13 MPa. 
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4.2.2.3. X-ray powder diffraction analysis (XRPD) 
The physical state of drugs in the samples was evaluated by XRPD. The patterns were produced 
with an X-ray Diffractometer Miniflex II (Rigaku Co. Tokyo, Japan), where the tube anode was 
Cu with Ka = 1.5405 Å. The pattern was collected with a tube voltage of 30 kV and a tube 
current of 15 mA in step scan mode (4º / min). The instrument was calibrated by using Si. The 
investigated 2θ data were as follows: 13.22, 15.06, 26.46 and 26.67. 
In case of combined milling, the crystallinity of the MEL in dried pre-dispersions was 
determined semi-kvantitatively via the mean of the decrease of the total area beneath the curve 
of 2 characteristic peaks (at 5.99 and 18.25 2θ) compared to the MEL-PVA physical mixture 
(MEL-PVA PM). 
 
4.2.2.4. Differential scanning calorimetry (DSC) 
DSC measurements were carried out with a Mettler Toledo DSC 821e thermal analysis system 
with the STARe thermal analysis program V9.0 (Mettler Inc. Schwerzenbach, Switzerland). 
Approx. 2-5 mg of pure API or product was examined in the temperature range of 25-300 ºC. 
The heating rate was 5 ºC/min. Argon was used as carrier gas at a flow rate of 10 L/h. 
 
4.2.2.5 Fourier transform infrared spectroscopy (FT-IR) 
FT-IR spectra were recorded with a Bio-Rad Digilab Division FTS-65A / 896 FT-IR 
spectrometer (Bio-Rad Digilab Division FTS-65A/869, Philadelphia, USA) between 4000-
400 1/cm, at the optical resolution of 4 1/cm (operating conditions: Harrick’s Meridian SplitPea 
single reflection, diamond, ATR accessory). Thermo Scientific GRAMS/AI Suite software 
(Thermo Fisher Sciencific Inc. Waltham, USA) was used for the spectral analysis. 
 
4.2.3. Investigation of pre-dispersions for nasal formulations 
4.2.3.1. Solubility testing of MEL in the pre-dispersions 
The MEL solubility in different pre-dispersions was determined. The pre-dispersions were 
stirred with a magnetic stirrer at 25 °C for 24 h and then filtered (0.1 μm, FilterBio PES Syringe 
Filter) (Labex Ltd., Budapest, Hungary), and the dissolved drug content was analysed 
spectrophotometrically (Unicam UV/VIS) (Thermo Fisher Scientific Inc., Waltham, MA, USA) 
(n = 3). The pH of each nasal spray was determined (Orion 3 star pH-meter), (Thermo Fisher 
Scientific Inc., Waltham, MA, USA). 
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4.2.3.2. Holding time determination of MEL in the pre-dispersions 
For intermediate products such as pre-dispersions, the holding time was determined using PSD. 
Pre-dispersions were stored in sealed glass bottles at room temperature (25 ± 1 ºC) for 3 days. 
The PSD of the MEL in the prepared samples were analysed on the production day (day 0) and 
after 1, 2 or 3 days storage. 
 
4.2.4. Investigations of nasal formulations 
4.2.4.1. Rheology and mucoadhesion of samples 
Rheological measurements were carried out at 37 °C with a Physica MCR101 Rheometer 
(Anton Paar GmbH, Graz, Austria). A concentric cylindrical measuring device with a diameter 
of 10.835 mm was used. Frequency sweep curves were plotted to determine the viscoelastic 
character of the samples. Storage modulus (G’) and loss modulus (G”) measurements were 
made over the frequency range from 0.01 to 100 Hz. The flow curves of the samples were also 
determined. The shear rate was increased from 0.1 to 100 1/s in controlled rate mode. The 
shearing time was 150 s. 
In order to clarify the role of MEL PS in mucoadhesion, samples with and without mucin were 
also prepared (Table 13). The mucoadhesivity was determined on the basis of rheological 
synergism between the polymer and the mucin. The synergism parameter (bioadhesive 
viscosity component, ηb) was calculated (Bartos et al., 2015B). 
 
Table 13 Samples for mucoadhesive measurements 
Sample name HA (mg/ml) PVA (mg/ml) MEL 
(mg/ml) 
PSA, D50 (µm) 
HA solution 5 - - - 
PVA solution - 0.225 - - 
blank 5 0.225 - - 
raw MEL spray* 5 0.225 1 34.26 
micro MEL spray** 5 0.225 1     1.887 
nano MEL spray*** 5 0.225 1    0.135 
       *raw MEL spray: nasal spray containing raw MEL 
**micro MEL spray: nasal spray containing micronized MEL 
***nano MEL spray: nasal spray containing nanonized MEL 
D50: particle diameter below which 50% of the sample volume exists 
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4.2.4.2. In vitro permeability of MEL 
In vitro permeability studies were performed on a vertical Franz diffusion cell system (Hanson 
Microette Topical and Transdermal Diffusion Cell and Autosampling System) (Hanson 
Research, Chatsworth CA, USA) (n = 5). The donor phase containing 300 mg of nasal 
formulation was placed on the polyvinylidene fluoride synthetic membrane (Durapore® 
Membrane Filter) (EMD Millipore, Billerica, MA, USA) impregnated with isopropyl myristate. 
The effective diffusion surface was 1.33 cm2. PBS (pH 7.4, 37 ºC) was used as an acceptor 
phase (7 ml). The rotation speed of stir-bar was set to 450 rpm. Sampling was carried out at 5, 
10, 15, 30 and 60 min diffusion time. 0.8 ml samples were taken from the acceptor phase by 
autosampler and were replaced with fresh receiving medium. The amount of diffused MEL was 
determined spectrophotometrically (Unicam UV/VIS). The API flux (J) was calculated from 
the quantity of MEL, which permeated through the membrane, divided by the insert membrane 
surface and the time duration [µg/cm2/h]. The permeability coefficient (Kp) was determined 
from J and the drug concentration in the donor phase (Cd [µg/cm
3]): 
Kp [cm/h] = J/Cd. 
 
For residual MEL content determination in the donor phase, the vertical Franz diffusion cell 
system was also used to mimic the nasal cavity. Therefore the membrane was impregnated with 
simulated nasal fluid (8.77 g NaCl, 2.98 g KCl and 0.59 g CaCl2, containing mucin, 1 %) (Jug 
and Bećirević-Laćan, 2007). The donor phase content was removed after 60 min diffusion time 
and the remaining MEL amount was determined with an Agilent 1260 RP-HLPC system (QP, 
DAD, ALS). 
 
4.2.4.3. In vivo study of MEL 
Intranasal administration and blood sample collection 
The intranasal formulations prepared directly from the pre-dispersions contained 1 mg/ml MEL 
and 5 mg/ml HA. A dose of 60 μg MEL per animal was administered into the right nostril of 
160-180 g male Sprague–Dawley rats (n = 5) via the pipette. Directly before the drug 
administration, the animals were narcotized with isoflurane. Blood samples were withdrawn 
from the tail vein before and at 5, 15, 30 and 60 min post-dosing. The experiments performed 
conformed to the European Communities “Council directive for the care and use of laboratory 
animals” and were approved by the Hungarian Ethical Committee for Animal Research 
(permission number: IV/198/2013). 
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Determination of MEL from the blood samples 
The MEL contents of blood samples were quantitated with an Agilent 1260 HLPC (high-
performance liquid chromatography) system. MEL and piroxicam as internal standard (IS) 
were separated on a 250 mm  4.6 mm column packed with 5 µm Kromasil C18, 100 Å 
(Phenomenex Inc., Torrance CA, USA). After the setting of the method (Bartos et al., 2015 B), 
the animal blood samples (200 µl) were diluted with 500 µl of extraction liquid and spiked with 
10 µl of the working IS solution at a final plasma concentration of 1.3 µg/ml. The solid-phase 
extraction (SPE) cartridges used (Strata-X-C 33 µm Polymeric Strong Cation tubes, 
Phenomenex Inc., Torrance CA, USA) were conditioned with 0.5 ml of methanol (MeOH), 
followed by 0.5 ml of extraction liquid. The prepared blood samples were allowed to run 
through the SPE cartridge at the flow rate of 1.0 ml/min. Cartridges were rinsed with 0.5 ml of 
extraction liquid and 0.5 ml MeOH and dried in vacuum for 5 min. The analytes were then 
eluted with 0.5 ml of 5:95 (v/v) ammonium hydroxide- MeOH elute. The eluent liquids were 
dried in a vacuum oven (Binder, Germany) at 20-30 mbar and 45 °C for 2-3 h. The dried residue 
was reconstituted in 300 µl of mobile phase and then vortexed (30 s), sonicated (2 min) and 
centrifuged at 12,000  g for 5 min. 20 µl of supernatant was injected onto the C18 column. 
 
Calculations of the area under the (time–concentration) curve (AUC) and statistical analysis 
Pharmacokinetic parameters were analysed by means of PK Solver 2.0 software (Zhang et al., 
2010) through non-compartmental analysis of plasma data using the extravascular input model. 
The AUC of the time (min)–concentration (µg/ml) curves of each animal were fitted with a 
linear trapezoidal method. The statistical analysis was performed with Prism 5.0 software 
(Graphpad Software Inc., La Jolla, CA, USA). All reported data are means ± SD. Student's 
unpaired t-test was used to determine statistical significance. Changes were considered 
statistically significant at p < 0.05. 
 
 
5. RESULTS 
5.1. Results of preliminary static sonication experiments 
5.1.1. Effects of process parameters on PSD 
During the procedure, the amplitude, temperature and sonication time were varied. At room 
temperature, in the case of IBU (D50 = 153.73 µm), the use of an amplitude of 30, 50 or 70% 
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resulted in a 50% decrease (approx. 85 µm) in the average PS. In the case of MEL 
(D50 = 85.39 µm), the application of an amplitude of 30% resulted in a 50% decrease 
(D50 = 41 µm) in the average PS, and higher amplitudes led to a 3-fold PS reduction 
(D50 ~ 26 µm). During the procedure, the temperature of the suspension increased from 25 °C 
to 77-85 °C. The utilization of continuous ice cooling (Tcooling water = 18 °C) resulted in a 
decrease of the temperature of the suspension to ~ 35 °C. In the case of IBU, sonication at an 
amplitude of 30% caused a further 50% decrease in the average PS (D50 = 39.44 µm). In the 
case of MEL, cooling did not cause a further PS reduction (D50 = 22-27 µm). The smallest 
particles were produced at an amplitude of 70% (the highest E input) with ice cooling. Although 
the sonication amplitude was increased (3070%), the ice cooling prevented the temperature 
of the suspensions from changing significantly. Increase of the sonication time (1020 min) 
had a stronger effect (a small IBU PS reduction and a considerable MEL PS reduction) than the 
combination of an increased amplitude and ice cooling. Further elevation of the sonication time 
(2030 min) did not result in changes in the PSs of IBU and MEL. A sonication time of 20 min 
was therefore considered to be optimum. 
 
5.1.2. Effects of stabilizers 
The choice of stabilizer depended on the drug candidate and on the formulation procedure. 
When the effects of different stabilizers were investigated, the suspensions were prepared with 
a fixed API concentration (300 mg/ml) and fixed parameters (70%, 18 ºC and 20 min). The 
stabilizer type has a pronounced effect on the PS and PSD. Four different stabilizers were tested 
in order to check the effect of the nature of the surfactant on the PSD of the drug. In the case of 
IBU, the smallest PS was achieved with Poloxamer: D50 ~ 11 μm. In the case of MEL, the most 
effective PS reduction was achieved with PVP (D50 = 4 μm). The low stabilizer concentration 
did not cause any significant variation in the PS. 
Static sonication can be applied to decrease the PS to the µm range and change the drug crystal 
habit. The reduction of the PS is more efficient in the presence of additives. Because of the 
small amount of sample, this method is recommended in pre-clinical studies. 
5.2. Comparison of static and dynamic sonication methods 
Following the preliminary experiments, MEL was used as API to compare static and dynamic 
sonication by means of a factorial design. As a result of its high melting point, MEL does not 
melt during sonication. Besides the other parameters, the sonication amplitude, temperature and 
time were examined to compare the sonication methods. 
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5.2.1. Static sonication 
Laser diffractometry revealed considerable decreases (25-70%) in the PS of MEL in response 
to static sonication at the various process parameters. The D10, D50 and D90 values are 
reported in Table 14. 
 
Table 14 Results of static sonication (pre-dispersion) of MEL 
Volum
e 
(ml) 
Sonotrod
e position 
Concentratio
n 
(mg/ml) 
Temperatur
e 
(ºC) 
Amplitud
e 
(%) 
time 
(min
) 
D10 
(µm) 
D50 
(µm) 
D90 
(µm) 
- - - - - - 
10.8
2 
34.0
3 
75.8
1 
25 0.75 2 36 70 30 1.51 
10.1
6 
19.5
3 
100 0.75 2 0 30 30 4.81 
23.0
7 
46.8
8 
25 0.25 2 0 70 10 2.75 
18.4
5 
42.8
7 
100 0.25 2 36 30 10 5.92 
26.5
2 
53.3
9 
25 0.75 18 36 30 10 3.95 
19.6
2 
41.5
1 
100 0.75 18 0 70 10 5.19 
24.1
6 
46.9
8 
25 0.25 18 0 30 30 3.53 
17.1
2 
29.2
2 
100 0.25 18 36 70 30 7.19 
20.8
3 
36.6
2 
D10: particle diameter below which 10% of the sample volume exists 
D90: particle diameter below which 90% of the sample volume exists 
 
The relationship with the sonication variables was analysed quantitatively on the basis of the 
D50 data in the main effects plots (Figure 7) and interaction plots (Figure 8). The D10 and D90 
data furnished similar results. The main effect plot for a given parameter was obtained by 
averaging the results of each run, where this parameter was set to low or high, and connecting 
these averages with a line. If the studied parameters are independent, the plot will give a clear 
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indication of the system response to the selected variable. The main effects plots for the MEL 
PSD indicated that a small sample volume, a high amplitude and a long sonication time were 
preferred for efficient PS reduction, whereas the PS was less influenced by the sonotrode 
position, the solution concentration and temperature (Figure 7). It can be seen that a small 
sample volume, high ultrasound amplitude and a long sonication time were preferred for 
efficient PS reduction. 
 
 
Figure 7 The main effect plots of the static sonication of MEL 
 
Interaction plots show the effects between variables, which are not necessarily independent, by 
demonstrating the means of the responses, pairwise for all factors, for each level of the first and 
second factors involved in the study. The D50 interaction plots (Figure 8) can be used to detect 
complex interactions between the sonication parameters. A longer sonication time resulted in a 
PS reduction, independently of the other process parameters. The connection between the 
physical parameters of sonication (amplitude, position and volume) was unequivocal. The high 
amplitude resulted in a PS decrease, independently of the sonotrode position and sample 
volume. The connection between concentration, temperature and amplitude demonstrated that 
the PS reduction effect of the increased amplitude occurred at low concentration and high 
temperature. The temperature–concentration and temperature–volume relationships were 
unidirectional, in contrast with the temperature–position relationship: increase of temperature 
was useful in the lower position. The upper or lower sonotrode position resulted in smaller 
particles at high or low MEL concentration, respectively. 
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Figure 8 Interaction plots of main effects and PS for the static sonication of MEL 
 
To summarize the results, the appropriate parameters for static sonication were a long 
sonication time (30 min), high amplitude (70%), a small sample volume (25 ml), high 
temperature (36 ºC), a lower sonotrode position (0.75) and low MEL concentration (2 mg/ml). 
As concerns static sonication, the ultrasound distribution was not homogeneous; the vibration 
was most effective surrounding the sonotrode (small volume). Because of the large energy input 
and long sonication time, increased amplitude was required to achieve small particles. The large 
energy input resulted in increased cavitation activities. When the temperature was raised, the 
kinetic energy of the particles increased, which affected the cohesive forces adversely. When 
low MEL concentration was used, the amount of energy per particle was greater. 
 
5.2.2. Dynamic sonication 
Analysis of the product MEL measured by laser diffraction revealed that dynamic sonication at 
the various sonication parameters resulted in a 15–60% decrease in average PS. The PSD 
function is reported in Table 15. 
 
 
 
 
 
  
 
26 
Table 15 Results of dynamic sonication (pre-dispersion) of MEL 
Pump 
speed 
(rpm) 
Concentration 
(mg/ml) 
Temperature 
(ºC) 
Amplitude 
(%) 
Time 
(min) 
D10(µm) D50(µm) D90(µm) 
- - - - - 10.82 34.03 75.81 
50 2 36 70 30 2.20 14.60 35.02 
50 2 0 30 30 4.56 24.22 47.05 
100 2 0 70 10 5.70 26.90 51.92 
100 2 36 30 10 5.90 26.15 52.20 
50 18 36 30 10 4.40 22.69 53.54 
50 18 0 70 10 6.27 23.54 46.77 
100 18 0 30 30 9.06 29.31 45.58 
100 18 36 70 30 2.87 16.73 38.03 
 
The relationships between the sonication variables were analysed quantitatively on the basis of 
the D50 data in the main effects plots (Figure 9) and interaction plots (Figure 10). The D10 and 
D90 data furnished similar results. The main effects plots for the MEL PSD indicated that the 
circulation of the sample at low rpm, high amplitude and long sonication time resulted in the 
most significant PS reduction, whereas the concentration of the suspension influenced the PS 
to a lesser extent. High temperature had a more significant effect on the PS under dynamic 
sonication than under static sonication. 
 
 
Figure 9 The main effect plots for the dynamic sonication of MEL 
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The interaction plots presented for D50 in Figure 10 can be used to gain an insight into the 
complex interactions between the sonication parameters. The increased amplitude and the 
higher temperature resulted in a significant PS reduction. A longer sonication time did not have 
an appreciable effect in the case of low temperature and low amplitude. Increase of the 
concentration had an adverse effect on the PS at a low circulation rate. 
 
 
Figure 10 Interaction plots for the dynamic sonication of MEL 
 
It was concluded that the most effective process parameters for dynamic sonication were a long 
sonication time (30 min), high amplitude (70%) and temperature (36 ºC), a slow rotation speed 
(50 rpm) and a low sample concentration (2 mg/ml). As a result of the continuous circulation 
of the samples, the distribution of the sonication effect was homogeneous. The PS was 
efficiently reduced at a low circulation rate by cavitation, because the particles were situated 
around the sonotrode for a longer period during one sonication cycle. The explanation of the 
effects of the other parameters is the same as for the static method. 
 
5.2.3. PSA 
The PSD of MEL (Figure 11) was determined in the suspensions after sonication. The raw MEL 
displayed a broad size distribution. The sonication methods resulted in decreased PSs. The SSA 
of the MEL increased as a consequence of acoustic cavitation in both sonication methods and 
for both suspensions relative to the raw MEL. Sonication of MEL by static process (MEL Stat.) 
led to smaller PSs compared with MEL, sonicated by dynamic process (MEL Dyn.) (Table 16). 
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Figure 11 PSDs of raw MEL and sonicated MEL from pre-dispersions 
 
Table 16 The SSA and PSD data on raw MEL and the sonicated pre-dispersions 
 SSA 
(m²/g) 
D10 
(µm) 
D50 
(µm) 
D90 
(µm) 
raw MEL 0.340 10.82 34.03 75.81 
Static sonicated sample 
(pre-dispersion) 
2.040 1.51 10.16 19.53 
Dynamic sonicated sample (pre-dispersion) 1.140 2.20 14.60 35.02 
 
5.2.4. SEM  
The SEM images (Figure 12) provided an indication of the morphology (shape and size) of the 
modified particles. The crystal habit of the pure MEL was changed significantly after the 
procedure. The raw MEL consisted mainly of angular, prismatic crystals with a broad PSD. The 
crystal lattice presumably demonstrated defects and cracks, along which the crystals 
disintegrated due to the energy input of acoustic cavitation. This factor is probably responsible 
for the presence of the broken pieces found on the surface of the larger particles. The drying of 
the samples could also cause cracks and broaden the PSD. The endurance during the treatment 
accounts for the roundness and smooth surfaces of the crystals. The yields of the samples by 
both methods were 95% at 0 ºC and 90% at 36 ºC. The average PS of the dried product was ~ 
10 µm in the case of static and 15 µm in the case of dynamic sonication. Due to the high SSA 
of the dried product and since PVP is washed out, agglomeration might occur. Furthermore, 
aging or washing might also change the crystal size and shape. 
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Figure 12 SEM pictures of raw MEL (A) and the dried products after static (B) and dynamic 
(C) sonication 
 
5.2.5. XRPD 
The XRPD pattern of pure MEL demonstrated the crystalline structure, as expected. The 
characteristic 2θ data were as follows: 13.22, 15.06, 26.46 and 26.67. The raw MEL and the 
sonicated dried MEL composite in both cases displayed the same XRPD patterns (Figure 13). 
This means that the crystalline form of the micronized MEL was not changed by the sonication 
and drying procedures. The intensities of the characteristic peaks were decreased in the case of 
the sonicated products, due to the reduced PS. 
 
 
Figure 13 XRPD examination of raw MEL and dried sonicated products 
 
5.2.6. DSC 
DSC was employed to investigate the crystallinity and the melting of MEL in the pure form and in the 
sonicated dried products. The DSC curve (Figure 14) of the raw MEL revealed a sharp endothermic 
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peak at 259.11 ºC, reflecting its melting point and confirming its crystalline structure. After drying, the 
DSC curves exhibited the sharp endothermic peak of the MEL at 258.62 ºC in the static case, and at 
259.81 ºC in the dynamic case, indicating that the crystallinity of the drug was retained. The value of 
the enthalpy and the onset–endset interval were not changed significantly for the sonicated products as 
compared with the values for raw MEL, and it can therefore be concluded that the degree of crystallinity 
was not decreased by the treatment. 
 
 
Figure 14 DSC curves of raw MEL and the dried sonicated products 
 
5.2.7. Chemical stability (FT-IR) 
To determine whether any decomposition occurred during the sonication process, FT-IR 
spectroscopy was carried out. This proved that no disintegration took place in the samples 
(Figure 15). Further, contamination of the solution with titanium particles resulting from 
cavitational erosion could not be detected. The E applied did not cause chemical changes in the 
MEL in aqueous medium during sonication (30 min) at 36 ºC. The characteristic bands of MEL 
were seen in all of the curves of the raw MEL and sonicated products, at 3289.76, 1550.04, 
1530.36, 1346.73, 1265.88 and 1184.90 1/cm, denoting the stretching vibration of -NH, the 
thiazole ring (together with that at 1184.90 1/cm), the amide II band of –CO– NH–C, the 
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asymmetric stretching vibration of the sulfone and the amide III band of –CO–NH–C, 
respectively. 
 
 
Figure 15 FT-IR curves of raw MEL and dried sonicated products 
 
Comparative experiments revealed that dynamic sonication is also applicable for micronization. 
Moreover, in the case of dynamic sonication, use of a larger volume of sample is possible, as 
are standardization and scaling-up, which is important for industry. 
Although the FT-IR investigations indicated that the process did not cause chemical 
degradation, metal contamination via degradation of the sonotrode could be expected. This 
problem should be investigated further through HPLC-MS analyses. 
 
5.3. Results of a preliminary study of combined wet milling technique 
5.3.1. Effects of milling parameters on PSD 
In the course of the investigations discussed above, it could be concluded that acoustic 
cavitation is feasible for micronization. Our aim was to find a possibility for the production of 
pre-dispersed micro- and nanosized particles applicable for the development of a nasal 
formulation. As a novel opportunity, a combined wet milling technique (planetary ball mill and 
pearls, as milling media) was analysed. During the milling without pearls, the drug crystals 
were fractured through collision with the drug itself and also from the impact of the drug 
crystals with the milling chamber, which resulted in a PS reduction of 20 µm. With the progress 
of the milling time, aggregation of the particles could be observed. The application of 10 g of 
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pearls resulted in a pronounced PS reduction: D50 values of ~ 3 µm after 10 min, and 0.150 µm 
after 30 min of milling, but aggregation occurred; the D90 value was high. The most effective 
milling was observed when 20 g of pearls was applied. After 10 min micronized, and after 
50 min nanonized particles were noted, with monodisperse PSD. Increase of the weight of 
pearls did not result in further PS reduction (Tables 17 and 18). 
 
With the chosen pearl weight, the milling was performed at a lower concentration of PVA 
(0.5%). The use of a lower concentration of PVA led to the extensive aggregation of the MEL 
particles because it was less effective in overcoming the cohesive forces. After milling for 
10 min, micronization could be attained, but with the advance of the milling time, the PS 
(primarily the D90 value) increased (Table 19). 
 
Table 17 MEL PSD in pre-dispersions milled with different weights of pearls (0, 10 or 20 g) 
containing 2.5% PVA solution as dispersant 
Milling time 
(min) 
Without pearls 10 g of pearls 20 g of pearls 
 D10 
(µm) 
D50 
(µm) 
D90 
(µm) 
D10 
(µm) 
D50 
(µm) 
D90 
(µm) 
D10 
(µm) 
D50 
(µm) 
D90 
(µm) 
0 11.40 34.26 73.59 11.40 34.26 73.59 11.40 34.26 73.59 
10 10.199 26.616 52.668 0.255 2.934 10.940 0.115 1.625 5.669 
20 9.239 25.285 55.202 0.108 1.254 4.775 0.070 0.151 1.951 
30 11.207 28.768 54.147 0.080 0.151 2.156 0.068 0.140 1.223 
40 8.585 23.848 45.489 0.069 0.146 1.667 0.070 0.135 0.729 
50 7.871 24.025 50.346 0.068 0.143 1.280 0.072 0.126 0.271 
60 5.203 14.269 27.548 0.068 0.141 1.082 0.069 0.129 0.295 
70 5.161 15.047 29.542 0.067 0.135 0.618 0.070 0.131 0.292 
80 8.966 25.478 47.930 0.067 0.135 0.538 0.068 0.127 0.288 
90 5.805 17.627 34.196 0.069 0.132 0.317 0.068 0.126 0.277 
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Table 18 MEL PSD in pre-dispersions milled with different weights of pearls (20, 50 or 150 g) 
containing 2.5% PVA solution as dispersant 
Milling time 
(min) 
20 g of pearls 50 g of pearls 150 g of pearls 
 D10 
(µm) 
D50 
(µm) 
D90 
(µm) 
D10 
(µm) 
D50 
(µm) 
D90 
(µm) 
D10 
(µm) 
D50 
(µm) 
D90 
(µm) 
0 11.40 34.26 73.59 11.40 34.26 73.59 11.40 34.26 73.59 
10 0.115 1.625 5.669 0.116 1.676 7.529 0.24 2.96 29.40 
20 0.070 0.151 1.951 0.082 0.137 1.841 0.084 0.169 2.863 
30 0.068 0.140 1.223 0.076 0.132 1.124 0.090 0.337 4.180 
40 0.070 0.135 0.729 0.082 0.139 0.606 0.074 0.134 1.358 
50 0.072 0.126 0.271 0.080 0.137 0.283 0.074 0.126 0.253 
60 0.069 0.129 0.295 0.074 0.136 0.360 0.072 0.122 0.219 
70 0.070 0.131 0.292 0.076 0.133 0.256 0.070 0.121 0.225 
80 0.068 0.127 0.288 0.077 0.134 0.246 0.072 0.119 0.209 
90 0.068 0.126 0.277 0.081 0.176 552.071 0.064 0.116 0.219 
 
Table 19 PSD of MEL on milling with 20 g of pearls and different PVA contents 
Milling time (min) 0.5% PVA 2.5% PVA 
 D10 
(µm) 
D50 
(µm) 
D90 
(µm) 
D10 
(µm) 
D50 
(µm) 
D90 
(µm) 
0 11.40 34.26 73.59 11.40 34.26 73.59 
10 0.096 1.373 4.515 0.115 1.625 5.669 
20 0.179 2.907 364.936 0.070 0.151 1.951 
30 0.156 2.996 405.118 0.068 0.140 1.223 
40 0.114 2.390 160.385 0.070 0.135 0.729 
50 1.156 3.109 251.947 0.072 0.126 0.271 
60 1.388 2.380 4.262 0.069 0.129 0.295 
70 0.731 3.198 369.449 0.070 0.131 0.292 
80 0.145 3.116 1472.283 0.068 0.127 0.288 
90 1.795 135.325 336.672 0.068 0.126 0.277 
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5.3.2. SEM 
Pre-dispersions containing micro- and nanosized MEL particles, prepared with chosen 
parameters (20 g of pearls, 10 or 50 min milling time and 2.5% PVA content), were dried and 
characterized. The SEM images (Figure 16) provided an indication of the morphology of the 
modified particles. The raw MEL consisted mainly of angular, prismatic crystals with a broad 
PSD. The micronized MEL particles (D50-1.625 µm) consisted of aggregations of nanosized 
particles. The nanonized MEL crystals (D50-126 nm) exhibited a regular shape and a smooth 
surface. The treatment accounted for the smooth surfaces of the particles. 
 
 
Figure 16 SEM images of raw MEL (A), and of MEL from microsized (B) and nanosized (C) 
particles containing dried pre-dispersions after milling in PVA–water solution as a dispersant 
medium 
 
5.3.3. XRPD 
After samples had been taken after 10 (micro MEL) and 50 (nano MEL) min of milling, the 
pre-dispersions in PVA–water solution as dispersant were dried and characterized. The XRPD 
pattern of the raw MEL demonstrated its crystalline structure, as expected. In the case of MEL-
PVA PM, the intensities of the characteristic peaks were decreased due to the PVA. In the 
course of the milling, a decrease in crystallinity was perceptible, which was determined semi-
kvantitatively via the mean of the decrease of the total area beneath the curve of 2 characteristic 
peaks (at 5.99 and 18.25 2θ) compared to the MEL-PVA physical mixture (MEL-PVA PM). 
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After milling for 10 min, ~ 33% of the drug remained crystalline, and this did not change 
subsequently (Figure 17). 
 
 
Figure 17 XRPD patterns of raw MEL, MEL-PVA PM, and of MEL from dried, microsized 
and nanosized particles containing pre-dispersions after milling in PVA–water solution as a 
dispersant medium 
 
5.3.4. DSC 
DSC was employed to investigate the crystallinity and the melting of MEL in the raw form, in 
the physical mixture and in the milled dried products. The DSC curves (Figure 18) of the raw 
MEL and of MEL in the MEL-PVA PM revealed a sharp endothermic peak at 259.11 and 
256.57 ºC, reflecting the melting point of MEL and confirming its crystalline structure. After 
milling and drying, the DSC curves in both cases exhibited the broad endothermic peak of MEL 
at 239.81 ºC (10 min), and at 240.08 ºC (50 min), indicating that the crystallinity of the drug 
was decreased. The residual MEL crystals in the products melted at a lower temperature than 
the crystals of raw MEL. This process was promoted by PVA, which was softened at 85 °C as 
glass transition temperature (Tg) value. 
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Figure 18 DSC curves of raw MEL, MEL-PVA PM, and of MEL from dried, microsized and 
nanosized particles containing pre-dispersions after milling in PVA–water solution as a 
dispersant medium 
 
It can be concluded that a combination of planetary ball and pearl milling can be applied as a 
wet milling procedure to decrease the PS of MEL. Depending on the milling time, micro- and 
nanosized particles can be produced. In the presence of an appropriate amount of pearls and 
PVA as additive, this wet milling technology was suitable for the preparation of pre-dispersions 
which was applicable for further usage. 
 
5.4. Characterization of the intranasal viscous liquid formulations prepared via the 
combined wet milling technique 
For the development of intranasal formulations, micro- and nanosized MEL-containing pre-
dispersions were prepared with determined parameters in PVA-PBS in order to ensure the pH, 
in accordance with the nasal conditions. 
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5.4.1. Characterization of the pre-dispersions 
5.4.1.1. PSD 
The MEL PS measured by laser diffraction decreased from ~ 35 µm to 1.887 µm during the 
10 min (D10 = 0.120; D90 = 6.429) and to 0.135 µm during the 50 min milling time 
(D10 = 0.077; D90 = 0.253) (Table 20). The SSA of MEL increased 46-fold and 135-fold as a 
result of the micronization and the nanonization, respectively, relative to the raw MEL in the 
pre-dispersion. The coating effect of PVA prevented aggregation, and the stability of the system 
was therefore improved. 
 
5.4.1.2. Solubility of MEL in the pre-dispersions 
In order to check on the effects of PS reduction on the solubility of MEL in the pre-dispersions, 
solubility tests were performed at 25 ºC and pH 5.6 (Table 20). Micronization did not result in 
a change in the solubility of MEL. Following nanonization, a slight increase in solubility was 
observed, but the difference did not attain an order of magnitude. 
 
Table 20 Solubility of MEL in the pre-dispersions 
 c (µg/ml) 
raw MEL pre-dispersion 6.4 ± 0.2 
micro MEL pre-dispersion 6.6 ± 0.3 
nano MEL pre-dispersion 9.3 ± 0.5 
 
5.4.1.3. Holding time determination 
Aggregation did not occur in the pre-dispersions during the first 24 h of storage (micro MEL 
pre-dispersion: D90 = 6.462 µm; nano MEL pre-dispersion: D90 = 0.270 µm). On the second 
day, however, aggregates were formed in both cases (micro MEL pre-dispersion: 
D90 = 1035.340 µm; nano MEL pre-dispersion: D90 = 695.767 µm), and the number and size 
of the aggregates increased still further during the third day. To avoid aggregation, the pre-
dispersions should be utilized to prepare the formulations within 24 h. 
 
5.4.2. Characterization of the nasal sprays 
Nasal sprays (raw MEL, micro MEL and nano MEL sprays) were prepared directly from the 
pre-dispersions with MEL of different PS, using HA as a mucoadhesive polymer. The pH of 
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the formulations did not change significantly after the addition of HA to the systems (pH 5.5) 
relative to the pH of the pre-dispersions (pH 5.6). 
The solubility of MEL in the nasal sprays was investigated in the freshly prepared formulations 
after stirring for 24 h. The solubility of the drug in the sprays was increased ~ 3-5-fold (raw 
MEL spray: 13.9 µg/ml; micro MEL spray: 32.1 µg/ml; nano MEL spray: 42.8 µg/ml). This 
can be explained by the interaction between the HA and MEL, which resulted in formation of 
a complex between the carboxylic groups in HA and the protonable groups in MEL (Battistini 
et al., 2013). 
 
5.4.2.1. Rheology and mucoadhesion 
The viscoelastic characters of the sprays were determined by frequency sweep measurements 
in the range from 0.01 Hz to 100 Hz. G’ corresponds to the elastic (storage) and G” to the 
viscous (loss) modulus. Figure 19 presents frequency sweep curves of samples with different 
PSs (blank = MEL-free spray, raw MEL spray, micro MEL spray and nano MEL spray). The 
cross-over points of these curves, which are typical for gel-containing hyaluronans, could not 
be seen (Berkó et al., 2013). The ratio of G’ and G” indicates the sol state of the samples. The 
findings can be explained by the pH of the formulations (pH = 5.6) and the low concentration 
of HA. 
 
 
Figure 19 Frequency sweep curves of the sprays with different MEL PSs 
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The intranasal formulations containing MEL displayed shear-thinning behaviour, i.e. the shear 
viscosity depended on the degree of the shear load and the flow curve displayed a decreasing 
slope, which is typical for polymer solutions. The different formulations did not indicate 
changes in the flow characters (Figure 20). The presence of MEL and variation of its PS did not 
affect the viscosity of the samples, and this HA-containing drug carrier system is therefore 
suitable for the formulation of drugs with different PS without alteration of the flow behaviour. 
 
 
Figure 20 Flow curves of sprays with different MEL PSs 
 
For the rheological determination of mucoadhesivity, the samples were mixed with mucin (final 
mucin concentration 5%) and the synergism parameter (ηb) was calculated. The mucoadhesivity 
values of the HA solution in PBS (pH 5.6) without PVA, of the PVA solution without HA, of 
the blank and of the three sprays with different MEL PSs were investigated. 
The synergism parameter indicated the mucoadhesivity of the samples, with interaction 
between the HA and the mucin (Figure 21). PVA did not reveal mucoadhesive features, and it 
even broke down the mucin–HA interactions, and accordingly the mucoadhesivity of the blank 
was lower than that of the HA solution without PVA. Addition of MEL to the blank increased 
the mucoadhesivity of the formulation relative to the HA solution without PVA. This can be 
explained by the interactions between the mucin and the dispersed particles, and significant 
differences were observed between the calculated synergism data for the raw, micro and nano 
MEL samples (p < 0.05). The highest synergism was observed between the nasal spray 
containing nanonized MEL and mucin; the mucoadhesivity increased 2-fold as compared with 
that of the MEL-free blank, and hence the longest residence time could be attained. This could 
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be explained by the PS of the MEL: the nanosized particles possess an increased adhesiveness 
to surfaces (Müller et al., 2011). On the other hand, nano MEL has a PS similar to those of 
polymeric molecules such as HA, PVA and mucin chains, which can result in a well-structured 
complex, and better interactions among the components and it therefore displays more 
pronounced mucoadhesivity. 
 
 
Figure 21 Calculated synergism parameters at a shear rate of 100 1/s of samples 
 
5.4.2.2. In vitro permeability of MEL 
The cumulative amount of MEL that diffused through a synthetic membrane from a nasal spray 
was measured against time with a Franz diffusion cell system. The diffusion from the 
formulation containing MEL nanoparticles was quickest, due to the rapid dissolution of the 
drug. The diffusion from the nanonized MEL-containing spray started in the first 5 min (Figure 
22). As concerns the fastest diffusion, the question arose as to whether it was influenced by the 
PS or some other factor. It should be excluded that the nanosized MEL particles 
(D50 = 0.135 µm) passed through the membrane without dissolving (they dissolved in the 
acceptor phase). Since the PS was larger than the membrane pore size (100 nm) and the 
membrane was impregnated with isopropyl myristate, this phenomenon was not observed. In 
this case, therefore, the PS and the resulting surface area had significant effects on the rate of 
passive diffusion. 
The flux, which shows the amount of MEL that permeates through 1 cm2 of the membrane 
within 1 h, was significantly higher in the case of the nasal formulation which contained 
nanoparticles as compared with the sprays containing micronized or raw MEL. The 
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permeability coefficient calculated from the flux data for the nanonized MEL was also 
significantly higher than in the other two cases (Table 21). 
The PS was a determining factor as regards the amount of diffused MEL. In the spray containing 
nanonized MEL, the faster dissolution of the particles resulted in higher permeability. 
 
 
Figure 22 In vitro permeability of MEL-containing sprays with different PSs through a 
synthetic membrane 
 
Table 21 Flux and permeability coefficient values of nasal sprays containing MEL with different PS 
 J (µg/cm2/h) Kp (cm/h) 
raw MEL spray 3.41 0.00341 
micro MEL spray 4.25 0.00425 
nano MEL spray 9.43 0.00943 
 
It emerged that the nasal mucosa retained the MEL and its PS did not influence the permeability. 
Figure 23 demonstrates significant differences between the MEL contents remaining in the 
donor phase: 71.38 ± 6.33% (raw MEL spray), 19.52 ± 4.18% (micro MEL spray) and 
8.85 ± 0.94% (nano MEL spray). The residual MEL content in the donor phase correlated with 
the decreasing MEL PS of the spray samples. 
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Figure 23 Residual MEL content in the donor phase 
 
5.4.2.3. In vivo study of MEL 
The drug concentrations in the blood plasma as a function of time after nasal administration of 
the sprays are shown in Figure 24. In the case of the spray containing MEL nanoparticles, a 
3 times higher plasma level of MEL was observed after 5 min as compared with the 
formulations containing raw or micronized MEL. This result is in accordance with the reduction 
of the PS of MEL, and especially with the faster dissolution of nanonized MEL as compared 
with that of the microsized agent. The plasma concentrations tended to increase slowly during 
the initial ~ 30 min, but the 3-fold difference between the sprays containing nanonized or 
micronized MEL remained during 60 min after treatment. The controlled release of MEL in the 
case of the nano MEL spray could be explained in terms of the better adhesion and distribution 
of the nanoparticles and the formation of a well-structured system. This controlled release was 
enhanced by the HA–PVA system (Battistini et al., 2013). The PVA-coated particles played a 
role in the release of the drug, because the synthetic polymers reduced the rate of degradation 
of the natural polymers and prevented their rapid dissolution in the biological fluids (Ding et 
al., 2012). 
The AUC is proportional to the amount of drug absorbed during the investigated time 
interval. The calculated AUC values gradually increased with decreasing PS (the highest AUC 
was observed for the nano MEL spray; Figure 25). The occurrence of micronization did not 
significantly increase the AUC as compared with the raw MEL (AUCraw MEL spray: 
13.97 ± 3.223 min µg/ml, AUCmicro MEL spray: 21.95 ± 5.527 min µg/ml, p = 0.1552), whereas 
nanonization led to a significant increase in the amount of MEL absorbed (AUCnano MEL spray: 
49.86 ± 5.632 min µg/ml; nano MEL spray vs raw MEL spray: p = 0.0021; nano vs micro MEL 
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spray: p = 0.0061). Our results demonstrated a strict correlation between the AUC and the MEL 
PS (R2 = 0.9848) (Figure 26). 
 
 
Figure 24 Plasma drug concentration vs. time profiles in rats after intranasal administration of 
sprays containing MEL with different PSs 
 
 
Figure 25 AUC values of the MEL-containing sprays with different PSs 
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Figure 26 Correlation between the AUC values and different MEL SSAs 
 
It can be concluded that the reduction of the PS of MEL into the nano range resulted in special 
features of nanocrystals (Müller et al, 2011) such as increased saturation and dissolution 
velocities, and increased adhesiveness to surfaces relative to micro-sized MEL particles. In the 
case of nano MEL spray, the high SSA and the increased saturation solubility resulted in rapid 
dissolution and better diffusion of the drug and a high AUC value. The linear correlation 
between the SSA of MEL and the AUC values (R2 = 0.9848) confirmed that the dissolution of 
particles with different sizes is the key factor determining the amount of absorbed drug. 
Different mucoadhesivities were measured for the nanonized MEL–HA–mucin system and in 
case of the micro-sized MEL-containing sprays. The in vivo studies revealed that the prolonged 
residence time and the uniform distribution of the nano MEL spray throughout the nasal mucosa 
resulted in higher AUC values. 
 
6. CONCLUSIONS 
In this work, effects of different wet milling techniques in reducing the PS were investigated. 
The results showed that these techniques are suitable for PS reduction and for the preparation 
of pre-dispersions as intermediates that which are directly applicable for the development of 
innovative liquid pharmaceutical formulations. The applicability of nanosuspensions in nasal 
formulations is a new approach in pharmaceutical technology. Drug delivery to the systemic 
circulation via the nose is considered to be a promising route. 
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i. The effect of acoustic cavitation in reducing the PS, based on the collapse of the bubbles 
created by ultrasound waves, was investigated. During the preliminary study, static sonication 
was investigated in the cases of IBU and MEL, and the optimum process parameters 
(temperature, amplitude, sonication period and stabilizers) were determined. The PSDs of these 
drugs were measured after sonication and compared with those of the raw drugs (IBU: 
D50 = 153 μm and MEL: D50 = 85 μm), as the response factor after sonication. Due to acoustic 
cavitation, the PS decreased (IBU: D50 = 25 μm and MEL: D50 = 14 μm), but the use of a 
stabilizer was needed for a further decrease (IBU–Poloxamer: D50 = 11 μm; MEL–PVP: 
D50 = 4 μm). It was established that static sonication can be applied to decrease the PS to the 
micrometre range in the presence of additives. 
 
ii. After the investigation of static sonication, the effects of static and dynamic sonication 
on PS reduction were compared. In dynamic sonication, the samples were circulated 
continuously during the sonication. The most effective process parameters were determined by 
a factorial design plan for the PSD of MEL. A long sonication (30 min), high amplitude (70%), 
a high temperature (36 ºC) and a low concentration of MEL (2 mg/ml) proved to play important 
roles in the sonication procedures. Samples sonicated with appropriate parameters were dried 
and investigated. The SEM images showed that the sonication resulted in rounded, micro-sized 
particles. XRPD and DSC examinations revealed the crystalline structure of the MEL produced 
by both sonication methods. FT-IR demonstrated that no chemical degradation occurred. 
These two methods are also appropriate for reduction of the PSs of materials, with application 
of a short-term E input. Static sonication is not suitable for scaling-up; this method is 
recommended primarily for PS reduction in preclinical samples, where the amount of the drug 
candidate is very small, while dynamic sonication may be suitable for the wet milling of 
different active substances to prepare pre-dispersions because larger volumes of sample can be 
used in this method. Scaling-up and standardization are possible, which is important for 
industry. 
 
iii. A combination of planetary ball and pearl milling was investigated in the case of MEL. 
In the presence of a stabilizer, at constant rotation rate, the effects of the milling time, the 
applied pearl weight and the additive concentration on the reduction of the PS were determined. 
Depending on the milling time, the PS of the drug could be reduced to the micro-(10 min) or 
nanometre (50 min) range. Increase of the pearl weight above 20 g did not result in the higher 
  
 
46 
effectiveness of milling. The use of a higher concentration of PVA was required to prevent the 
aggregation of the MEL particles. SEM images revealed the aggregation of nano-sized particles, 
resulting in micronized MEL particles (D50 = 1.625 µm). The nanonized MEL crystals 
(D50 = 126 nm) exhibited a regular shape and a smooth surface. XRPD and DSC examinations 
revealed the change in the crystallinity of MEL. This combined technique is applicable for the 
production of intermediate (in pre-dispersion form) and (after drying) dried products for 
additional pharmaceutical formulations. 
 
iv. Of the investigated techniques, the combined milling technique was suitable for the 
micro- and nanonization of MEL. At pH 5.6, pre-dispersions with different MEL PSs were 
prepared as intermediates for the design of intranasal liquid formulations with the addition of 
HA as mucoadhesive agent. Reduction of the MEL PS into the nano range led to increased 
saturation solubility and dissolution velocities, and increased adhesiveness to surfaces as 
compared with microsized MEL particles. A linear correlation was demonstrated between the 
specific surface area of MEL and the AUC. The in vitro and in vivo studies indicated that a 
longer residence time and uniform distribution of the nano MEL spray throughout an artificial 
membrane and the nasal mucosa resulted in better diffusion and a higher AUC. Nanosized MEL 
may be suggested for the development of an innovative dosage form with a different dose of 
the drug, as a possible administration route for pain management. 
 
v. It can be concluded that wet milling is applicable for the preparation of pre-
dispersions, whereby dosage forms can be prepared in one step. Sonication is suitable for 
reduction of the PS of drugs to the micro range, but it requires a large amount of dispersion 
medium, and it is therefore not applicable to obtain intermediate products for the preparation 
of dosage forms. Metal contamination through degradation of the sonotrode should be borne in 
mind. 
 In contrast, because of low need for dispersant medium, the combined method can be 
used for more efficient milling in comparison with sonication, and it is also suggested for the 
preparation of pre-dispersions with micro- and nanosized particles, and recommended for the 
development of PS-controlled intranasal therapeutic systems. 
 The applicability of a nanosuspension in a nasal formulation is a new approach in 
pharmaceutical technology, and consequently few data on such systems are available (the 
intranasal usage of other analgesic NSAID agents (e.g. a ketorolac tromethamine-containing 
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solution) (Li et al., 2015)). A patent has been granted which describes the nasal application of 
MEL in solution form (Castile et al., 2005), but there have been no publications on the 
development of MEL-containing nanosuspensions for nasal application. 
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This article reports on the micro- and nanonization of meloxicam (MEL) with the aim of developing pre-
dispersions as intermediates for the design of intranasal formulations. As a new approach, combined wet
milling technology was developed in order to reduce the particle size of the MEL. Different milling times
resulted in micro- or nanosized MEL in the pre-dispersions with polyvinyl alcohol as stabilizer agent,
which were directly used for preparing intranasal liquid formulations with the addition of sodium
hyaluronate as mucoadhesive agent. Reduction of the MEL particle size into the nano range led to
increased saturation solubility and dissolution velocities, and increased adhesiveness to surfaces as
compared with microsized MEL particles. A linear correlation was demonstrated between the speciﬁc
surface area of MEL and the AUC. The in vitro and in vivo studies indicated that the longer residence time
and the uniform distribution of nano MEL spray throughout an artiﬁcial membrane and the nasal mucosa
resulted in better diffusion and a higher AUC. Nanosized MEL may be suggested for the development of an
innovative dosage form with a different dose of the drug, as a possible administration route for pain
management.
ã 2015 Elsevier B.V. All rights reserved.
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journa l home page : www.e l sev ier .com/ loca te / i jpharm1. Introduction
Intranasal administration is an alternative route for the delivery
of drugs to reach the systemic circulation (Prommer and
Thompson, 2011), offering certain advantages, including rapid
absorption, avoidance of the hepatic ﬁrst-pass metabolism and
gastrointestinal side-effects and painless application, with sterility
not a requirement (Meng et al., 2014). Pharmaceutical formula-
tions delivered intranasally may be liquid (spray) (Baumann et al.,
2012), gel (Osth et al., 2002) or powder forms.
In order to achieve a systemic effect, intranasal compounds can
be mixed with different additives to ensure a longer residence
time, better mucoadhesion (Horvát et al., 2009) and increased
permeability (Chunga et al., 2010). Because of the rapid
mucociliary clearance in the nasal cavity, mucoadhesive formu-
lations are needed in order to prolong the contact time with the* Corresponding author at: Department of Pharmaceutical Technology, Universi-
ty of Szeged H-6720 Szeged, Eötvös u. 6, Hungary. Fax: +36 62 545571.
E-mail address: revesz@pharm.u-szeged.hu (P. Szabó-Révész).
http://dx.doi.org/10.1016/j.ijpharm.2015.06.046
0378-5173/ã 2015 Elsevier B.V. All rights reserved.nasal mucosa, thereby enhancing the delivery of the drugs
(Hasçiçek et al., 2003). Different agents are used to increase the
mucoadhesive strength in the intranasal formulation (carbomers,
chitosans, lectins, thiomers, alginate poly-ethylene glycol acrylate
or poloxamer) (Pathak, 2011 and Anand et al., 2012). One of the
most important biocompatible, mucoadhesive agent is sodium
hyaluronate (HA). This natural anionic polysaccharide has an
excellent mucoadhesive capacity (Liao et al., 2005), high biocom-
patibility and low immunogenicity (Ding et al., 2012). Besides its
mucoadhesive properties, it may enhance the absorption of drugs
and proteins via the mucosal tissues (Lim et al., 2000).
The solubility, the rate of dissolution and the permeability of
drugs are of great importance (Zelkó and Süvegh, 2005), and
reduction of the particle size to the micro- or nano range is
therefore the strategy of ﬁrst choise with the aim of increasing the
bioavailability of poorly-soluble drugs (Sinha et al., 2013 and
Anarjan et al., 2015). Nanoparticles are controlled by surface forces
and, if the particles are not stabilized, they may coagulate because
of the high particle mobility. Different additives are used to
stabilize these particles: polysorbate, hydroxypropyl methylcellu-
lose, poloxamer, polyvinylpyrrolidone, etc (Paltonen and Hirvonen,
C. Bartos et al. / International Journal of Pharmaceutics 491 (2015) 198–207 1992010). Polyvinyl alcohol (PVA) is frequently used as a stabilizer,
coating the particles and promoting their separation from each
other.
For particle size reduction, dry (Branham et al., 2012) and wet
milling (Afolabi et al., 2014) processes are commonly used. Wet
milling requires less energy and time than dry milling. Thanks to
the closed system, dust is not produced and the material is less
heated up (Merisko-Liversidge and Liversidge, 2011). Dry milling is
used for micronization (Zhang et al., 2009), while wet milling is
required for nanonization (Juhnke et al., 2012). The pre-dispersion
prepared by wet milling can be utilized directly to develop liquid or
semisolid formulations.
Nanosuspension drug delivery via the nose into the systemic
circulation and the brain is considered a promising route. The
applicability of a nanosuspension in a nasal formulation is a new
approach in pharmaceutical technology, and consequently few
data are available on this system. Saindane et al. (2012)
incorporated a carvedilol-containing nanosuspension into an in
situ gelling nasal spray, in order to improve the therapeutic efﬁcacy
and patient compliance. Bhavna et al. (2014) developed a
donepezil-loaded nanosuspension for direct olfactory administra-
tion.
MEL, a non-steroidal anti-inﬂammatory drug (NSAID) was
chosen in our work as a model crystalline drug because it can be
administered intranasally in order to attain an analgesic effect.
WHO (World Health Organization) developed the model to guide
the management of different pain. NSAIDs are suggested for acute
pain therapy or are co-administered as adjuvants to enhance
analgesia (WHO, web reference1). Other analgesic NSAID agents
(e.g. a ketorolac tromethamine-containing solution) have been
administered intranasally (Li et al., 2015). A dissolved MEL-
containing nasal formulation was patented by Castile et al. (2005),
but a MEL-containing nanosuspension has not been described to
date. MEL proved not to be toxic in a cell culture model of the nasal
epithelium and did not inﬂuence the paracellular pathway (Kürti
et al., 2013). MEL has poor aqueous solubility (4.4 mg/ml) (Ambrus
et al., 2009) and high melting point (270 C) (Hughey et al., 2011).
We earlier investigated “top-down” methods with the aim of
reducing the particle size of MEL and hence improving its
bioavailability, such as dry ball-milling (Kürti et al., 2011) and
high-pressure homogenization (Pomázi et al., 2013).
In order to enhance the bioavailability of MEL-containing
intranasal formulations, (i) its solubility should be improved
through the use of solubility-enhancing agents, e.g. co-solvents
such as benzyl alcohol, complexing agents such as cyclodextrins,
etc (for intranasal solutions) (Castile et al., 2005), (ii) its dissolution
rate should be increased, e.g. by particle size reduction (for a liquid
or gel form containing the suspended active agent), and (iii) the
residence time of the formulation in the nasal cavity should be
lengthened through the use of mucoadhesive agents.
We set out to utilize particle size reduction to increase the
dissolution rate so as to reach a higher saturated concentration of
MEL and better absorption. Pre-dispersions of micronized and
nanonized MEL were produced through wet milling, applying a
combination of planetary ball and pearl milling. PVA was used as
an aggregation inhibiting polymer. To prepare the intranasal
formulations directly from the pre-dispersions containing micro-
or nanonized MEL, a low concentration of HA was used. Pre-
dispersions were tested from the aspects of the particle size
distribution (PSD), the habit of the MEL and the holding time. The
viscoelastic character and the mucoadhesivity of the intranasal
formulation was determined rheologically. We additionally1 WHO; Pain guidelines: http://www.who.int/medicines/areas/quality_safety/
delphi_study_pain_guidelines.pdf, Accessed: 02/04/2015.investigated the inﬂuence of the MEL particle size reduction of
the intranasal formulations on the in vitro and in vivo perme-
abilities.
2. Materials
Meloxicam (MEL) (4-hydroxy-2-methyl-N-(5-methyl-2-thia-
zolyl)-2H-benzothiazine-3-carboxamide-1,1-dioxide) was
obtained from EGIS Ltd. (Budapest, Hungary). Piroxicam, the
internal standard for the HPLC method, was purchased from Alfa
Aeasar Co. (Alfa Aeasar GmbH & Co. KG, Karlsruhe, Germany). The
grinding additive, PVA 4-98 (Mw 27000), was procured from
Sigma Aldrich (Sigma–Aldrich Co. LLC, St. Louis MO, US). HA
(Mw= 1400 kDa) was obtained a gift from Gedeon Richter Plc.
(Budapest, Hungary). Mucin (porcine gastric mucin type II) was
from Sigma Aldrich (Sigma Aldrich Co. LLC, St. Louis MO, US).
3. Methods
The intranasal viscous liquid formulations containing sus-
pended MEL (referred to below as nasal sprays) were prepared and
characterized according to an investigational protocol (Fig. 1). The
PSD, the morphology (scanning electron microscopy-SEM), the
solubility of the MEL and the holding time of the pre-dispersions
were determined. Nasal sprays prepared directly from the pre-
dispersions were characterized in terms of the solubility of MEL
and the pH and mucoadhesivity of the sprays. These intranasal
formulations were subjected to both in vitro and in vivo studies.
3.1. Preparation of pre-dispersions containing micronized or
nanonized MEL and preparation of intranasal formulations
On the basis of preliminary experiments, a modiﬁed wet milling
technique (a combination of planetary ball and pearl milling) was
employed to prepare the pre- dispersions. Intranasally adminis-
tered formulations usually contain particles with a particle size
from 5 to 40 mm (Billotte et al., 2003). In the optimization of the
milling parameters, the particle size was set to the micro- or
nanometer range in order to investigate the inﬂuence of the
particle size on the dissolution rate and absorption through the
nasal mucosa. 0.5 g PVA was dissolved in 17.5 ml phosphate buffer
(at pH 5.6, the pH of the nasal mucosa); the solution was used as a
dispersant medium in which 2.0 g of MEL was suspended. The
suspension (10% drug content) was wet-milled for 10 or 50 min in
the milling chamber (50 ml) of the planetary mill (Retsch PM 100)
(Retsch GmbH, Haan, Germany), which resulted micronized or
nanonized MEL (Table 1). The milling medium for this study was
zirconium dioxide beads. The milled suspensions were separated
from the beads through sieving.
The intranasal formulations were prepared directly from the
pre-dispersions. 3.0 ml of the pre-dispersions were diluted with
phosphate buffer (pH 5.6) in order to reach 1 mg/ml concentration
of MEL and 0.15 g HA was added, therefore the ﬁnal formulation
contained 5 mg/ml HA. The formulations were stored in a fridge for
24 h. (in the text: raw MEL spray, micro MEL spray and nano MEL
spray).
3.2. Determination of PSD
The volume-based PSD of MEL in the pre-dispersions was
measured by laser diffraction (Mastersizer 2000) (Malvern Instru-
ments Ltd, Worcestershire, UK) with the following parameters:
300RF lens; small volume dispersion unit (2500 rpm); refractive
index for dispersed particles 1.720; refractive index for dispersion
medium 1.330. A dynamic laser light scattering method was used
to determine the PSD. Water was applied as dispersant and the
Fig. 1. Protocol of the development and characterization of nasal sprays containing MEL.
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cases, the volume-weighted PSDs, D10, D50 and D90 (where, for
example, D50 is the maximum particle diameter below which 50%
of the sample volume exists—also known as the median particle
size by volume) were determined and evaluated. The size analysis
was repeated three times. The speciﬁc surface area (SSA) was
derived from the PSD data. The assumption was made that all the
particles measured were spherical.
3.3. Image analysis (SEM)
Pre-dispersions were dried in a vacuum dryer (Binder GmbH,
Tuttlingen, Germany) at 40 C in order to obtain solid products for
physical–chemical investigations. After drying, the shape and
surface characteristics of the samples were visualized by using
SEM (Hitachi S4700, Hitachi Scientiﬁc Ltd., Tokyo, Japan). The
samples were sputter-coated with gold–palladium under an argon
atmosphere, using a gold sputter module in a high-vacuum
evaporator, and the samples were examined at 15 kV and 10 mA.
The air pressure was 1.3–13 MPa.
3.4. Solubility testing of MEL
The solubility of MEL in the different pre-dispersions was
determined. The pre-dispersions were stirred with a magnetic
stirrer at 25 C for 24 h and then ﬁltered (0.1 mm, FilterBio PES
Syringe Filter) (Labex Ltd., Budapest, Hungary), and the content of
dissolved drug was analysed spectrophotometrically (Unicam UV/Table 1
Pre-dispersions: MEL suspended in a dispersant medium consisting of PVA and phosp
Abbreviation in the text (pre = pre-dispersion) rpm 
Raw MEL pre – 
Micro MEL pre 400 
Nano MEL pre 400 
Table 2
Samples for mucoadhesive measurements.
Sample name HA (mg/ml) PVA (mg/m
HA solution 5 – 
PVA solution – 0.225 
Blank 5 0.225 
Raw MEL spray 5 0.225 
Micro MEL spray 5 0.225 
Nano MEL spray 5 0.225 VIS) (Thermo Fisher Scientiﬁc Inc., Waltham, MA, USA). Each
sample was analysed in triplicate. The pH of each nasal spray was
determined (Orion 3 star pH-meter), (Thermo Fisher Scientiﬁc Inc.,
Waltham, MA, USA).
3.5. Holding time determination
For intermediate products such as pre-dispersions, the holding
time was determined through the PSD. Pre-dispersions were
stored in sealed glass bottles at room temperature (25 1 C) for
3 days. The PSD of the MEL in a prepared sample was analysed on
the day of production (day 0) and after 1, 2 or 3 days of storage.
3.6. Rheology and mucoadhesion
Rheological measurements were carried out at 37 C with a
Physica MCR101 rheometer (Anton Paar GmbH, Graz, Austria). A
concentric cylindrical measuring device with a diameter of
10.835 mm was used. Frequency sweep curves were plotted to
determine the viscoelastic character of the samples. Storage
modulus (G’) and loss modulus (G”) measurements were made
over the frequency range from 0.01 to 100 Hz. The ﬂow curves of
the samples were also determined. The shear rate was increased
from 0.1 to 100 1/s in controlled rate mode. The shearing time was
150 s.
In order to clarify the role of MEL particle size in mucoadhesion,
samples with and without mucin were also prepared (Table 2); the
samples containing mucin were stirred for 3 h before thehate buffer.
Volume of the milling chamber (ml) Milling time (min)
– 0
50 10
50 50
l) MEL (mg/ml) MEL size; D50 (mm)
– –
– –
– –
1 34.26
1 1.887
1 0.135
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mucoadhesivity was determined on the basis of rheological
synergism between the polymer and the mucin. The synergism
parameter (bioadhesive viscosity component, hb) can be calculat-
ed from the following equation:
hb ¼ ht  hm  hp;
where ht is the viscosity of the mucin and polymer-containing
samples, and hm and hp are the viscosities of the mucin and nasal
spray, respectively (Hassan and Gallo, 1990). Three parallel
measurements were used to determine the viscosity values (ht,
hm and hp) and the standard deviations.
3.7. In vitro permeability of MEL
In vitro permeability studies were performed on a vertical Franz
diffusion cell system (Hanson Microette Topical and Transdermal
Diffusion Cell System) (Hanson Research, Chatsworth CA, USA).
5 parallel measurements were carried out. The donor phase
contained 300 mg of nasal formulation, which was placed on the
polyvinylidene ﬂuoride synthetic membrane (Durapore1 Mem-
brane Filter) (EMD Millipore, Billerica, MA, USA) impregnated with
isopropyl myristate. The effective diffusion surface was 1.33 cm2.
Phosphate buffer (PBS, pH 7.4, 37 C) was used as an acceptor phase
(7 ml). The rotation of the stir-bar was set to 450 rpm. Sampling
was carried out at 5, 10, 15, 30 and 60 min of diffusion. 0.8 ml
samples were taken from the acceptor phase by autosampler
(Hanson Microette Autosampling System) (Hanson Research,
Chatsworth CA, USA) and were replaced with fresh receiving
medium. The amount of MEL diffused was determined spectro-
photometrically (Unicam UV/VIS). The ﬂux (J) of the drug was
calculated from the quantity of MEL which permeated through the
membrane, divided by the surface of the membrane insert and the
duration [mg/cm2/h]. The permeability coefﬁcient (Kp) was
determined from J and the drug concentration in the donor phase
(Cd [mg/cm3]):
Kp½cmh  ¼
J
Cd
:
For determination of the residual MEL content in the donor
phase, the vertical Franz diffusion cell system was used to model
the nasal cavity. The donor phase contained 300 mg of nasal
formulation, which was placed on the polyvinylidene ﬂuoride
synthetic membrane (Durapore1 Membrane Filter) (EMD Milli-
pore, Billerica, MA, USA). To model the nasal environment, the
membrane was impregnated with simulated nasal ﬂuid (8.77 g
NaCl, 2.98 g KCl and 0.59 g CaCl2, containing 1% of mucin) (Jug and
Becirevic-Lacan, 2007). The effective diffusion surface was
1.33 cm2. Phosphate buffer (PBS, pH 7.4, 37 C) was the acceptor
phase (7 ml). The rotation of the stir-bar was set to 450 rpm. The
content of the donor phase was removed after 60 min of diffusion
and the amount of MEL remaining was determined with an Agilent
1260 RP-HLPC system (QP, DAD, ALS).
3.8. In vivo study of MEL
3.8.1. Intranasal administration and blood sample collection
The intranasal formulations prepared directly from the pre-
dispersions contained 1 mg/ml MEL and 5 mg/ml HA. A dose of
60 mg MEL per animal was administered into the right nostril of
160–180 g male Sprague-Dawley rats (n = 5) via a pipette. Directly
before the drug administration, the animals were narcotized with
isoﬂurane. Blood samples were withdrawn from the tail vein
before and at 5, 15, 30 and 60 min post-dosing. The experiments
performed conformed to the European Communities “Councildirective for the care and use of laboratory animals” and were
approved by the Hungarian Ethical Committee for Animal Research
(permission number: IV/198/2013).
3.8.2. Determination of MEL from the blood samples
The MEL contents of blood samples were quantitated with an
Agilent 1260HLPC system (QP, DAD, ALS). MEL and piroxicam as
internal standard were separated on a 250 mm  4.6 mm column
packed with 5-mm Kromasil C18, 100 Å (Phenomenex Inc., Torrance
CA, USA).
Isocratic elution was performed with 45:55 (v/v) acetonitrile-
potassium phosphate buffer solution (0.05 M) (pH adjusted to
2.7 with orthophosphoric acid) at a ﬂow rate of 1.1 ml/min. Before
use, the eluent was degassed and all the samples were ﬁltered
through a 0.20 mm PES syringe membrane ﬁlter (Phenomenex Inc.,
Torrance CA, USA). The total run-time was 12 min. Detection was
achieved through the UV absorbance at 254  4 nm. The sample
injection volume was 10 ml, and the elution was performed at a
column temperature of 30 C. Qualitative determination was
carried out by comparison of the spectra of standards. Primary
stock solutions of MEL and piroxicam (both 0.1 mg/ml) were
prepared in methanol and stored at 8 C. Working standards of
MEL and piroxicam (0.25, 0.5, 1, 2, 5, 7.5 and 10 mg/ml) were freshly
prepared by diluting the stock solution with mobile phase prior to
the HPLC analysis. Calibration plots of MEL and piroxicam were
freshly prepared and were linear (R2 > 0.9996 and 0.999, respec-
tively) in the concentration range 0.25–10.0 mg/ml (n = 3). The
retention times of MEL and piroxicam were 10.12  0.01 and
7.36  0.003 min, respectively.
Blank (drug-free) rat plasma was pooled, stored at 8 C and
used for the QC samples. The QC samples were spiked with the
appropriate amount of working standard MEL and piroxicam
solutions (0.5, 1, 1.5, 2 and 2.5 mg/ml (n = 3). Potassium phosphate
buffer solution (0.03 M) (pH adjusted to 2.7 with orthophosphoric
acid) was prepared as an additional extraction liquid. The limit of
quantiﬁcation (LOQ) was determined via the formula LOQ = SD  3/
S in which SD is the standard deviation and S is the mean slope of
the calibration curve. Based on these data, the LOQ of MEL and
piroxicam was calculated to be 0.171 and 0.275 mg/ml (n = 3),
respectively.
The animal blood samples (200 ml) were diluted with 500 ml of
extraction liquid and spiked with 10 ml of the working IS solution
at a ﬁnal plasma concentration of 1.3 mg/ml. The SPE cartridges
used (Strata-X-C 33 mm Polymeric Strong Cation tubes, Phenom-
enex Inc., Torrance CA, USA) were conditioned with 0.5 ml of
methanol, followed by 0.5 ml of extraction liquid. The prepared
blood samples were allowed to run through the SPE cartridge at a
ﬂow rate of 1.0 ml/min. Cartridges were rinsed with 0.5 ml of
extraction liquid and 0.5 ml methanol and dried in vacuum for
5 min. The analytes were then eluted with 0.5 ml of 5:95 (v/v)
ammonium hydroxide-methanol elution solution. The eluent
liquids were dried in a vacuum oven (Binder, Germany) at 20–
30 mbar and 45 C for 2–3 h. The dried residue was reconstituted in
300 ml of mobile phase and then vortexed (30 s), sonicated (2 min)
and centrifuged at 12,000  g for 5 min. 20 ml of supernatant was
injected onto the C18 column.
Calculations of the area under the time-concentration curve
(AUC) and statistical analysis
Pharmacokinetic parameters were analysed by means of PK
Solver 2.0 software (Zhang et al., 2010) through non-compart-
mental analysis of plasma data using the extravascular input
model. The area under the curve (AUC) of the time (min)–
concentration (mg/ml) curves of each animal were ﬁtted with a
linear trapezoidal method. The statistical analysis was performed
with Prism 5.0 software (Graphpad Software Inc., La Jolla, CA, USA).
All reported data are means  SD. Student’s unpaired t-test was
Table 3
PSD of MEL in the pre-dispersions.
D10 (mm) D50 (mm) D90 (mm) SSA (m2/g)
Raw MEL pre 11.40  1.62 34.26  4.86 73.59  27.11 0.332
Micro MEL pre 0.120  0.005 1.887  0.112 6.429  0.318 15.3
Nano MEL pre 0.077  0.005 0.135  0.002 0.253  0.010 44.8
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ered statistically signiﬁcant at p < 0.05.
4. Results and discussion
4.1. Characterization of the pre-dispersions
4.1.1. PSD and morphology of MEL
The MEL particle size measured by laser diffraction decreased
from approximately 35 mm to 1.887 mm during the 10 min, and to
0.135 mm during the 50 min milling time (Table 3). The SSA of MEL
rose 46-fold and 135-fold as a result of the micronization and the
nanonization, respectively, relative to the raw MEL in the pre-
dispersion. The coating effect of PVA prevented aggregation, and
the stability of the system was therefore improved.
The SEM images (Fig. 2) provided an indication of the
morphology of the modiﬁed particles. We checked how the
surface and shape were changed after the milling and drying as
compared with the raw MEL. After milling, the pre-dispersions
were dried and characterized. The raw MEL consisted mainly of
angular, prismatic crystals with a broad size distribution. The
micronized MEL particles (1.887 mm) consisted of aggregations of
nano-sized particles. The nanonized MEL crystals (135 nm)
exhibited a regular shape and a smooth surface. The treatment
accounted for the smooth surfaces of the particles.Fig. 2. SEM images of meloxicam from raw (A4.1.2. Solubility of MEL in the pre-dispersions
In order to check on the effects of particle size reduction on the
solubility of MEL in the pre-dispersions, solubility tests were
performed at 25 C, pH 5.6 (Table 4). Micronization did not result in
a change in the solubility of MEL. Following nanonization, a slight
increase in solubility was observed, but the difference did not
attain an order of magnitude.
4.1.3. Holding time determination
Aggregation did not occur in the pre-dispersions during the ﬁrst
24 h of storage (micro MEL pre: D90 = 6.462 mm; nano MEL pre:
D90 = 0.270 mm). During the second day, however, aggregates were
formed in both cases (micro MEL pre: D90 = 1035.340 mm; nano
MEL pre: D90 = 695.767 mm), and the number and size of the
aggregates increased still further during the third day. To avoid
aggregation, the pre-dispersions should be utilized to prepare the
formulations within 24 h.
4.2. Characterization of the nasal sprays
Nasal sprays (raw MEL, micro MEL and nano MEL sprays) were
prepared directly from the pre-dispersions with MEL of different
particle sizes, using HA as a mucoadhesive polymer. The pH of the
formulations did not change signiﬁcantly after the addition of HA
to the systems (pH 5.5) relative to the pH of the pre-dispersions
(pH 5.6).
The solubility of MEL in the nasal sprays was investigated in the
freshly prepared formulations after stirring for 24 h. The solubility
of the drug in the sprays was increased approximately 3–5-fold
(raw MEL spray: 13.9 mg/ml; micro MEL spray: 32.1 mg/ml; nano
MEL spray: 42.8 mg/ml). This can be explained by the interaction
between the HA and MEL which resulted in complex between the
carboxylic groups in HA and the protonable groups in MEL
(Battistini et al., 2013).), micro (B) and nano (C) pre-dispersions.
Table 4
Solubility of MEL in the pre-dispersions.
c (mg/ml)
Raw MEL pre 6.4  0.2
Micro MEL pre 6.6  0.3
Nano MEL pre 9.3  0.5
Fig. 4. Flow curves of the sprays with different MEL particle sizes.
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The viscoelastic characters of the sprays were determined by
frequency sweep measurements in the range from 0.01 Hz to
100 Hz. G’ corresponds to the elastic (storage) and G” to the viscous
(loss) modulus. Fig. 3 presents frequency sweep curves of samples
with different particle sizes (blank, MEL-free) spray, raw MEL
spray, micro MEL spray, nano MEL spray). The cross-over points of
these curves, which is typical for gel-containing hyaluronans,
could not be seen (Berkó et al., 2013). The ratio of G’ and G”
indicates the sol state of the samples. The ﬁndings can be explained
by the pH of the formulations (pH 5.6) and the low concentration of
HA.
The intranasal formulations containing MEL displayed shear-
thinning behaviour, i.e. the shear viscosity depended on the degree
of shear load and the ﬂow curve displayed a decreasing slope,
which is typical for polymer solutions. The different formulations
did not indicate changes in the ﬂow characters (Fig. 4). The
presence of MEL and variation of its particle size did not affect the
viscosity of the samples, and this HA-containing drug carrier
system is therefore suitable for the formulation of drugs with
different particle sizes without alteration of the ﬂow behaviour.
For the rheological determination of mucoadhesivity, the
samples were mixed with mucin (ﬁnal mucin concentration 5%)
and the synergism parameter (bioadhesive viscosity component,
hb) was calculated. The mucoadhesivity of the HA solution in
phosphate buffer (at pH 5.6), without PVA, of the PVA solution
without HA, of the blank and of the three sprays with different MEL
particle size were investigated.Fig. 3. Frequency sweep curves of the sprThe synergism parameter indicated the mucoadhesivity of the
samples, with an interaction between the HA and the mucin
(Fig. 5). PVA did not reveal mucoadhesive features, even destroy
the mucin-HA interactions, accordingly the mucoadhesivity of
blank decreased compared to the HA solution without PVA.
Addition of MEL to the blank increased the mucoadhesivity of the
formulations compared to the HA solution without PVA. This can
be explained by interactions between the mucin and dispersed
particles, and signiﬁcant differences were observed between the
calculated synergism data for the raw, micro and nano MEL
samples (p < 0.05). The highest synergism was observed between
the nasal spray containing nanonized MEL and the mucin, the
mucoadhesivity increased 2-fold compared to the MEL-free blank,
and hence the longest residence time could be reached. This could
be explained in the one hand by the particle size of MEL; the
nanosized particles have increased adhesiveness to surfaces
(Müller et al., 2011). On the other hand nano sized MEL is in
size of polymeric molecules, such as HA, PVA and mucin chains,
which can result a well-structured complex, and better interaction
among the components and thus it shows more remarkable
mucoadhesivity.ays with different MEL particle sizes.
Fig. 5. Calculated synergism parameters at a shear rate of 100 1/s of samples.
Fig. 6. In vitro permeability of the sprays through a synthetic membrane containing MEL with different particle sizes.
Table 5
Flux (J) and permeability coefﬁcient (Kp) values of nasal sprays containing MEL with
different particle sizes.
J [mg/cm2/h] Kp [cm/h]
Raw MEL spray 3.41 0.00341
Micro MEL spray 4.25 0.00425
Nano MEL spray 9.43 0.00943
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The cumulative amount of MEL that diffused through a
synthetic membrane from a nasal spray was measured against
time on a Franz diffusion cell system. The diffusion from the
formulation containing MEL nanoparticles was the quickest, due to
the rapid dissolution of the drug. The diffusion started in the ﬁrst
5 min from the nanonized MEL-containing spray (Fig. 6). As
concerns the fastest diffusion, the question arose as to whether it
was inﬂuenced by the particle size or some other factor. It should
be excluded that the nanosized MEL particles (D50 = 0.135 mm)
passed through the membrane without dissolving (they dissolved
in the acceptor phase). Since the particle size was larger than the
membrane pore size (100 nm) and the membrane was impregnat-
ed with isopropyl myristate, this phenomenon was not observed.
In this case, therefore, the particle size and the resulting surface
area had signiﬁcant effects on the rate of passive diffusion.The ﬂux (J), which shows the amount of MEL that permeates
through 1 cm2 of the membrane within 1 h, was signiﬁcantly
increased in the case of the nasal formulation which contained
nanoparticles as compared with the sprays containing micronized
or raw MEL. The permeability coefﬁcient (Kp) calculated from the
ﬂux data for the nanonized MEL was also signiﬁcantly higher than
in the other two cases (Table 5).
Fig. 7. Remained MEL content in the donor phase.
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amount of diffused MEL. In the spray containing nanonized MEL,
the faster dissolution of the particles resulted in higher perme-
ability.
It was revealed that the nasal mucosa retained the MEL and its
particle size did not inﬂuence the permeability. Fig. 7 demon-
strates signiﬁcant differences between the MEL content remaining
in the donor phase: 71.38  6.33% (raw MEL spray), 19.52  4.18%
(micro MEL spray) and 8.85  0.94% (nano MEL spray). The residual
MEL content in the donor phase correlated well with the
decreasing MEL particle size of the spray samples.
4.2.3. In vivo studies of MEL
The drug concentration in the blood plasma as a function of
time after nasal administration of the sprays is shown in Fig. 8. In
the case of the spray containing MEL nanoparticles, a 3 times
higher plasma level of MEL was observed after 5 min as comparedFig. 8. Plasma drug concentration vs. time proﬁles in rats after intranasal adwith the formulations containing raw or micronized MEL. This
result is in accordance with the particle size reduction of MEL, and
especially with the faster dissolution of nanonized MEL as
compared with that of the microsized agent. The plasma
concentrations tended to increase slowly during the ﬁrst
approximately 30 min, but the 3-fold difference between the
sprays containing nanonized or micronized MEL remained during
60 min after treatment.
The AUC is proportional to the amount of drug absorbed during
the investigated time interval. The calculated AUC values gradually
increased with decreasing particle size (the highest AUC was
observed for the nano MEL spray; Fig. 9). Micronization did not
signiﬁcantly increase the AUC as compared with raw MEL
(AUCrawMELspray: 13.97  3.223 min mg/ml, AUCmicroMELspray:
21.95  5.527 min mg/ml, p = 0.1552), whereas nanonization led
to a signiﬁcant increase of the amount of MEL absorbed
(AUCnanoMELspray: 49.86  5.632 min mg/ml; nano MEL spray vsministration of the sprays containing MEL with different particle sizes.
Fig. 9. AUC of the sprays containing MEL with different particle sizes.
Fig. 10. Correlation between the AUC and different MEL particle sizes.
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Our results demonstrated a strict correlation between the AUC and
the MEL particle size (R2 = 0.9848) (Fig. 10).
5. Conclusions
A combination of planetary ball and pearl milling can be applied
as a wet milling procedure to decrease the particle size of MEL.
Depending on the milling time, micro- and nanosized particles can
be produced. This wet milling technology was suitable for the
preparation of pre-dispersions in the presence of PVA as additive,
which were then directly applicable for the development of
innovative liquid nasal pharmaceutical formulations.
Intranasal viscous sprays were prepared from micronized and
nanonized MEL-containing pre-dispersions with HA as mucoad-
hesive agent, which is important from the aspect of a longer
residence time. The pre-dispersions as intermediate products were
suitable for preparing intranasal formulations for use within 24 h.
Nasal absorption can be improved not only by increasing the
transcellular and paracellular uptake of a drug through the nasal
mucosa; increase of its saturation solubility in the nasal ﬂuid
results in passive diffusion and a higher plasma concentration.
Reduction of the MEL particle size into the nano range resulted in
special features of the nanocrystals (Müller et al., 2011), such as
increased saturation solubility and dissolution velocities, and
increased adhesiveness to surfaces as compared with microsized
MEL particles. The higher SSA and the enhanced saturation
solubility of the nano MEL spray resulted in rapid dissolution of
the drug and a higher AUC. The linear correlation between the SSAof MEL and the AUC (R2 = 0.9848) conﬁrmed that the dissolution of
particles with different sizes is the key factor determining the
amount of drug absorbed.
The adhesiveness of nanonized MEL to the nasal mucosa is
another important advantage of this system because of the longer
contact time in the nasal cavity. Different mucoadhesivities were
measured for the nanonized MEL-HA-mucin system and micro-
sized MEL-containing sprays. The in vitro and in vivo studies
indicated that the longer residence time and the uniform
distribution of the nano MEL spray throughout an artiﬁcial
membrane and the nasal mucosa resulted in better diffusion
and a higher AUC. Thanks to the better adhesion and distribution of
the nanoparticles and the formation of a well-structured system,
the release of MEL was controlled. This controlled release was
enhanced by the HA-PVA system (Battistini et al., 2013). The PVA-
coated particles played a role in the release of the drug, because the
synthetic polymers reduced the rate of degradation of the natural
polymers and prevented their rapid dissolution in the biological
ﬂuids (Ding et al., 2012).
Our results indicate that nanosized MEL may be suggested for
the development of an innovative intranasal liquid dosage form to
decrease the acute pain or it may be added as an adjuvant to
enhance analgesia.
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A B S T R A C T
This article reports on particle engineering by a top-down method involving organic solvent-free acoustic
cavitation as a wet-grinding procedure. The effects of static and dynamic sonication on particle size
reduction methods were compared to each other. The most effective process parameters were
determined by a factorial design plan for the particle size distribution of an important active
pharmaceutical ingredient, meloxicam, as response factor after sonication. Samples sonicated with
appropriate process parameters were dried and investigated. Scanning electron microscopy images
showed that the sonication resulted in a rounded shape and micronized size of the particles. Differential
scanning calorimetry and X-ray powder diffraction examinations revealed the crystalline structure of the
produced meloxicam by both sonication methods. Fourier transform infrared spectroscopy demonstrat-
ed that no chemical degradation occurred. Static sonication is recommended primarily for particle size
reduction in preclinical samples, where the amount of the drug candidate is very small (e.g. nasal
formulation), while dynamic sonication may be suitable for wet-grinding of different active substances to
prepare pre-suspension (e.g. micronization and nanonization).
ã 2014 Published by Elsevier B.V.
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Particle design techniques are widely used for the modiﬁcation
of the physico-chemical and biopharmaceutical properties of
Active Pharmaceutical Ingredients (APIs) [1]. Particle engineering
techniques, controlling the crystal size distribution and morphol-
ogy can offer improvements for the solubility, dissolution rate and
permeability of poorly water-soluble drugs and can open up new,
alternative administration routes, e.g. intranasally route, where the
particle size (over 10 mm) is a determining factor [2–4]. Process
Intensiﬁcation (PI) has the goal of making substantial improve-
ments to the efﬁciency of chemical processes and plants by
developing innovative methods and equipment [5]. Innovative
methods for these improvements can be the useage of alternative
energy forms, like centrifugal ﬁelds, ultrasounds, microwaves,
solar energy, electric ﬁelds, or plasmas [6]. The advantages of* Corresponding author. Tel.: +36 62545571.
E-mail address: kefehu@gmail.com (N. Radacsi).
http://dx.doi.org/10.1016/j.cep.2014.10.015
0255-2701/ã 2014 Published by Elsevier B.V.intensiﬁed product design processes consist of intensiﬁed process
control, and/or improved product quality.
There are many different types of size reduction techniques; dry
and wet grinding can be distinguished. During the wet grinding,
due to the closed system the formation of dust is prevented. Less
energy and time is required for grinding, the heating of the
materials is reduced and after grinding the suspension can be
directly used for production formulations.
Acoustic cavitation is a novel wet grinding possibility for
controlling the crystal size distribution and morphology of drugs,
primarily with the aim of particle size reduction [7,8]. It has the
ability to erode and break down particles and increase the speciﬁc
surface area of crystals [9]. It has been proven that application of
ultrasound technology in the frequency range of 20–100 kHz can
induce particle size reduction [10]. During the sonication process,
the ultrasound waves that form in the liquid media result in
alternating high-pressure and low-pressure cycles, with rates
depending on the frequency. In the low-pressure cycle the high-
intensity ultrasonic waves evolve small gas- or vapor-ﬁlled bubbles
(cavities) in the liquid. When the bubbles reach a volume at which
they can no longer absorb energy, they collapse violently during a
C. Bartos et al. / Chemical Engineering and Processing 87 (2015) 26–34 27high-pressure cycle. This phenomenon is called ultrasonic cavita-
tion. The implosion of vacuum bubbles breaks down particles [11].
Ultrasonic liquid processing is described by a number of
parameters (amplitude, pressure, temperature and concentrations
of compounds). The effect of the process may be determined as a
function of the energy (E) divided by the processed volume (V):
effect ¼ f E
V
 
The energy (E[Ws]) can calculate from the power output (P[W]) and
the duration of exposure (t[s]):
EJ ¼ PW  tS
The function alters with changes in the individual parameters.
Additionally, the actual power output per surface area of the
sonotrode of an ultrasonic unit depends on the parameters as was
written by Hielscher [12].
There are two sonication routes for wet-grinding to achieve
particle size reduction. One is the static method, which means that
a sample at rest is sonicated. Another possibility is the dynamic
method, which allows the continuous circulation of the sample by
means of a pump during the sonication. These two methods are
appropriate for particle size reduction of materials with different
physico-chemical properties [13]. The production of intermediates
(suspension form for example for preparation of nasal spray and
gel) and powder products (after drying) is carried out by applying a
short-term ultrasound energy input. Application of ultrasounds
can be easily scaled up, e.g. soniﬁcation is successfully applied at
industrial level for the preparation of metal nanoparticles [14].
Sonochemistry involves the use of an ultrasound technique to
promote chemical reactions [15]. As regards pharmaceutics, power
ultrasound can be applied for emulsiﬁcation and to investigate the
sedimentation of emulsions and suspensions [16,17]. Supercritical,
solvent diffusion [18] and melt emulsiﬁcation are well-known
bottom-up methods techniques in the ﬁeld of sonocrystallization
for solving solubility problems of drugs [19]. The disintegration of
drug particles (top-down approach) has not widely investigated so
far for improving properties of drugs.
Meloxicam (MEL) is a NSAID (non-steroidal anti-inﬂammatory
drug) with anti-inﬂammatory, analgesic and antipyretic effects, it
can be used intranasally. MEL was chosen as a model crystalline
drug because of its poor aqueous solubility [20] and high melting
point (270 C) [21].
This research investigates the applicability of ultrasound
technology for intensiﬁed particle size reduction and the setting
of the process. Since the literature data relating to the application
of ultrasound for the particle size reduction of drug materials are
lacking, in this study the static and dynamic sonication methods
are compared to each other (as organic solvent-free wet-grinding
techniques) and their effects in reducing the particle size of MEL
are investigated, using the excipient, PVP K-25, as anFig. 1. Sonotrode positions in the aqueagglomeration inhibitor. A two-level fractional factorial design
was used to determine the most effective process parameters, and
the effects of ultrasound on the physico-chemical properties of
MEL were studied.
2. Experimental
2.1. Materials
Meloxicam (4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-
2H-benzothiazine-3-carboxamide-1,1-dioxide) was obtained from
EGIS Ltd. (Budapest, Hungary). The grinding additive, PVP K-25
(polyvinylpyrrolidone), was purchased from BASF (Ludwigshafen,
Germany).
2.2. Methods
2.2.1. Preparation of sonicated formulations
In our systems water was used as a liquid for the sonication
studies. Meloxicam has poor aqueous solubility (4.4 mg/mL). PVP is
a dispersant, it is used in the pharmaceutical industry as a
synthetic polymer vehicle for dispersing and suspending drugs.
The presence of weak bonding between the carboxyl group of
Meloxicam and the PVP helps the molecules to separate from each
other. The aggregation is prevented, therefore stability of the
system could be improved. In other case, PVP can work as a wetting
agent, but does not increase the solubility and dissolution of the
drug signiﬁcantly. In each sample, 0.5% of PVP K-25 was dissolved
in an appropriate volume of water (25 and 100 mL respectively for
static and dynamic sonication) at pH 5.56. Before sonication, the
suspensions were stirred with a magnetic stirrer for 5 min. A high-
power ultrasound device (Hielscher UP 200 S Ultrasonic processor,
Germany) operating at 200 W was applied as the energy input in
the sample preparation in order to achieve a particle size
reduction. The working wavelength of the ultrasound used in
the treatment was 6.6 cm. T. During the sonication energy is
transmitted from the probe directly into the sample with high
intensity and the sample is processed quickly. In the case of static
sonication, samples at rest were treated (the suspensions were not
circulated). In the case of dynamic sonication, the samples were
circulated continuously with a peristaltic pump (Heidolph PD
5006 Pump drive) in a double-walled ﬂow cell (Flow Cell GD14 K)
during the sonication. The temperature was set with a thermostat
in both cases (Julabo, Germany).
The height of the medium was 8 cm in case of the dynamic
sonication and 2 cm by 25 mL and 3.5 cm by 100 mL in the case of
static sonication. The wavelength of the ultrasound used in the
treatment was 6.6 cm. Applying different sonotrode positions, the
immersed surface area of the ultrasonic horn could be changed
(Fig. 1). The surface area of the ultrasonic horn in contact with the
sample was determined by the amount of the immersed area of the
cylinder and of the tip surface of the probe. It was 0.15 cm2 in caseous suspension of MEL with PVP.
Fig. 2. Results of the adiabatic investigations for appropriate volume of 0.5% PVP
solution without the presence of MEL.
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0.25 position (means that the sonotrode was immersed to 25%
of the total depth of the liquid); and 8.8 cm2 by the position of 0.75
(the sonotrode was immersed to 75% of the total depth of the
liquid). In the case of the static sonication and 100 mL sample
volume, at the 0.75 position the immersed surface area was
6.77 cm2 and at position 0.25 the immersed surface area was
1.23 cm2. During the dynamic sonication the immersed surface
area of the ultrasonic horn was constant 12 cm2. The applied
sonication parameters are given in Table 1.
Adiabatic experiments were carried out to reveal the efﬁciency
of the transmission of the ultrasonic energy into the liquid (Fig. 2).
The appropriate volume of 0.5% PVP-solution was used without the
presence of meloxicam. The temperature was mesured in every
5 min, from 0 to 30 minutes under sonication processing. The
temperature rise was the most notable in the case of small sample
volume (25 mL). Within 5 min 90 C could be reached using 25 mL
solution. The dynamic and static methods were compared with the
following parameters: 100 mL sample volume, 0.25 sonotrode
position. In the case of static sonication after 10 min the
temperature was higher, meaning higher energy input. In the
case of the dynamic method the temperature increase was slower,
due to the circulation in the vessel.
2.2.2. Preparation of solid products for physical-chemical
investigations of pure MEL
Suspensions prepared with the chosen parameters were dried
in order to obtain solid products for physical-chemical inves-
tigations. Samples were ﬁltered through ﬁlter paper (MUNKTELL
Filter Discs, Grade: 1290, pore size: 3–5 mm, diameter: 185 mm),
the ﬁltrate was washed with the medium of the suspension (0.5%
aqueous solution of PVP K-25, pH 5.56) and the wet crystals were
dried in a vacuum dryer (Binder, Germany) at 40 C in order to
obtain solid products. After drying, the percentage yield was
determined and the physico-chemical properties of the products
were investigated.
2.2.3. Determination of particle size distribution and speciﬁc surface
area by a laser diffraction method
The volume based particle size distribution (PSD) of the raw
MEL was measured by laser diffraction (Mastersizer 2000, Malvern
Instruments Ltd. Worcestershire, UK) with the following param-
eters: 300RF lens; small volume dispersion unit (2500 rpm);
refractive index for dispersed particles 1.720; refractive index for
dispersion medium 1.330. Dynamic Laser Light Scattering method
was used to determine the PSD. The MEL particle size was
determined directly on the initial suspension in water in which PVP
was dissolved. The size analysis was repeated three times. Water
was used as dispersant and the obscuration was in the range 11–
16% for all measurements in both cases. In all cases, the volume
weighted particle size distributions, D10, D50, and D90 (where for
example D50 is the maximum particle diameter below which 50%
of the sample volume exists–also known as the median particle
size by volume) were determined and evaluated.Table 1
The applied sonication parameters.
Static sonication Dynamic sonication
Volume (mL) 25; 100 100
Position 0.25; 0.75 0.25
RPM (pump)
–
50; 100
Concentration of MEL (mg/mL) 2; 18 2; 18
Temperature (C) 0; 36 0; 36
Amplitude (%) 30; 70 30; 70
Time (min.) 10; 30 10; 30The speciﬁc surface area was derived from the particle size
distribution data. The assumption was made that all the particles
measured were spherical.
2.2.4. Image analysis
The shape and surface characteristics of the samples were
visualized by using a scanning electron microscope (Hitachi S4700,
Hitachi Scientiﬁc Ltd. Tokyo, Japan). The samples were sputter-
coated with gold–palladium under an argon atmosphere, using a
gold sputter module in a high-vacuum evaporator and the samples
were examined at 15 kV and 10 mA. The air pressure was 1.3–
13 MPa. In suspensions prepared with the most effective param-
eters PVP was washed out and the crystals were dried in order to
obtain solid particles for SEM analyses.
2.2.5. Design of experiments
Six parameters were screened in the static sonication experi-
ments, using a two-level fractional factorial design of resolution III.
Here, the main effects are not confounded with each other,
whereas they are confounded with two-factor interactions. This
design is typically used for the rapid identiﬁcation of the main
effects governing the behavior of a multi-parameter system. High
and low values for each parameter were set on the basis of our
prior experience with similar tasks (reported in Table 1). Dynamic
sonication experiments were run by screening ﬁve parameters,
using the same experimental design type. High and low parameter
values for the dynamic sonication experiments are presented in
Table 1, as well. All the experiments were run as triplicates.
2.2.6. Further investigations of the products
2.2.6.1. X-ray powder diffraction analysis (XRPD). The physical state
of the MEL in the samples was evaluated by XRPD. XRPD patterns
were produced with an X-ray Diffractometer Miniﬂex II (Rigaku Co.
Tokyo, Japan), where the tube anode was Cu with Ka = 1.5405 Å.
The pattern was collected with a tube voltage of 30 kV and a tube
current of 15 mA in step scan mode (4min1). The instrument was
calibrated by using Si.
2.2.6.2. Differential scanning calorimetry (DSC). DSC
measurements were carried out with a Mettler Toledo DSC 821e
thermal analysis system with the STARe thermal analysis program
V9.0 (Mettler Inc. Schwerzenbach, Switzerland). Approximately 2–
5 mg of pure drug or product was examined in the temperature
range between 25 C and 300 C. The heating rate was 5 C min1.
Argon was used as carrier gas at a ﬂow rate of 10 Lh1 during the
DSC investigations.
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spectra were recorded with a Bio-Rad Digilab Division FTS-65A/
896 FTIR spectrometer (Bio-Rad Digilab Division FTS-65A/869,
Philadelphia, USA) between 4000 and 400 cm1, at an optical
resolution of 4 cm1, operating conditions: Harrick’s Meridian
SplitPea single reﬂection, diamond, ATR accessory. Thermo
Scientiﬁc GRAMS/AI Suite software (Thermo Fisher Scienciﬁc
Inc. Waltham, USA) was used for the spectral analysis.
For all of these investigations PVP was washed out and the
crystals were dried.
3. Results and discussion
3.1. Effects of process parameters on particle size distribution
3.1.1. Static sonication
An analysis of the results measured by laser diffraction revealed
that the static sonication under the various sonication parameters
resulted in a roughly 25–70% decrease in average MEL particle size.
The D10, D50 and D90 values are reported in Table 2.
Their relationship with the sonication variables was analyzed
quantitatively on the basis of the D50 data in the main effects plots
(Fig. 3.) and interaction plots (Fig. 4.). The D10 and D90 data
furnished similar results. A main effect plot for a given parameter is
obtained by averaging the results of each run where this parameter
was set to low or to high, and connecting these averages with a line.
If the studied parameters are independent, the plot gives a clear
indication of the response of the system to the selected variable.
The main effects plots for the MEL particle size distribution
indicated that the small sample volume, the high amplitude and
the long sonication time were preferred for efﬁcient particle size
reduction whereas the position of the sonotrode, the concentration
of the solution and the temperature inﬂuenced the particle size
less (Fig. 3.). It can be seen that small sample volume, high
ultrasound amplitude and the long sonication time were preferred
for efﬁcient particle size reduction.
Interaction plots show the effects between variables, which are
not necessarily independent, by showing the means of the
responses for each level of a factor for each level of a second
factor pairwise for all factors involved in the study. The interaction
plots presented in Fig. 4 for D50 can be used to gain insight into the
complex interactions between the sonication parameters. Longer
sonication time resulted in a particle size reduction, independently
of the other process parameters. The connection between the
physical parameters of sonication (amplitude, position and
volume) was unequivocal. The high amplitude resulted in a
particle size decrease independently of the sonotrode position and
sample volume. The connection between concentration, tempera-
ture and amplitude demonstrated that the particle size reduction
effect of the increased amplitude occurred at low concentration
and high temperature. The relationships between temperature and
concentration, and temperature and volume, were unidirectional,Table 2
Results of static sonication (suspension).
Volume (mL) Position of sonotrode Conc (mg/mL) Temp (C) 
– – – – 
25 0.75 2 36 
100 0.75 2 0 
25 0.25 2 0 
100 0.25 2 36 
25 0.75 18 36 
100 0.75 18 0 
25 0.25 18 0 
100 0.25 18 36 in contrast with the temperature position relationship: increase of
the temperature was useful in the lower position. At the high
concentration the upper, while at the low concentration the lower
position resulted in smaller particles.
To summarize the results, the appropriate parameters found for
static sonication were the long time sonication (30 min), the high
amplitude (70%), the small sample volume (25 mL), the high
temperature (36 C), the lower position of the sonotrode (0.75) and
the low MEL concentration (2 mg/mL). In the sample at rest, the
distribution of the sonication effect was inhomogeneous; the
region near the sonotrode (therefore in a small volume) was the
most effective. Because of the large energy input and long
sonication, increased amplitude was required to achieve small
particles. The larger energy investment resulted in increased
cavitation activities. When the temperature was raised, the kinetic
energy of the particles increased, which adverse affected the
cohesive forces. When the low concentration of MEL was used, the
amount of energy per particle was greater.
3.1.2. Dynamic sonication
Analysis of the produced MEL measured by laser diffraction
revealed that the dynamic sonication under the various sonication
parameters resulted in a roughly 15–60% decrease in the average
particle size. The size distribution function is reported in Table 3.
The relationship between the sonication variables were analyzed
quantitatively on the basis of the D50 data in the main effects plots
(Fig. 5.) and interactionplots (Fig. 6). The D10 and D90 data furnished
similar results. The main effects plots for the MEL particle size
distribution indicated that the circulation of the sample at the low
rpm, the high amplitude and the long sonication time resulted in the
most signiﬁcant particle size reduction, whereas the concentration
of the suspension inﬂuenced the particle size less. The high
temperature had a more signiﬁcant effect on the particle size under
dynamic sonication than under static sonication.
The interaction plots presented in Fig. 6. for D50 can be used to
gain insight into the complex interactions between the sonication
parameters. The increased amplitude and the higher temperature
resulted in signiﬁcant particle size reduction. The longer sonication
time had no appreciable effect in the case of the low temperature
and the low amplitude. The increase of the concentration had an
adverse effect on the particle size at the low circulation rate.
As a conclusion, it may be stated that the most effective process
parameters for dynamic sonication were the long sonication time
(30 min.), the high amplitude (70%) and temperature (36 C), the
low rotation rate (50 rpm) and the low concentration of the
samples (2 mg/mL). Due to the continuous circulation of the
samples, the distribution of the sonication effect was homoge-
neous. The cavitation reduced the particle size efﬁciently at the low
circulation rate. The sample was resident in the cavitation space for
a longer period during one sonication cycle. The explanation of the
effects of the other parameters is the same as in the case of the
static method.Amplitude (%) Time (min) D10 (mm) D50 (mm) D90 (mm)
– –
10.82 34.03 75.81
70 30 1.51 10.16 19.53
30 30 4.81 23.07 46.88
70 10 2.75 18.45 42.87
30 10 5.92 26.52 53.39
30 10 3.95 19.62 41.51
70 10 5.19 24.16 46.98
30 30 3.53 17.12 29.22
70 30 7.19 20.83 36.62
Fig. 3. The main effect plots for the case of static sonication.
Fig. 4. Interaction plots of the main effects for the static sonication.
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The particle size distribution of MEL (Fig. 7) was determined in
the suspensions after sonications. During the dynamic sonicationTable 3
Results of dynamic sonication (suspension).
Pump (rpm) Conc (mg/mL) Temp (C) Amplitude (%) 
– – – – 
50 2 36 70 
50 2 0 30 
100 2 0 70 
100 2 36 30 
50 18 36 30 
50 18 0 70 
100 18 0 30 
100 18 36 70 the sample is circulated continuously by a pump, which ensures
the homogeneous sonication effect. In case of the static sonication
a sample at rest is sonicated, so the cavitation effect distribution
can be inhomogeneous. The raw MEL had a broad size distribution.Time (min) D10 (mm) D50 (mm) D90 (mm)
–
10.82 34.03 75.81
30 2.20 14.60 35.02
30 4.56 24.22 47.05
10 5.70 26.90 51.92
10 5.90 26.15 52.20
10 4.40 22.69 53.54
10 6.27 23.54 46.77
30 9.06 29.31 45.58
30 2.87 16.73 38.03
Fig. 5. The main effect plots for the case of dynamic sonication.
Fig. 6. Interaction plots for the dynamic sonication.
Fig. 7. Particle size distribution of raw MEL and sonicated MEL from suspensions.
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Table 4
The speciﬁc surface area and size distribution of the raw MEL and the two suspensions from sonication.
Speciﬁc surface area (m2/g) D10 (mm) D50 (mm) D90 (mm)
raw MEL 0.340 10.82 34.03 75.81
Static sonicated sample (suspension) 2.040 1.51 10.16 19.53
Dynamic sonicated sample (suspension) 1.140 2.20 14.60 35.02
32 C. Bartos et al. / Chemical Engineering and Processing 87 (2015) 26–34The sonication methods resulted in decreased particles size. The
speciﬁc surface area of the MEL increased as a consequence of
acoustic cavitation in both sonication methods and for both
suspensions relative to the raw MEL. The static sonication
produced smaller particle sizes compared to the dynamic
sonication (Table 4).
3.3. Characterization of the dried products
3.3.1. Particle shape and size
The SEM images (Fig. 8) provided an indication of the
morphology of the modiﬁed particles. PVP was washed out to
check how the surface and shape changed after the sonications
compare with raw MEL. The crystal habit of the pure MEL has
changed signiﬁcantly after the procedure. The raw MEL consisted
mainly of angular, prismatic crystals with a broad size distribution.
The crystal lattice presumably demonstrated defects and cracks.
Along them the crystals disintegrated due to the energy input of
acoustic cavitation. Probably this factor is responsible for the
presence of the broken pieces, which are found on the surface of
the larger particles. The drying of the samples could also cause
cracks and widen the PSD. The endurance during the treatment is
accounted for the roundness and smooth surfaces of the crystals.
The yields of the samples were 95% at 0 C and 90% at 36 C by both
methods. The average size of the dried product was approximately
10 mm in the case of static and 15 mm in the case of dynamic
sonication. Due to the high speciﬁc surface area of the dried
product and since PVP is washed out, agglomeration might occur.
Furthermore, aging or washing might also change the crystal size
and shape.Fig. 8. SEM pictures of raw MEL (A) and the dried products after static (B) an3.3.2. X-ray diffraction
The XRPD pattern of pure MEL demonstrated its crystalline
structure, as expected. The raw MEL and the sonicated dried MEL
composite in both cases displayed the same X-ray diffraction
patterns (see supporting information, Fig. S1.). This means that the
crystalline form of the micronized MEL was not changed by the
sonication and drying procedure.
3.3.3. Differential scanning calorimetry (DSC)
DSC was employed to investigate the crystallinity and the
melting of MEL in the pure form and in the sonicated dried
products. The DSC curve (Fig. 9) of the raw MEL revealed a sharp
endothermic peak at 259.11 C, reﬂecting its melting point and
conﬁrming its crystalline structure. After drying, the DSC curves
exhibited the sharp endothermic peak of the MEL at 258.62 C in
the static case, and at 259.81 C in the dynamic case, indicating that
the crystallinity of the drug was retained. The value of the enthalpy
and the onset-endset interval were not changed signiﬁcantly for
the sonicated products as compared with the values for raw MEL,
and it can therefore be concluded, that the degree of crystallinity
was not decreased by the treatment.
3.3.4. Chemical stability
To determine whether any decomposition occurred during the
sonication process, FT-IR spectroscopy was carried out. This proved
that no disintegration took place in the samples (Fig. 10). Also the
contamination of solution with titanium particles by the cavita-
tional erosion could not be detected. The applied energy did not
cause chemical changes in the MEL in aqueous medium during
sonication (30 min) at 36 C. The characteristic bands of MEL wered dynamic (C) sonication after 30 min treatment (PVP was washed out).
Fig. 9. DSC curves of the raw MEL and the dried sonicated products.
Fig. 10. FT-IR curves of raw MEL and dried sonicated products.
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3289.76, 1550.04, 1530.36, 1346.73, 1265.88 and 1184.90 cm1,
denoting the stretching vibration of -NH, the thiazole ring
(together with that at 1184.90 cm1), the amide II band of–CO–
NH–C, the asymmetric stretching vibration of the sulfone and the
amide III band of–CO–NH–C, respectively.
4. Conclusions
Acoustic cavitation, as a wet-grinding procedure, can be applied
to decrease the particle size and change the crystal morphology of
drugs. High-intensity ultrasound equipment is easy to clean
because of the few moving parts. The parameters can be set
precisely and reproduced. Sonication in aqueous medium adheres
to green technology: the product does not contain organic solvent
residues.
This study applied a two-level factorial design plan to compare
the process parameters of static and dynamic sonication methods
based on their particle size reduction effects. A long sonication, a
high amplitude, a high temperature and a low concentration of
MEL proved to play important roles in the sonication procedures.
Both of these disintegration methods with adequate process
parameters involving a change in crystal habit, may decrease the
particle size of MEL signiﬁcantly in the presence of PVP as additive.
The investigation of the dried products showed that in both
cases the crystallinity of the MEL was retained during the
sonication and the process did not cause chemical degradation.
The static method is applicable for the preparation of preclinical
samples with a reduced particle size of the drug candidate, for
which a small sample volume is sufﬁcient.
Dynamic sonication is suitable for preformulation of a micro-
suspension, because a larger volume of sample can be used in this
method. Standardization is possible, which is important for
industry.
These two methods are also appropriate for particle size
reduction of materials with different physico-chemical properties,
applying a short-term energy input, and for the production of
intermediate (in suspension form) and (after drying) dried
products for additional pharmaceutical formulations.
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1. Bevezetés
A nedves őrlés jól ismert eljárás különböző ható-
anyagok pre-szuszpenziójának előállítására, ame-
lyek közti termékként felhasználhatók gyógyszer-
forma előállítására (kapszula, tabletta, injekció, 
orrspray, orrgél stb.) [1]. Mint ismeretes, a nedves 
őrlés a száraz őrléshez képest kevesebb energiát és 
időt vesz igénybe. A zárt rendszer miatt nincs ki-
porzás, továbbá csökken az anyag felmelegedése is 
[2]. Nedves őrlés golyós malmok, kolloid malmok 
és kavitáción alapuló eljárások segítségével való-
sítható meg.
Az ultrahangos szonotróddal generált kavi-
táción alapuló homogenizálás széles körben hasz-
nált a gyógyszertechnológia területén [3]. Alkal-
mazható emulziók [4], szuszpenziók [5] előállításá-
ra, valamint kristályosításnál alkalmas a szemcse-
méret csökkentésére (bottom up- integráló eljárás) 
[6]. A szónikus kavitáción alapuló ultrahangos 
nedves őrlés, mint dezintegráló művelet (top 
down) új irányvonalként jelenik meg ebben a té-
mában. Az akusztikus kavitáció fizikai jelenség, 
amely akkor következik be, amikor az ultrahang 
hullámok által keltett buborékok, üregek összerop-
pannak, az egymásnak csattanó folyadékfelületek 
lökéshullámot keltenek, ami rezgéssel és a környe-
ző szilárd testek eróziójával jár [7]. A méretcsök-
kentés – dezintegráció révén – a kavitáció eredmé-
nye; az általa generált nagy nyíróerő képes szétsza-
kítani a részecskéket, legyőzve az azokat összetartó 
erőket. A részecskék elsősorban a rácshibák, repe-
dések mentén dezintegrálódnak [8].  Szemcseméret 
csökkentésre az ultrahangos energiát 20-100 kHz 
közötti frekvencia tartományban alkalmazzák [9]. 
A statikus szonikáció esetében a nyugalomban 
lévő mintát ultrahangozzuk, így a kavitáció hatása 
Summary
Bartos,  Cs. ,  Ambrus,  R. ,  Szabó-Révész,  P.: Particle 
size reduction using acoustic cavitation
Different pharmaceutical technological processes have been used 
for modification of the physico-chemical and biopharmaceutical 
properties of drugs. Changes of crystal size, distribution and mor-
phology can open up new, alternative administration routes, e.g. 
intranasally and the pulmonary route, where the particle size is a 
determining factor. A wet grinding method based on acoustic cav-
itation (the collapse of bubbles or voids formed by sound waves) 
is a novel possibility for modification of the properties of particles. 
During our work this wet grinding technique was studied. The 
effect of this method was investigated on particle size reduction. 
The samples were treated with extreme sonication parameters. 
The effect of the concentration of the polymer was examined on the 
particle size reduction. Meloxicam was chosen as a model crystal-
line drug because of its poor aqueous solubility. The structural 
characterization and the morphological analysis of the dried prod-
ucts were carried out by DSC, XRPD and SEM. It was found that 
the acoustic cavitation resulted in crystalline micronized product.
Keywords: meloxicam, particle size reduction, acoustic cavita-
tion, extreme sonication parameters
Összefoglaló
A hatóanyagok fizikai-kémiai és biofarmáciai sajátságainak vál-
toztatására számos gyógyszertechnológiai megoldás ismeretes. A 
részecskeméret csökkentés és a morfológia módosítása egy ható-
anyag esetében új, alternatív beviteli kapukat nyithat meg, mint 
pl. a nazális vagy a pulmonáris bevitelt. Ilyen gyógyszerformák 
esetében a szemcseméret, szemcseméret megoszlás meghatáro-
zó paraméter. A szónikus kavitáción alapuló őrlés új lehetőséget 
nyújt a hatóanyagszemcsék sajátságainak megváltoztatására. 
Munkánk során akusztikus kavitáción alapuló ultrahangos ned-
ves őrlést alkalmaztunk szemcseméret csökkentés céljából. Adott 
szonikációs paraméterek mellett az alkalmazott polimer koncent-
rációjának hatását vizsgáltuk a szemcseméret csökkentésre. Mo-
dellanyagként meloxikámot, mint rossz vízoldékonyságú, nem 
szteroid gyulladásgátlót alkalmaztunk. A szilárd fázis kinyerését 
követően vizsgáltuk a termékek fizikai-kémiai és morfológiai sa-
játságait (DSC, XRPD, SEM). Megállapítottuk, hogy kristályos 
szerkezetű, mikronizált hatóanyagot tartalmazó termék állítható 
elő.
Kulcsszavak: meloxikám, szemcseméret csökkentés, akusztikus 
kavitáció, szélsőséges szonikációs paraméterek
1 A szerzők a cikket Kata Mihály emeritus professzornak 
ajánlják 80. születésnapja alkalmából, tiszteletük jeléül.
2 Acta Pharmaceutica Hungarica 2014/4.
a szo no tródtól távolodva 
csökken (a rendszerre nézve 
inhomogén).
Az ultrahangos folyadék-
kezelést számos paraméter 
befolyásolja (amplitúdó, nyo-
más, hőmérséklet, a kezelen-
dő mintában lévő komponen-
sek koncentrációja). A szoni-
kálás hatékonysága az egy-
ségnyi térfogatra (V) jutó 
energiamennyiség (E) függ-
vénnyel (f) fejezhető ki:
hatás = f (E/V),
ahol az energia (E) a teljesítményből (P) és a keze-
lés időtartamából (t) tevődik össze:
E[J] = P[W] * t[s]
A függvény az egyes paraméterek változtatásával 
módosul [10].
Jelen kísérletes munka előzményeként ultra-
hangos nedves őrlést alkalmaztunk. Faktoriális kí-
sérleti tervet készítettünk és meghatároztuk az el-
járási paramétereket. Az optimalizálás a termék 
szemcseméretére történt [11]. Munkánk során az 
optimalizált paraméterekhez képest olyan „szélső-
séges” paramétereket alkalmazva készítettünk 
mintákat, amelyekkel tovább kívántuk csökkente-
ni a szemcseméretet. Modellanyagként rossz víz-
oldékonyságú hatóanyagot, a meloxikámot (MEL) 
választottuk. Célunk volt annak vizsgálata, hogy 
az így előállított termékben a MEL szemcseméret 
csökkenthetőségén kívül, a kavitáció milyen válto-
zásokat idéz elő a termék fizikai-kémiai és morfo-
lógiai sajátságaiban.
2. Anyagok és termék előállítása ultrahangos 
technikával
Anyagok
Felhasznált anyagok: meloxikám (MEL) – EGIS 
Gyógyszergyár (Budapest, Magyarország); PVP 
K-25 (PVP) (polivinilpirrolidon) – ISP Customer 
Service GmBH (Köln, Németország).
Szemcseméret-csökkentés  ultrahangos eljárás 
alkalmazásával
A MEL szemcseméretét nagy intenzitású ultra-
hanggal (Hielscher UP 200S, 200W, Németország), 
statikus szonikációval csökkentettük. A korábban 
optimalizált paraméterekhez képest (70%-os amp-
litúdó, 36 ºC, 30 perc) „szélsőséges” paramétereket 
alkalmaztunk. A mintákat 90%-os amplitúdóval, 
50 ºC-on (Julabo, Németország), 60 percen át ultra-
hangoztuk, a szonotród minden minta esetében a 
teljes folyadéktest 75%-áig merült a rendszerbe (1. 
ábra). A MEL koncentrációja 20 mg/10 ml volt. Az 
eljárás során minden minta esetében diszperziós 
közegként 25 ml térfogatú, különböző koncentrá-
ciójú PVP K-25-oldatot (0,1, 0,5 és 2,0%) alkalmaz-
tunk. A PVP, mint polimer a gyógyszeriparban is 
széles körben alkalmazott diszpergálószer. A MEL 
karboxil-csoportja és a PVP között kialakuló gyen-
ge másodlagos kötés segít egymástól távol tartani 
a hatóanyag-részecskéket csökkentve ezzel az 
aggregáció veszélyét [12].
3. Vizsgálati módszerek
3.1 Szemcseméret megoszlás, morfológia
A MEL szemcseméretét és méreteloszlását 
Malvern Mastersizer 2000 készülékkel (Malvern 
Inst ruments, Worcestershire, UK) határoztuk 
meg, Hydro 2000 SM kis térfogatú diszpergáló 
egységgel. A D0,1, D0,5, D0,9 értékeket térfogat 
szerinti méretanalízissel határoztuk meg.
A kiindulási hatóanyag és a szilárd minta mor-
fológiai jellemzése pásztázó elektronmikroszkóp-
pal történt (Hitachi S4700, Hitachi Scientific Ltd., 
Japan). A minta töltődésének megakadályozása 
céljából arany-palládium bevonó anyagot használ-
tunk, 18 mA plazmaáram alkalmazásával.  A fel-
vételek 15 kV nagyfeszültség, 10 µA elektronáram 
és 0,1 Pa élővákuum beállításával készültek.
1. ábra: Az ultrahangos homogenizálás sematikus ábrája
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3.2 Szerkezeti sajátságok
A termékek termoanalitikai 
sajátságait Mettler Toledo 
stAr® termoanalitikai ké-
szülékkel (Mettler Inc., 
Schwer zenbach, Svájc) hatá-
roztuk meg. A DSC (differen-
ciál pásztázó kalorimetria) 
méréseket argon gáz átára-
moltatásával (10l/óra) végez-
tük (2-5 mg-os minta, 25-300 
ºC, 5 ºC/perc fűtési sebesség).
A hatóanyag kristályos jel-
legét porröntgen diffrakciós 
vizsgálatokkal határoztuk 
meg (Miniflex II Rigaku por-
röntgen diffraktométer, Rigaku Co. Tokyo, Japan). 
Mérési paraméterek: Cu (Kα=1,5405 Å), 30 kV, 15 
mA.
4. Eredmények értékelése
4.1 MEL szemcseméret csökkentése különböző PVP-
koncentráció mellett
A minták szemcseméret megoszlását ultrahango-
zott pre-diszperzióban határoztuk meg. Az ered-
mények az 1. táblázatban láthatók, amelyek alap-
ján elmondható, hogy a kiindulási mérethez ké-
pest mindhárom minta esetében jelentős mérték-
ben lecsökkent a MEL szemcsemérete. Mivel a 
PVP mennyisége nem befolyásolta lényegesen a 
szemcseméret-megoszlást, egymáshoz viszonyítva 
a három termékben, ezért a legkisebb PVP-tar-
talmú mintát vizsgáltuk tovább. Az alacsony se-
gédanyag-koncentráció mellett végzett mikroni-
zálás mind gazdasági, mind citotoxicitás szem-
pontjából is előnyösebb.
4.2 Szilárd fázisú termék jellemzése
A 0,1% PVP-tartalmú szuszpenzióból (UH MEL/
PvP0,1) 40 ºC-on vákuum szárítóban távolítottuk el 
a vizet (Binder, Németország) abból a célból, hogy 
szilárd fázisú terméket nyerjünk. A szárítást köve-
tően a termék fizikai-kémiai sajátságait vizsgáltuk 
és annak fizikai keverékével (MEL-PVP PM) ha-
sonlítottuk össze. A kezelt minta hőmérséklete 
szonikálás során 53 ºC-ig emelkedett, tehát hő ha-
tására bomlás nem következett be.
DSC felvételek
A kezeletlen MEL-nek 259,27 ºC-on jól definiálható 
olvadáspontja van. A PVP amorf sajátságú segéd-
anyag, olvadásponttal nem rendelkezik. A MEL-
PVP fizikai keverékében és a szilárd fázisú minta 
görbéjén is megfigyelhető a hatóanyag kristályok 
olvadáspontja, amivel a MEL kezelés és szárítás 
utáni kristályos jellegét bizonyítottuk (2. ábra). A 
fizikai keverék esetében az olvadáspont-csökkenés 
annak köszönhető, hogy a PVP az üvegesedési hő-
mérsékletén (Tg = 34 ºC ) meglágyul, ennek követ-
keztében a MEL olvadása alacsonyabb hőmérsék-
leten következik be (242 ºC). A kezelt, szárított 
mintában megfigyelhető további olvadáspont-
csökkenés (236 ºC) azzal magyarázható, hogy a ki-
sebb kristályok megolvadásához kevesebb energi-
ára van szükség.
XRPD eredmények
A porröntgen-diffrakciós eredmények ugyan-
csak a minta kristályos jellegét bizonyítják. A ka-
1. táblázat 
Szonikált termékek szemcseméret-megoszlása különböző PVP-koncentráció mellett
PVP-oldat (%) D0,1 D0,5 D0,9
MELkiindulási - 10,82 34,03 75,81
UH MEL/PVP0,1 0,1 0,16 3,08 16,80
UH MEL/PVP0,5 0,5 0,14 2,79 19,09
UH MEL/PVP2,0 2,0 0,28 3,93 12,91
2. ábra: A MEL PVP-vel alkotott fizikai keverékének (MEL-PVP PM) és a 0,1% PVP-
tartalmú szuszpenzióból nyert szilárd fázisú termék (UH MEL/PVP0,1) DSC görbéje
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rakterisztikus csúcsok a fizikai keverék és a szi-
lárd fázisú minta esetében is megjelennek. A 
MEL-re jellemző csúcsok 13,22, 15,06, 26,46 és 
26,67 2θ értékeknél olvashatók le (3. ábra). Mivel 
a fizikai keverék és a termék jellemző csúcsai 
egybeesnek – azon túl, hogy a MEL kristályos 
maradt – az is megállapítható, hogy polimorf 
módosulat a kezelés hatására nem keletkezett. A 
szonikációval előállított mintában a csúcsok in-
tenzitása kisebb a fizikai keverékben található 
MEL csúcsaihoz képest, ami a méretcsökkenés-
sel magyarázható.
Elektronmikroszkópos felvételek
Az elektronmikroszkópos képek alapján látha-
tó, hogy a kiindulási MEL kristályai nagy, oszlo-
pos kristályok. A szilárd fá-
zisú termék hatóanyag kris-
tályai szabálytalan alakú-
ak, egyenetlen felszínűek. 
A MEL kristályok a felvéte-
leken is látható, nagymére-
tű, amorf PVP-részecskék 
között detektálhatók (4. 
ábra).
5. Összegzés
Közleményünk összefogla-
lót adott a kavitáció jelensé-
géről, az ultrahangos ned-
ves őrléses eljárásról. Mun-
kánk során statikus szo-
nikációt alkalmaztunk a 
MEL szemcseméretének 
csökkentése céljából, s vizsgáltuk a különböző 
PVP-koncent rá ció szemcseméretre gyakorolt ha-
tását. Megállapítottuk, hogy az alkalmazott eljá-
rási paraméterekkel (90%-os amplitúdó, 50 ºC, 60 
perc, 75% szo notród pozíció) mikronizált MEL-t 
tartalmazó pre-szuszpenzió állítható elő, amely 
alkalmas közvetlenül szuszpenziós orrspray és 
orrgél fejlesztésére. A 0,1% PVP-t tartalmazó 
minták szárítását követően, fizikai-kémiai vizs-
gálatokat végeztünk. Megállapítottuk, hogy kris-
tályos szerkezetű, mikronizált hatóanyagot tar-
talmazó termék állítható elő. Terveink között sze-
repel nátrium-hialu ronát, mint mukoadhezív se-
gédanyag, továbbá Cremophor RH 40, illetve 
kitozán, mint perme abilitást fokozó segédanya-
gok alkalmazásával nazális gyógyszerforma fej-
lesztése.
3. ábra: A MEL PVP-vel alkotott fizikai keverékének (MEL-PVP PM) és a 0,1% PVP-
tartalmú szuszpenzióból nyert szilárd fázisú termék (UH MEL/PVP0,1) porröntgen 
felvétele
4. ábra: A kiindulási MEL és a 0,1% PVP-tartalmú szuszpenzióból nyert szilárd fázisú termék (UH MEL/PVP0,1)  
elektronmikroszkópos felvétele
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Abstract 
This article reports on particle engineering by a top-down method involving the 
organic solvent-free acoustic cavitation of ibuprofen (IBU). The process parameters 
(temperature, amplitude, sonication period and stabilizers) were optimized. The particle 
size distribution of IBU was measured after sonication and compared with the raw IBU (D 
0.5=153 µm). Due to acoustic cavitation, the particle size decreased (D 0.5=25 µm), but the 
use of a stabilizer was needed for further decrease (D 0.5=11 µm). Samples sonicated with 
optimized process parameters, containing the most efficient stabilizer, were dried, their 
morphology was characterized by scanning electron microscopy and the structure was 
determined by differential scanning calorimetery and X-ray powder diffraction (XRPD). 
During the thermoanalytical and XRPD characterization, the crystalline structure of IBU 
was detected after the sonication procedure. 
 
Rezumat 
Prezentul articol se încadreazǎ în domeniul ingineriei particulelor prezentând o 
metodǎ de cavitare acusticǎ fǎrǎ solvent organic a ibuprofenului (IBU). Parametrii 
procedeului (temperaturǎ, amplitudine, timp de sonicare şi stabilizatori) au fost optimizaţi. 
Dupǎ sonicare s-a mǎsurat distribuţia mǎrimii particulelor de IBU. Datoritǎ cavitǎrii 
acustice, dimensiunea particulelor a scǎzut (D = 0.5=25 µm), dar a fost necesarǎ utilizarea 
unui stabilizator pentru o scǎdere mai pronunţatǎ (D 0.5=11 µm). Probele sonicate, cu 
parametrii de proces optimizaţi, conţinând cel mai eficient stabilizator, au fost uscate şi 
caracterizate morfologic prin microscopie de scanare electronicǎ, precum şi structural, prin 
calorimetrie de scanare diferenţialǎ şi difracţie de raze X (XRPD). În timpul analizei 
termice şi XRPD, structura cristalinǎ a IBU a fost identificatǎ dupǎ sonicare. 
 
Keywords: Acoustic cavitation, Particle engineering, Particle size reduction 
 
Introduction 
 Particle engineering techniques have been developed to produce 
drug particles with modified physico-chemical and biopharmaceutical 
properties. Different procedures are employed in order to optimize the habit 
of the particles [17, 15, 21]. The procedures involve either particle size 
reduction of larger crystals (top-down approach - disintegration) or the 
building-up of particles (bottom-up approach-integration) [4, 5, 3, 2]. 
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Energy input may be important for the particle size reduction of 
active substances, and is possible by cavitation [20]. Cavitation is the 
formation and immediate implosion of cavities in a liquid. Cavitation is 
usually divided into two classes: inertial and non-inertial cavitation. Inertial 
cavitation is the process where a void or bubble in a liquid rapidly collapses, 
producing a shock wave. Non-inertial cavitation is the process in which a 
bubble in a fluid is forced to oscillate in size or shape due to some form of 
energy input. In pharmaceutical technology, hydrodynamic (high-pressure 
homogenization) and acoustic (power ultrasound) cavitation, are generally 
used, which are of non-inertial cavitation type. Acoustic cavitation, a novel 
possibility to decrease particle size [2, 8, 22], has the ability to erode and 
break down particles [13]. Particle engineering uses ultrasound power in the 
frequency range 20-100 kHz to induce particle size reduction [23]. 
 Power ultrasound is used for the processing of liquids, e. g. mixing, 
emulsifying, dispersing and de-agglomeration or milling. During sonication, 
the sound waves that propagate into the liquid media result in alternating 
high-pressure and low-pressure cycles, with rates depending on the 
frequency. During the low-pressure cycle, high-intensity ultrasonic waves 
create small vacuum bubbles or voids in the liquid. If the acoustic intensity 
is sufficiently high, the bubbles will first grow in size and then rapidly 
collapse during a high-pressure cycle. This phenomenon is termed 
ultrasonic cavitation [24]. Ultrasonic liquid processing is described by a 
number of parameters (amplitude, pressure, temperature and concentrations 
of compounds). The effect of the process may be determined as a function 
of the energy per processed volume: 
 
effect = f (E/V) 
where the energy (E) is the product of the power output (P) and the duration 
of exposure (t): 
E[Ws] = P[W] * t[s] 
  The function alters with changes in the individual parameters. 
Additionally, the actual power output per surface area of the sonotrode of an 
ultrasonic unit depends on the parameters [10]. 
Ibuprofen is a non-steroidal anti-inflammatory drug, which is often 
used for the relief of symptoms of arthritis or fever, and as an analgesic [26, 
16]. We chose IBU as a model crystalline drug because of its large particle 
size (D 0.5=153.73 µm) and low melting point (approximately 75 °C) [12]. 
Formulation of the IBU-β-cyclodextrin complex [6] and amorphization of 
this drug are known as feasible ways to increase its solubility [25]. The 
rapid expansion of supercritical solutions (supercritical fluid technology) 
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[11, 19], melt emulsification [14] and the solvent diffusion method [12] are 
well known to decrease the particle size of IBU through use of an organic 
solvent, but the residual organic solvent may be a problem in the 
pharmaceutical formulation. 
 In the present work, the use of acoustic cavitation, as a novel organic 
solvent-free, static wet grinding technique in pharmaceutical technology is 
reported. The aims of our work were to reduce the particle size of IBU to 
the micrometer range by using power ultrasound, with optimization of the 
process parameters (temperature, amplitude and sonication period) and 
excipients, and to study the effects of power ultrasound on the physico-
chemical properties of IBU. 
 
Materials and Methods 
 
Materials 
IBU 2-[4-(2-methylpropyl)phenyl]propanoic acid, was purchased 
from Aldrich Chemie, Deisenhofen, Germany; PVP K-25 
(polyvinylpyrrolidone) was purchased from ISP Customer Service GmBH, 
Köln, Germany; Poloxamer 188 (polyethylene-polypropylene-glycol) was 
from BASF, Ludwigshafen, Germany; Tween 80 (Polysorbat 80; 
polyoxyethylenesorbitan-monooleate) was from Hungaropharma, Budapest, 
Hungary; and Solutol HS 15 (polyethylene glycol 15-hydroxystearate) was 
from BASF, Ludwigshafen, Germany. 
 
Methods  
Optimization of process parameters 
A power ultrasound device (Hielscher UP 200S Ultrasonic processor 
with 200 W, Germany) was applied for energy input in the sample 
preparation. The samples (suspensions containing 300 mg of pure IBU in 30 
mL of water) were sonicated at room temperature without cooling (the 
initial suspension temperature was 25°C ) and using an ice bath with 
standardized temperature at around 18°C (the initial suspension temperature 
was 18°C, the temperature of the cooling water was monitored 
continuously). A range of ultrasonic amplitudes (30%, 50% and 70%) were 
tested in order to determine the optimum amplitude via a 200 W model 
ultrasound device for 10, 20 or 30 min during the procedures (Table I) 
(Figure 1). 
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Table I 
Parameters applied during sonication 
Temperature (°C) room temperature, ice cooling 
Amplitude (%) 30, 50, 70 
Time (min) 10, 20, 30 
 
 
 
Figure 1 
Scheme of preparation 
 
Effects of stabilizers on particle size distribution 
During the content optimization, different additives were applied: 
PVP K-25, Poloxamer 188, Tween 80 and Solutol HS 15. PVP K-25 is a 
stabilizer, Poloxamer 188 is a non-ionic surfactant, Tween 80 is an 
emulsifier and solubilizer, and Solutol HS 15 is a non-ionic solubilizer. 
These may promote particle size reduction and prevent agglomeration by 
stabilizing the particles against inter-particle forces [9, 8]. When the 
influence of these stabilizers was investigated, the stabilizer was dissolved 
in water and a fixed concentration of IBU was suspended in an aqueous 
solution of the excipient. The effects of the concentration of IBU (1 and 
0.25 m/v %) on the particle size decrease were also studied (Table II). The 
concentrations of the stabilizers were determined as in previous studies: 0.5 
and 0.25 m/v % of excipients were tested [12]. 
Table II 
Applied additives, concentration of IBU and additives 
Additives PVP K-25, Poloxamer 188, Tween 80, Solutol HS 15 
Concentration (m/v %) 1, 0.25 (IBU) 
0.5, 0.25 (additive) 
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Preparation of solid products 
Suspensions prepared with the optimized parameters with efficient 
stabilizer were dried in a static bed dryer (Memmert, Germany) at 50 °C  in 
order to obtain solid products. 50 °C was chosen because of the low melting 
point of IBU, which could fuse at higher temperature. The yield of IBU was 
approximately 90%. After drying, the physico-chemical properties of the 
products were investigated. 
 
Particle size distribution and morphology 
The volume particle size distribution of raw IBU was measured by 
laser diffraction (Mastersizer 2000, Malvern Instruments Ltd, 
Worcestershire, UK) with the following parameters: 300RF lens; small 
volume dispersion unit (3000 rpm); refractive index for dispersed particles 
1.4364; refractive index for dispersion medium 1.330. Water was used as 
dispersant and the obscuration was in the range 11-16% for each 
measurement. The IBU particle size was determined immediately on the 
initial water suspension. After drying, the solid product was resuspended in 
water using an ultrasonic bath for 5 min. Water was applied as dispersion 
phase, in which the additives were dissolved, and therefore only IBU 
particles could be detected. In all cases the average size volume distribution, 
D 0.1, D 0.5, and D 0.9 were determined and evaluated. 
The shape and surface characteristics of the various samples were 
visualized by using a scanning electron microscope (Hitachi S4700, Hitachi 
Scientific Ltd., Tokyo, Japan). Briefly, the samples were sputter-coated with 
gold–palladium under an argon atmosphere, using a gold sputter module in 
a high-vacuum evaporator and the samples were examined at 15 kV and 10 
µA. The air pressure was 1.3-13.0 mPa. 
 
Structural analysis 
DSC measurements were carried out with a Mettler Toledo DSC 821e 
thermal analysis system with the STARe thermal analysis program V9.0 
(Mettler Inc., Schwerzenbach, Switzerland). Approximately 2-5 mg of pure 
drug or product was examined in the temperature range between 25 °C and 
300 °C. The heating rate was 5 °C min-1. Argon was used as carrier gas at a 
flow rate of 10 L h-1 during the DSC investigations. 
The physical state of IBU in the samples was evaluated by X-ray 
powder diffraction (XRPD). XRPD patterns were produced with an X-ray 
Diffractometer Miniflex II (Rigaku Co. Tokyo, Japan), where the tube 
anode was Cu with Kα = 1.5405 Ǻ. The pattern was collected with a tube 
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voltage of 30 kV and a tube current of 15 mA in step scan mode (4° min-1). 
The instrument was calibrated by using Si. 
 
Results and Discussion 
 
Effects of process parameters on particle size distribution  
During the procedure, the experimental parameters were first 
investigated. The amplitude, temperature and sonication time were varied 
(Table III). In the starting suspensions, the concentration of IBU (with an 
average particle size of about 154 µm) was 300 mg in 30 mL of water. For 
each sample, three parallel measurements were performed to check the 
reproducibility. 
 At room temperature, the application of an amplitude of 30, 50 or 
70% resulted in a 50% decrease in the average IBU particle size. During the 
procedure, the temperature of the suspension increased from 25 °C to 77-
85 °C. We presumed that some of the invested energy was transformed to 
heat, and the D 0.9 value was therefore increased by amplitudes of 30 and 
50% (Sample 1 and Sample 2) relative to raw IBU (Figure 2 on the left). 
The reason for these phenomena is the melting of IBU, due to the 
temperature of the system increasing to above the melting point of IBU 
(75°C). After the impaction, therefore, the sample presented large 
precipitated IBU crystals.  
For Samples 4-6, continuous ice cooling (Tcooling water = 18 °C) was 
applied. After the procedure, the temperature of the suspension was 
decreased to approximately 35 °C, which prevented the melting of IBU. 
Furthermore, the cohesive forces (which promote the aggregation of the 
particles) were lower at low temperature, and this helped achieve smaller 
particles.  Sonication with an amplitude of 30% caused a further 50% 
decrease in the average particle size. The smallest particles were produced 
by the application of an amplitude of 70%, with the largest energy 
investment, on use of an ice bath (Sample 6).  
Increase of the amplitude of sonication did not cause a significant 
alteration in the temperatures of the suspensions relative to one another at 
18 °C on ice cooling. Increasing of the duration of sonication to 20 min 
resulted in a lower size reduction than with a combination of increased 
amplitude and cooling (Figure 2). No difference in particle size was 
observed when the sonication time was increased from 20 min to 30 min. A 
sonication time of 20 min was therefore, considered to be optimum (Sample 
7 and Sample 8). 
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Consequently, the increased amplitude-due to the largest energy 
investment and decreased temperature-due to lower cohesive forces and less 
energy-transformation to heat-jointly resulted in the most effective particle 
size reduction; the best combination was sonication with an amplitude of 
70% for 20 min with ice cooling, which resulted in an average IBU particle 
size of more than 25 µm because of grinding resistance (Figure 2). 
The use of a lower concentration of active substance might be 
predicted to yield a smaller particle size after the sonication, energy is 
directed to less material and the cohesive forces are weaker. Decrease of the 
concentration of IBU (0.25 m/v%) did not cause a further particle size 
reduction (Sample 9) as compared with the results at a higher concentration 
of IBU (Figure 2), which allows formulation with a larger quantity of active 
substance. 
 
Table III 
Effects of acoustic cavitation on particle size distribution at different parameters 
 
Batch 
code 
Investi-
gated 
factor 
Amp-
litude 
% 
Starting 
temperature of 
suspension 
(°C) 
Temperature of 
suspension after 
sonication 
(°C) 
Time 
(min) 
Conc. of 
IBU 
(mg/30 
mL 
water) 
Particle size 
distribution 
(µm) 
 
D 0.5 
Raw IBU  ------- ------- ------- ------- -------  153.73  
Sample 1 
Amp. 
30 25 77.7 10 300  85.16±9.14  
Sample 2 50 25 73.7 10 300  85.35±3.85  
Sample 3 70 25 85.0 10 300  84.49±1.63  
Sample 4 
Temp. 
30 18 32.3 10 300  39.44±2.10  
Sample 5 50 18 34.5 10 300  31.92±2.63  
Sample 6 70 18 40.0 10 300  28.19±2.30  
Sample 6 
Time 
70 18 40.0 10 300  28.19±2.30  
Sample 7 70 18 40.0 20 300  25.78±2.20  
Sample 8 70 18 37.6 30 300  24.88±2.87  
Sample 7 
Conc. 
70 18 40.0 20 300  25.78±2.20  
Sample 9 70 18 37.8 20 75  22.24±5.82  
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Figure 2 
Particle size distribution of IBU after sonication under different conditions 
(Samples 1-9) 
 
Effect of stabilizers 
The choice of stabilizer is specific for each drug candidate and each 
formulation procedure. The stabilizer should exhibit sufficient affinity for 
the particle surface in order to stabilize the suspension. When the influence 
of different stabilizers was investigated, the suspensions were prepared with 
a fixed concentration of the drug and optimized parameters (see Sample 7). 
The type of compound employed for stabilization has a pronounced effect 
on the particle size and distribution (Table IV). Four different stabilizers 
were tested to check the effect of the nature of the surfactant on the IBU 
particle size. Micronized drugs have a tendency to agglomerate as a result of 
their hydrophobicity, thus reducing their available surface area [8, 1]. One 
of the most common methods to reduce the tendency to drug agglomeration 
is a steric technique. Steric stabilization is achieved by adsorbing polymers 
onto the drug particle surface [9], forming a protective layer on the surface 
of the particles and overcoming the cohesive forces. Solutol was least 
effective, followed by PVP and Tween 80. The smallest particle size was 
achieved with Poloxamer: the average size was approximately 11 µm. When 
Poloxamer was used, this stabilizer exerted a strong steric stabilization 
effect preventing aggregation of the particles. An important function of 
polymers (e. g. Poloxamer) is that they can form a substantial mechanical 
and thermodynamic barrier at the interface, which retards the approach and 
coalescence of individual emulsion droplets [7]. Non-ionic non-polymeric 
surfactants (e.g. Tween) offer an advantage over polymers in that they have 
a higher adsorption potential than an equal-chain-length polymer [18]. 
The use of a lower concentration of Poloxamer might be expected to 
lead to a large IBU particle size because it could well be less effective as 
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regards overcoming the cohesive forces. However, a decreased 
concentration of Poloxamer did not cause a particle size reduction: no 
significant change in average particle size occurred. 
 
Table IV 
Effects of additives on IBU particle size distribution 
Sample Type of additive Size 
  D 0.1 (µm) D 0.5 (µm) D 0.9 (µm) 
Sample 7 ------- 10.97±1.65 25.78±2.20 59.18±1.73 
Sample 10 0.5% PVP 5.82±0.08 12.56±0.11 24.55±1.09 
Sample 11 0.5% Tween 5.29±0.03 11.14±0.11 23.64±2.33 
Sample 12 0.5% Solutol 6.71±0.11 14.57±0.28 27.74±0.63 
Sample 13 0.5% Polox 5.13±0.23 11.09±0.03 21.47±0.62 
Sample 14 0.25% Polox 5.26±0.43 11.53±0.40 22.49±0.23 
 
 Table V lists the optimum experimental factors for the most efficient 
IBU particle size reduction. The batch containing 0.25% Poloxamer as 
stabilizer and sonicated with an amplitude of 70% for 20 min under ice 
cooling was dried in a static bed dryer at 50 °C in order to obtain a solid 
product. 
 
Table V 
Sample produced with optimized parameters using the most appropriate additive 
 Additive Amp/T 
(%)/(°) 
T (Susp) 
(°) 
Time 
(min) 
Conc. 
(mg/30 mL) 
Size 
D 0.5 (µm) 
Dried Sample 
14 
0.25% Polox. 70/ 18 35.5 20 300 11.5 
Characterization of dried product 
 
Particle size distribution and morphology 
The change in average particle size on drying was not significant as 
compared with the suspension of Sample 14: aggregation did not occur. The 
specific surface area of IBU increased 10-fold due to acoustic cavitation and 
was not altered after drying (Table VI). 
 
Table VI 
Specific surface and size distribution of pure IBU and two samples 
 Spec. surface 
(m²/g) 
D 0.1  
(µm) 
D 0.5 
(µm) 
D 0.9 
(µm) 
Raw IBU 0.062 48.50 153.73 319.36 
Sample 14 
(suspension) 
0.598 5.26 11.53 22.49 
Dried Sample 14 0.614 5.52 12.44 25.38 
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The SEM pictures (Figure 3) provided an indication of the 
morphology of the modified particles. The crystal habit of pure IBU 
changed significantly. The raw IBU consisted mainly of roundish crystals 
with a broad focal size distribution. The dried product comprised irregular-
shaped crystals with an average size of 10-15 µm. Poloxamer adsorbed 
strongly onto the surfaces of IBU particles via its poly(ethylene oxide) 
central block and formed a layer on the IBU surface after drying. The crystal 
lattice of IBU demonstrated defects and cracks, along which the crystals 
were disintegrated due to acoustic cavitation. These two factors accounted 
for the relatively rough surface. 
 
   A 
   B 
Figure 3 
SEM picture of raw IBU (A), and dried Sample 14 (B) 
 
Structure (DSC and XRPD) 
DSC was employed in order to investigate the crystallinity and the 
melting of IBU and Poloxamer in the pure forms and in the sonicated dried 
product. The DSC curve (Figure 4) of pure IBU revealed a sharp 
endothermic peak at 76.93oC, which is its melting point, confirming its 
crystalline structure. Poloxamer is a semi-crystalline additive (melting point: 
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55.84°C). The DSC curves exhibited sharp endothermic peaks of the two 
materials at 72.80°C (IBU) and 42.18°C (Poloxamer), indicating that the 
crystallinity of the drug was retained in the product. The IBU crystals in the 
product melted at a lower temperature than the melting point of pure IBU. 
This is due to the smaller particle size of IBU and the fact that the 
Poloxamer melted at a lower temperature, which promoted the melting of 
IBU. Both components melted at lower temperature in the product 
compared with melting point of pure materials. Several different materials 
alongside each other are present such as impurity of other components, 
which causes the melting of substances at lower melting points. 
 
Figure 4 
DSC curves of raw materials and of the product 
 
The XRPD pattern of pure IBU demonstrated its crystalline structure, 
as expected. The characteristic 2θ data: 6.50, 17.00 20.20 and 22.00. The 
XRPD pattern of pure Poloxamer exhibited peaks at 2θ values of 19.50 and 
22.00. The raw IBU and the sonicated dried IBU composite displayed 
similar X-ray diffraction patterns (Figure 5). This means that the crystalline 
form of the micronized IBU was not changed by the sonication and drying 
procedure.The differences in intensity of the IBU diffractogram peaks in the 
product as compared with raw IBU are due to the Poloxamer, a semi-
crystalline additive with a crystallization inhibitory effect besides its 
stabilizer effect. 
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Figure 5 
XRPD examination of IBU, Poloxamer and dried Sample 14 
 
Conclusions 
The top-down method can be applied to decrease the particle size and 
change the crystal habit, and in this way may it be useful for the formulation 
of original preparations and also to facilitate generic formulation. 
Our study has illustrated the important role of power ultrasound in 
drug formulation. Because of the small amount of the samples, this method 
is recommended in preformulation studies. Acoustic cavitation, a static 
disintegration method with optimized process parameters, involving a 
change in crystal habit, may decrease the IBU particle size to the 
micrometer range. For further particle size reduction, additives are needed. 
The most efficient combination proved to be sonication with an amplitude 
of 70% for 20 min under ice cooling, with Poloxamer 188 as a stabilizer, 
which resulted in an average particle size of approximately 11.5 µm. The 
specific surface area of IBU increased 10-fold compared to the initial 
particle size of pure drug due to the treatment. The crystallinity of the drug 
was retained in the product after the sonication and drying procedure. 
Wet grinding at a controlled temperature may be favourable in the 
grinding of materials with low melting points: the melting of the materials 
may be avoided. 
In the future, we plan to compare static sonication with dynamic 
sonication in a double-walled flow cell, which allows a continuous flow of 
the sample during sonication. 
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PharmacokineticsThe nasal pathway represents a non-invasive route for delivery of drugs to the systemic circulation. Nan-
onization of poorly soluble drugs offers a possibility to increase dissolution properties, epithelial perme-
ability or even bioavailability. The aim of the present study was to use in vitro methods to screen
formulations which were intended for nasal application, and to perform animal experiments for recogniz-
ing the differences in plasmakinetics of intranasal- and oral-administered meloxicam nanoparticles. Due
to nanonization the solubility of meloxicam elevated up to 1.2 mg/mL, additionally the extent of disso-
lution also increased, complete dissolution was observed in 15 min. Favorable in vitro diffusion proﬁle
of meloxicam nanoparticles was observed and their epithelial permeability through human RPMI 2650
cells was elevated. The pharmacokinetic parameters were signiﬁcantly increased when meloxicam was
administered as nanoparticles to rats either nasally (increase of Cmax 2.7-fold, AUC 1.5-fold) or orally
(increase of Cmax 2.4-fold, AUC 2-fold) as compared to physical mixture of the drug and the excipients.
 2013 Elsevier B.V. All rights reserved.1. Introduction
Alternative sites of drug administration for systemic delivery
and novel solutions of pharmaceutical technology offer numerous
opportunities for the development of innovative pharmaceutical
compositions (Mäder and Weidenauer, 2010). The nasal pathway
represents a non-invasive drug administration route (Illum,
2003), although the nasal epithelium forms a restricting barrier
(Wolburg et al., 2008). The tightness of the intercellular junctional
complex is low in the nasal mucosa, it is considered as a leaky epi-
thelial tissue, while brain capillaries and the skin epithelial cells
form very tight barriers (Deli, 2009).
During the formulation of a pharmaceutical dosage form in-
tended for intranasal application, several factors should be taken
into consideration (Ugwoke et al., 2005). The poor aqueous solubil-
ity of a drug and the low rate of dissolution can lead to insufﬁcient
absorption or delayed pharmacological effect. Indeed the nasally
administered pharmaceutical preparations will be cleared rapidly
from the nasal mucosa into the gastrointestinal tract by the muco-
ciliary clearance (Chien et al., 2008).Nanonization is a way to increase drug solubility (Müller et al.,
2011) and permeability through mucosal barriers (Morgen et al.,
2012). Two basic technologies are involved in the production of
nanoparticles, the integration techniques (controlled precipitation,
crystallization) and the disintegration methods (high pressure
homogenization, wet milling, co-grinding).
A possible approach to augment drug absorption is the applica-
tion of different types of polymers. Polymer additives of the grind-
ing process enhance the efﬁcacy of size reduction and particle
agglomeration can be prevented by steric stabilization (Rabinow,
2004). Mucoadhesive polymers increase residence time of the
pharmaceutical formulation on the nasal epithelium (Schiller
et al., 2011). Sodium hyaluronate, a naturally occurring anionic lin-
ear polysaccharide has an excellent mucoadhesive capacity and is
used in many bioadhesive drug delivery systems. In our previous
work sodium hyaluronate was selected as a component of an intra-
nasal formulation (Horvát et al., 2009). This study further con-
ﬁrmed that viscosity and mucoadhesion are key factors in nasal
drug delivery.
For successful formulation of a nasal delivery system, testing
with reliably established in vitro, cell culture, ex vivo tissue and
in vivo animal models are crucial. Vertical Franz cell diffusion mod-
el is a valid in vitro model for evaluating drug penetration (Siewert
et al., 2003). Basically, donor and acceptor compartments are
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(Östh et al., 2002; Schmidt et al., 1998). Several in vivomodels were
reported to deliver pharmacons via the nasal route (Chien et al.,
2008; Costantino et al., 2007). Although there are drawbacks of
the ex vivo tissue and in vivo animal models, including differences
between the species, specialities in many anatomical and physio-
logical features in various animal nasal cavities (Chien et al., 2008).
A cell culture model based on human RPMI 2650 cell line has
been mostly used for nasal metabolism studies and toxicity assays
but it can provide information on nasal permeability as well (Bai
et al., 2008; Wengst and Reichl, 2010; Kürti et al., 2013).
Undoubtedly animal experiments are unavoidable in preclinical
studies, but the number of animals can be reduced by the use of
proper in vitro screening techniques. Based on the in vitro results,
the most promising pharmaceutical formulations will further un-
dergo in vivo pharmacokinetic veriﬁcations in animals.
In an earlier study the preparation of meloxicam (MEL) nano-
particles was investigated, the inﬂuence of different parameters
on MEL particle size reduction was discussed and the optimization
of the co-grinding process was performed by using a three-level
full factorial design (Kürti et al., 2011).
The aim of the present study was to investigate MEL nanoparti-
cles, intended for nasal and oral drug delivery, by in vitro and
in vivo methods to verify their potential relevance helping to con-
sider their further use in therapy.2. Materials and methods
2.1. Preparation of meloxicam nanoparticles and the nasal
formulations
MEL was obtained from Egis Ltd. (Hungary). The grinding addi-
tive, polyvinylpyrrolidone C30 (PVP) was purchased from BASF
(Germany). Sodium hyaluronate (HA; Mw = 1400 kDa) was ob-
tained as a gift from Gedeon Richter Ltd. (Hungary).
MEL was co-ground with PVP in a planetary monomill (Fritsch
Pulverisette 6, Fritsch GmbH, Germany) in 1:1 drug–carrier ratio
(Kürti et al., 2011). All experiments were carried out with two
MEL formulations: (i) physical mixture of MEL and PVP and (ii)
co-ground product of MEL and PVP. The nasal formulations con-
tained MEL in 1 mg/mL concentration and HA in 5 mg/mL concen-
tration, the vehicle was phosphate buffer (PBS; pH 7.4) or cell
culture medium (pH 7.4). All samples were prepared freshly
1 day prior the in vitro and in vivo experiments.
2.2. Meloxicam thermodynamic solubility and extent of dissolution
The thermodynamic solubility of MEL was determined in PBS at
pH 7.4, 37 C, and the content of dissolved drug was measured
spectrophotometrically at 362 nm (Unicam UV/vis spectrophotom-
eter, Germany).
The extent of MEL dissolution was studied in 50 mL PBS at
pH 7.4, 37 C with Pharma test equipment (Germany) at a paddle
speed of 100 rpm. At predetermined time points, 1 mL samples
were withdrawn and immediately ﬁltered (cut-off 0.2 lm,Minisart
SRP 25, Sartorius, Germany) and the amount of dissolved drug was
determined spectrophotometrically. Withdrawn samples were re-
placed with 1 mL of fresh medium.
2.3. In vitro permeability of meloxicam
In vitro permeability studies were performed on a vertical
Franz-diffusion cell system (Microette Topical and Transdermal
Diffusion Cell System, Hanson Research, USA) containing six cells
(Makai et al., 2003; Csóka et al., 2005) in PBS at pH 7.4, 37 C.The donor phase contained MEL at 1 mg/mL and sodium hyaluro-
nate at 5 mg/mL concentration, which were placed on the syn-
thetic membrane impregnated with isopropyl myristate. The
effective diffusion surface was 1.8 cm2. PBS (pH 7.4, 37 C) was
used as an acceptor phase. The rotation of the stir-bar was set to
100 rpm. At predeﬁned time points, samples of 0.8 mL were taken
from the acceptor phase by the autosampler (Microette Autosam-
pling System, Hanson Research, USA) and were replaced with fresh
receiving medium. The diffused amount of MEL was determined
spectrophotometrically.2.4. Nasal epithelial toxicity and permeability of meloxicam
nanoparticles
MEL nanoparticles were tested on a cell culture model of the
nasal epithelium (Kürti et al., 2013), RPMI 2650 human nasal epi-
thelial cell line (ATCC, USA) was applied for toxicity and perme-
ability assays. Cells were grown in Eagle’s minimal essential
medium (Invitrogen, USA) supplemented with 10% foetal bovine
serum (Lonza, Switzerland). For all assays conﬂuent RPMI 2650
layers were used. Cell conﬂuency was checked by phase contrast
microscopy and measurement of transepithelial electrical resis-
tance. The resistance of RPMI 2650 layers varied between 50
and 100X cm2, in accordance with our previous data (Kürti
et al., 2012, 2013).
To study the effects and toxicity of MEL nanoparticles on the
human nasal epithelial cells a colorimetric viability assay was per-
formed. Living cells convert the yellow dye 3-(4,5-dimethyltiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) to purple, insoluble
formazan crystals. RPMI 2650 cells were cultured on sterile, colla-
gen-coated 96-well plates. After 1-h treatment the cells were incu-
bated with 0.5 mg/mL MTT solution for 3 h in CO2 incubator. The
amount of formazan crystals was dissolved in dimethyl-sulfoxide
and determined by measuring absorbance at 570 nm with a micro-
plate reader (Fluostar Optima, BMG Labtechnologies, Germany).
To measure the ﬂux of MEL across the cell layers, RPMI 2650
cells were seeded onto Transwell ﬁlter inserts (polycarbonate
membrane, 0.4 lm pore size, 1.1 cm2 surface area, Corning Costar
Co., USA) and grown for 2 days (Kürti et al., 2013). The inserts were
transferred to 12-well plates containing 1.5 mL Ringer–Hepes solu-
tion in the basolateral compartments. In apical chambers culture
medium was replaced by 500 lL formulations containing 1 mg/
mL MEL prepared in Ringer–Hepes buffer. The plates were kept
for 1 h in a 37 C incubator containing 5% CO2 on a rocking plat-
form. After incubation, the concentration of MEL was determined
spectrophotometrically from the basolateral compartments. The
ﬂux of the drug was calculated from the quantity of MEL, which
permeated through the RPMI 2650 cells, divided by the surface of
the ﬁlter insert and the duration of time.
Real-time cell microelectronic sensing (RT-CES) was used
(xCELLigence, Roche, Switzerland) to measure changes in the
impedance of individual microelectronic wells. Electric impedance
correlates linearly with cell index reﬂecting cell number, adher-
ence and cell growth (Solly et al., 2004; Kürti et al., 2012). The cells
were seeded into a special 96-well E-plate (Roche, Hungary), which
was coated with gelatine-PBS solution. Culture media was added to
each well for background readings, than cell suspension was dis-
pensed at the density of 6  103 cells per well. The cells were kept
in an incubator at 37 C for 24 h and monitored every 5 min. The
cell index at each time point was deﬁned as (Rn  Rb)/15, where
Rn is the cell-electrode impedance of the well when it contains cells
and Rb is the background impedance of the well with the medium
alone. After cells grew to conﬂuency and the cell index reached a
plateau level, nasal formulation containing MEL nanoparticles
and sodium hyaluronate was added to the wells. The control group
Table 1
Instrumental operating conditions for UHPLC-ESI-MS/MS.
RP-UHPLC
Column Kinetex C18 (100 mm  2.1 mm  2.6 lm)
Mobile phases (A): 20 mM ammonium-acetate
(B): methanol
0–1 min: 80% A–20% B
1.1–3 min: 0% A–100% B
3.1–6 min: 80% A–20% B
Flow rate 400 lL min1
Injection volume 15 lL
Column heating 40 C
ESI-MS/MS
CAD 4
CUR 25
GS1 40
GS2 50
IS 5500
TEM 400 C
MRM transitions Compound MRM (m/z) DP CE CXP
Meloxicam 352/115 81 25 8
Piroxicam 332/95 76 31 8
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treated with 10 mg/mL TritonX-100 detergent.2.5. In vivo pharmacokinetics of meloxicam nanopartices in rats
For nasal delivery, MEL was dispersed in PBS (pH 7.4) contain-
ing 5 mg/mL sodium hyaruronate to reach a ﬁnal concentration
of 1 mg/mL. A dose of 60 lg per animal was administered to the
right nostril of male Sprague–Dawley rats (n = 5) via a polyethyl-
ene tube by using a syringe. During drug administration the ani-
mals were narcotised by isoﬂurane. Blood samples were
withdrawn from the tail vein before and at 5, 15, 30, 60, 120,
360 and 1440 min post-dosing, respectively.
For oral delivery, the formulation, which was diluted 10 times
with PBS (pH 7.4) from that prepared for nasal delivery, was given
at a dose of 60 lg MEL per animal to male Sprague–Dawley rats
(n = 5) by gastric gavages. During drug administration the animals
were narcotised by isoﬂurane. Blood samples were withdrawn
from the tail vein before and at 5, 15, 30, 60, 120, 360 and
1440 min post-dosing, respectively.
The experiments performed conform to European Communities
‘‘Council directive for the care and use of laboratory animals’’ and
were approved by the Hungarian Ethical Committee for Animal Re-
search (permission number: IV/01758-0/2008).Fig. 1. (A) Thermodynamic solubility of meloxicam in case of the physical mixture (MEL/
(B) The extent of dissolution of meloxicam in case of the MEL/PVP and the nanoMEL/PVP
C30 mass ratio 1:1. Data are presented as mean ± S.D., n = 3. Statistically signiﬁcant diff2.6. Determination of meloxicam from biological samples
The blood samples were centrifuged (4000 rpm, 10 min) in CR
132 centrifuge (Jouan, France) to obtain blood plasma for further
analysis. The biological samples were stored at 20 C, protected
from light.
An LC–MS/MS system was applied to the analysis of MEL in bio-
logical samples. For sample introduction an Agilent 1260 chro-
matographic system with an HTS autosampler was used (Agilent
Technologies, Japan). A triple-quadrupole mass spectrometer (API
4000 MS/MS AB Sciex) equipped with a TurboV ion source in posi-
tive mode.
Multiple-reaction-monitoring (MRM) mode was used for quan-
tiﬁcation by monitoring the transitions: m/z 352? 115 for MEL
and m/z 332? 95 for piroxicam (internal standard).
Gradient chromatographic separation was performed on a Kine-
tex C18 column (100 mm  2.1 mm  2.6 lm) (Phenomenex, Tor-
rance, USA) using ammonium acetate and methanol as mobile
phases. Supplementary information is listed in Table 1. The meth-
od had a detection limit of 0.2 ng/mL. The calibration curve was
demonstrated to be linear over the concentration range of 1–
1000 ng/mL.2.7. Materials and reagents for analytical procedures
MEL (purity; 99.2%) and piroxicam (purity; 98.4%) were pur-
chased from Egis Ltd. (Hungary) and Sigma–Aldrich (USA). Ammo-
nium acetate, acetonitrile and methanol of analytical grade were
obtained from Merck KGaA (Germany).2.8. Sample preparation before analytical procedures
To a 50 lL of plasma sample, 100 lL acetonitrile containing pir-
oxicam (internal standard at 30 ng/mL concentration) was added
and the mixture was vortex-mixed for 30 s. Supernatant was ob-
tained by centrifugation of the mixture for 25 min at 16,100 g at
4 C. The resulted supernatant was injected into the LC–MS/MS
system for analysis.
Rat plasma calibration standards and quality control samples of
MEL were prepared by spiking the working standard solutions (2–
1000 ng/mL) into a pool of drug-free rat plasma and the procedure
described above was followed.PVP) and the co-ground product (nanoMEL/PVP) in phosphate buffer (pH 7.4, 37 C).
in phosphate buffer (pH 7.4, 37 C). MEL/PVP, meloxicam and polyvinylpyrrolidone
erences between groups are indicated as P < 0.05; P < 0.01 and P < 0.001.
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analysis
Pharmacokinetic parameters were analyzed by PK. Solver 2.0
software. In case of oral data the analysis was made with one com-
partment extravascular model, while the nasal data were analyzed
with non-compartmental extravascular model. The statistical anal-
ysis was performed with Prism 4.0 (Graphpad Software Inc., USA)
software through unpaired t-test.
All data presented are means ± S.D. The values were compared
using the analysis of variance followed by Dunnett tests using
GraphPad Prism 5.0 software. Changes were considered statisti-
cally signiﬁcant at P < 0.05.3. Results
3.1. Meloxicam thermodynamic solubility and extent of dissolution
Our earlier study described and characterized binary mixtures
of MEL and PVP-C30 which were co-ground for 2 h in a planetary
monomill. The optimum co-grinding parameter set was a MEL to
carrier ratio 1:1, and a rotation frequency of 400 rpm. The nanon-
ized MEL particles displayed an uniform size distribution and an
average particle size of 140.4 (±69.2) nm. Due to the co-grinding
process the crystallinity of MEL was decreased, the typical charac-
teristic peaks of MEL disappeared (Kürti et al., 2011).
In the present work amorphous MEL nanoparticles showed
favorable dissolution properties at 37 C, pH 7.4. In one hand the
thermodynamic solubility of MEL elevated up to 1.2 mg/mL
(Fig. 1A), on the other hand the extent of dissolution also increased,
complete dissolution of MEL was observed in 15 min (Fig. 1B). In
lower, acidic pH the thermodynamic solubility of MEL remained
poor in artiﬁcial gastric ﬂuid (37 C, pH 1.2), 3.6 lg/mL in the case
of MEL nanoparticles vs. 1.1 lg/mL in the case of MEL with PVP.3.2. In vitro permeability experiments through an artiﬁcial membrane
The cumulative amount of MEL that diffused through a syn-
thetic membrane from the different pharmaceutical formulations
was measured against time on a Franz cell diffusion system. The
diffusion from the formulation containing MEL nanoparticles and
sodium hyaluronate was quicker, 25% of MEL was diffused fromFig. 2. In vitro permeability of meloxicam through an artiﬁcial membrane in case of
the physical mixture (MEL/PVP) and the co-ground product (nanoMEL/PVP) in
phosphate buffer (pH 7.4, 37 C). MEL/PVP, meloxicam and polyvinylpyrrolidone
C30 mass ratio 1:1; HA, sodium hyaluronate (5 mg/mL). Data are presented as
mean ± S.D., n = 6.the formulation containing MEL in nanonized form vs. 10% in case
of the physical mixture after the ﬁrst 2 h (Fig.2).3.3. In vitro cell culture experiments on human RPMI 2650 cells
To test the biological effects of the MEL nanoparticles a cell cul-
ture model of the nasal barrier, human RPMI 2650 cells were used.
The effect of the pharmaceutical formulations, which contained
MEL in nanonized form or the pure drug, was studied by MTT cell
viability assay. The viability of human RPMI 2650 cells did notFig. 3. (A) MTT dye conversion cytotoxicity assay provides information from the
nasal epithelial cell viability after 1-h treatment with the physical mixture (MEL/
PVP) and the co-ground product (nanoMEL/PVP) as compared to vehicle-treated
cells (control). Data are presented as mean ± S.D., n = 8. (B) Flux of meloxicam in
case of MEL/PVP + HA and nanoMEL/PVP + HA across human RPMI 2650 nasal
epithelial cell layers. Data are presented as mean ± S.D., n = 3. C: Real-time cell
microelectronic sensing measurement of cell viability and integrity of human
RPMI 2650 nasal epithelial cells treated by vehicle and the nanoMEL/PVP + HA. Data
are presented as mean ± S.D., n = 4. MEL/PVP, meloxicam and polyvinylpyrrolidone
C30 mass ratio 1:1; HA, sodium hyaluronate (5 mg/mL); MTT, 3-(4,5-dim-
ethyltiazol-2-yl)-2,5- diphenyltetrazolium bromide; TX-100, TritonX-100 (10 mg/
mL). Statistically signiﬁcant differences between groups are indicated as P < 0.05;
P < 0.01 and P < 0.001.
Fig. 4. Plasma drug concentrations vs. time proﬁle in rats after nasal and oral administration of 60 lg meloxicam. MEL/PVP, meloxicam and polyvinylpyrrolidone C30 mass
ratio 1:1; HA, sodium hyaluronate (5 mg/mL). Data are presented as mean ± S.D., n = 5.
Table 2
Pharmacokinetic parameters after nasal and oral administration of 60 lg meloxicam in rats.
Per os
MEL/PVP + HA
(±S.D.)
Per os
nanoMEL/PVP + HA
(±S.D.)
Nasal
MEL/PVP + HA
(±S.D.)
Nasal
nanoMEL/PVP + HA
(±S.D.)
P
p.os
P
nas
P p.os/
nas
P nano p.os/nas
ka (1/min) 0.13 ± 0.12 0.12 ± 0.10 NA NA ns NA NA NA
ke (1/min) 5.3 (±2.0)  104 8.3 (±1.9)  104 5.6 (±3.6)  104 8.8 (±0.7)  104  ns ns ns
tmax (min) 110.6 (±140.8) 88.0 (±90.2) 312.0 (±107.3) 5.0 (±0.0) ns   ns
Cmax (lM) 2.15 (±0.32) 5.03 (±0.59) 2.92 (±0.96) 7.95 (±0.23)   ns 
AUC 0-t (lmol min/L) 2.287.0 (±466.7) 4.478.0 ± (412.1) 3,342.0 (±1,236.0) 4,838.0 (±384.4)   ns ns
AUMC (lmol min2/L) 1.42 (±1.65)  107 0.89 (±0.39)  107 3.24 (± 3.69)  107 7.17 (±1.32)  107 ns ns ns ns
MRT (min) 2.292 (±1.346) 1.277 (±293) 2.882 (±2.298) 1.064 (±98) ns ns ns ns
Statistically signiﬁcant differences between groups are indicated as P < 0.05; P < 0.01 and P < 0.001. Abbreviations: AUC, area under the curve; AUMC, area under the ﬁrst
moment curve; Cmax, the peak plasma concentration; ka, absorption rate constant; ke, elimination rate constant; MEL/PVP + HA, meloxicam and polyvinylpyrrolidone C30
mass ratio 1:1 with sodium hyaluronate (5 mg/mL); MRT, mean residence time; NA, not applicable; nanoMEL/PVP + HA, nanonized meloxicam and polyvinylpyrrolidone C30
mass ratio 1:1 with sodium hyaluronate (5 mg/mL); ns, not signiﬁcant; p.os, per os drug administration; S.D., standard deviation; tmax, time to reach Cmax.
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formulations in the applied concentrations as compared to the con-
trol group which was treated with culture medium used as the
vehicle of the formulations. These results indicate that nasal for-
mulations do not inﬂuence nasal epithelial cell viability (Fig. 3A).
The ﬂux of MEL through human RPMI 2650 cell layers was sig-
niﬁcantly increased in the case of the nasal formulation which con-
tained nanoparticles and sodium hyaluronate (Fig. 3B).
Impedance measured by RT-CES non-invasively quantiﬁes
adherens cell proliferation, viability and cell layer integrity. The
RT-CES results indicated no sign of disruption in the integrity of
the human RPMI 2650 cell layers, which could be observed in the
toxicity control group (Fig. 3C).
3.4. In vivo experiments on rats to study nasal and oral delivery of
meloxicam
Nasal and oral administration of MEL nanoparticles to Sprague–
Dawley rats led to completely different pharmacokinetic proﬁle of
MEL. During the ﬁrst 60 mins after intranasal and oral treatment
with 60 lg MEL/animal, the drug concentration in blood plasma
vs. time is shown in Fig. 4. The differences in maximum plasma
concentration (Cmax), time to reach the maximum plasma concen-
tration (tmax) and other important pharmacokinetic parameters
were summarized by the plasma concentration–time proﬁle
(Table 2).
In the case of nasal administration of MEL nanoparticles extre-
mely high, about 8 lM plasma level of MEL was observed in the
ﬁrst time point, after 5 min. The differences between the nasal
and oral drug administration route almost disappeared after
30 min, but the two formulations remained entirely different, the
average plasma level of MEL was 6 lM vs. 2 lM.The absorption coefﬁcients (ka), the tmax values were not signif-
icantly different in case of the oral administration route, nor the
mean residence time (MRT) of MEL, although the Cmax and AUC
were doubled in case of oral delivery of nanoparticles. Concerning
nasal administration of both the formulations, there was no statis-
tical difference in MRT but almost 5 lmol min/L AUC could be
reached with the nanonized drug. The AUC and Cmax were found
to be signiﬁcantly elevated when meloxicam was administered na-
sally to rats as drug nanoparticles compared to orally given phys-
ical mixture of the drug and the excipients (2-fold higher AUC, 4-
fold higher Cmax).
4. Discussion
MEL, a non-steroidal anti-inﬂammatory drug (NSAID) with
analgesic properties, is an enolic acid oxicam derivative (Hanft
et al., 2001; Fahmy, 2006). The aqueous thermodynamic solubility
of MEL is poor (4.4 lg/mL in water) and the rate of dissolution is
low (15% in 5 min). MEL has low molecular mass (351.4 kDa) and
relatively well-permeable. The poor dissolution property of the
drug is a limiting factor for its absorption rate and its onset of ac-
tion, although its bioavailability is 89% after dissolution (Del Tacca
et al., 2002; Ambrus et al., 2009). The usual recommended oral
dose is 7.5–15 mg/day; a dose as high as 30 mg/day may also be
applied (Euller-Ziegler et al., 2001). A parenteral formulation of
MEL (15 mg/1.5 mL) has been developed for situations requiring
rapid analgesia, such as acute mechanical lower back pain, sciatica
and acute ﬂares of osteoarthritis (Davies and Skjodt, 1999).
However the mean Cmax value was achieved within 4–5 h after
oral administration of MEL incorporated to a solid dosage form,
indicating elongated drug absorption (Busch et al., 1998). Accord-
ing to our results with MEL nanoparticles the Cmax was reached
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the case of the nasal formulation. However Illum et al. (2001)
and Wang et al. (2011) described that very short tmax values (15–
20 min) could be achieved by nasal administration of hydrophilic
and lipophilic active agents as well. Considerably the plasmakinet-
ics of MEL in the case of nasally applied drug nanoparticles was
similar to an intravenous injection, the Cmax was reached in the
ﬁrst time point (5 min).
The relationship between solubility and permeability was
investigated by other research groups (Frank et al., 2012a,b). Solu-
bility enhancement is not always accompanied by increase in per-
meability; it depends on the chosen method. Of all the strategies to
increase the apparent solubility of poorly soluble drugs, enhance-
ment of the molecularly dissolved drug concentration (induction
of true supersaturation) would lead to better permeation though
membranes as demonstrated by di Cagno and Luppi (2013).
Nanonization of MEL led to signiﬁcant increase in thermody-
namic solubility and subsequent permeability. Several factors
may contribute to the signiﬁcantly better dissolution properties
of MEL nanoparticles, namely (i) the particle size reduction, (ii)
the increase in speciﬁc surface area, (iii) the presence of hydro-
philic polymers, (iv) the amorphization of MEL and (v) the interac-
tion between the drug and the polymer additive. These differences
in the dissolution properties of MEL were more remarkable in case
of nasal conditions (pH 5.6; 30 C; Kürti et al., 2011), while the
thermodynamic solubility of MEL is pH-dependent (Seedher and
Bhatia, 2003).
NSAIDs, including MEL, can cause serious gastrointestinal ad-
verse events including inﬂammation, bleeding, ulceration, and per-
foration of the stomach, small intestine, or large intestine, which
can be fatal (Hanft et al., 2001). Therefore nasal pathway of drug
administration is preferable to reduce gastrointestinal side-effects
and to circumvent the ﬁrst-pass metabolism in the liver (Illum
et al., 2001).
Information on epithelial toxicity is crucial for pharmaceutical
use of nanoparticles. In vitro cell culture assays are useful tools
to investigate the toxicity of nanonized drugs. In comparison to
animal models, cell viability assays allow for a simpler, faster
and more cost-efﬁcient assessment of toxicity. Limitation of
in vitro test systems is the lack of the complexity of animal models
or the human body. Nanoparticles can interfere with conventional
end-point colorimetric in vitro toxicity assays (Kroll et al., 2009).
Therefore novel technologies such as marker-free, real-time assays
greatly help to reveal the interaction of nanoparticles with cells.
Furthermore the continuous monitoring of the biological status
of the cells can be integrated in conventional medium or high-
throughput plate formats (Ressler et al., 2004; Ózsvári et al., 2010).
By using a MTT test and a real-time assay we demonstrated for
the ﬁrst time that the liquid pharmaceutical formulation contain-
ing MEL nanoparticles and sodium hyaluronate is not toxic for hu-
man nasal epithelial cells. By comparing the results of RT-CES on
nasal epithelial cells with other data from the epithelial toxicity
of sucrose esters (Kürti et al., 2012), the lack of change in cell index
indicates that MEL nanoparticles are not toxic and do not inﬂuence
the paracellular pathway.
The in vitro permeability results on a synthetic membrane and
the cell-based assays suggest the potential usefulness of the phar-
maceutical formulation containing nanoMEL/PVP + HA for nasal
delivery. In animal experiments the MEL drug nanoparticles
administered nasally or orally to rats as compared to physical mix-
ture of the drug and the excipients showed better pharmacokinetic
parameters. In the case of drug nanoparticles administered either
by the nasal or oral route the individual differences in plasma drug
levels were smaller indicating a more uniform absorption.
Based on our results it can be concluded that the pharmacoki-
netic parameters were signiﬁcantly increased when MEL wasadministered as nanoparticles to rats either nasally or orally as
compared to physical mixture of the drug and the excipients. Drug
nanoparticles administered intranasally show a very quick and
high plasma peak. Further experiments are necessary to prove
the therapeutic relevance of this innovative pharmaceutical
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1. A kavitáció jelensége és csoportosítása
A kavitáció (1. ábra) fi zikai jelenség, amely akkor 
következik be, ha egy anyag folyadék fázisból hir-
telen gáz fázisba megy át a nyomás esése követ-
keztében. Ha a folyadék sebessége hirtelen megnő, 
akkor az energia-megmaradás törvénye értelmé-
ben (Bernoulli törvénye) a nyomása leesik. Ha a 
keletkező gőzbuborék, az áramlás mentén olyan 
helyre ér, ahol a nyomás nagyobb az ott ani hőmér-
séklethez tartozó telített  gőz nyomásnál, akkor a 
buborék hirtelen összeroskad, az egymásnak csat-
tanó folyadékfelületek erős akusztikus lökéshullá-
mot keltenek, ami egyrészt erős zajjal, rezgéssel, 
másrészt a környező szilárd testek eróziójával jár 
[1].
Summary
A m b r u s ,  R . ,  B a r t o s ,  C s . ,  S z a b ó - R é v é s z ,  P . : 
Optimization of technological parameters using acustic 
cavitation to reach particle size reduction of pharmacon
The main aspect in the fi eld of pharmaceutical technology is 
the preformulation of the poorly water soluble drugs. The habit 
of particles can eﬀ ect the physico-chemical properties which are 
important factors by drug administration. In the past years the 
role of the procedures by acustic cavitation increased in the fi eld 
of particle engineering. Application of high power ultrasound by 
integration and dezintegration can lead to particle size decreas-
ing. Meloxicam as a nonsteroid anti-infl ammatory model drug 
was used to study the eﬀ ect of power ultrasound on the particle 
size decreasing. During our work technological parameters, as 
amplitude, temperature, time, excipients and concentration were 
optimized based on particle size distribution. Physico-chemical 
stability tests were also performed (XRPD, DSC, SEM, particle 
size). With optimized parameters (70% amplitude, 20 min, 47 °C) 
using excipients, crystalline micronized product was produced.
Key-words: meloxicam, particle size decreasing, acustic cavita-
tion, optimization.
Összefoglaló
Napjainkban az egyik legnagyobb kihívást a gyógyszertechnoló-
gus számára a rossz vízoldékonyságú hatóanyagok preformulá-
lása jelenti. A szemcsék habitusa, morfológiai sajátságai nagy 
befolyással vannak a hatóanyagok fi zikai-kémiai sajátságaira, 
ezen kívül meg kell felelniük egyes formulálási és alkalmazási 
követelményeknek. Az utóbbi években a szemcseméret csökkentés 
területén az akusztikus kavitáción alapuló eljárások előretörése 
fi gyelhető meg. Aktív ultrahanggal integráláson vagy dezintegrá-
láson alapuló szemcseméret csökkentés érhető el.
Modellanyagként a meloxikámot, nem szteroid gyulladás-
csökkentőt választott uk a szónikus kavitáció szemcseméret csök-
kentésre gyakorolt hatásának tanulmányozása céljából. Vizs-
gálataink során technológiai paraméterek, mint amplitúdó, 
hőmérséklet, idő, segédanyag és koncentráció optimalizálását 
végeztük el. Az eljárási paraméterek optimalizálásánál a minták 
szemcseméret megoszlását vett ük alapul. Munkánk során fi zikai-
kémiai stabilitási vizsgálatokat (XRPD, DSC, SEM, szemcse-
méret) végeztünk. Optimalizált paraméterekkel (70% amplitúdó, 
20 perc, 47 °C) segédanyag jelenlétében kristályos, mikronizált 
terméket kaptunk.
Kulcsszavak: meloxikám, szemcseméret csökkentés, szónikus ka-
vitáció, optimalizálás.
1. ábra: A kavitáció jelensége és csoportosítása
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Tranziens kavitáció során a kavitációs üreg egy 
ciklus során megnövekszik, majd hevesen össze-
omlik. A folyamat során a molekulák szétt örede-
zése is megfi gyelhető, a vele szemben elhelyezke-
dő szilárd falat, így például sejteket, készüléket 
erőteljesen erodálja [2]. Stabil kavitáció akkor törté-
nik, ha a buborék számos cikluson keresztül osz-
cillál, a térből való távozás, vagyis felszínre ván-
dorlás, illetve összeomlás nélkül, és a depresszió 
alatt  mérete csökken, majd az ellenkező fázisban 
újra kitágul, mivel gőzt tartalmaz. Bizonyos ese-
tekben a depressziós akusztikai/mechanikai ciklus 
alatt  tágul, az ellenkező fázisban pedig zsugoro-
dik a buborék, amelynek erőteljes több ezer kelvi-
nes hőképződés lehet az eredménye. A stabil 
kavitációs buborék az oszcilláló akusztikai tér mi-
att  saját frekvenciával rendelkezik, illetve általá-
ban további felületi rezgések is kialakulhatnak raj-
ta, amelyek a buborék környezetében erőteljes tur-
bulenciákat indukálnak. Ezeket a turbulenciákat 
nevezzük mikroáramlásoknak, amelyekre nagy 
nyíróerő a jellemző [3].
Az ultrahang 16 kHz frekvencia felett i mechani-
kai hullámokat jelent. Az ultrahangot aktív és 
passzív tartományra oszthatjuk, vagyis megálla-
podás szerint az 1 W/cm2 vagyis a 10000 W/m2 tel-
jesítmény alatt  passzív, míg felett e aktív ultra-
hangról beszélünk. A passzív ultrahangot legin-
kább az anyagtulajdonságok vizsgálatára, míg az 
aktív ultrahangot az anyag tulajdonságainak meg-
változtatására alkalmazzuk. Tipikusan nemlineá-
ris jelenség az állandó folyadékmozgás, amit az 
intenzív ultrahang okoz. Ennek során a folyadék-
ban szemmel látható keveredés, turbulencia ta-
pasztalható. A keverés mellett  megvalósítható a 
diszpergálás is (pl. emulzió és szuszpenzió előállí-
tás). Az ultrahangot rezgéskeltőkkel állítjuk elő. 
Legelterjedtebbek az elektromechanikus átalakí-
tók. Az adszorpció miatt  az ultrahang intenzitása 
a távolsággal exponenciálisan csökken. A modern 
ultrahang-berendezések aktív elemei legtöbbször 
ólom cirkonát titanát (PZT) kerámiák [4-7].
Munkánk során célul tűztük ki a nagyintenzitá-
sú ultrahang alkalmazhatóságának tanulmányo-
zását a gyógyszerformulálás területén, továbbá kí-
sérletes eredményekkel mutatjuk be a szemcsemé-
ret csökkentésben betöltött  szerepét.
2. Aktív ultrahang a gyógyszerészet területén
A nagyintenzitású ultrahang alkalmazása a 
gyógyszertechnológiai preformulációban új irány-
vonalként jelent meg az utóbbi időben, ahol az 
akusztikus kavitáció szemcseméretre és morfoló-
giára gyakorolt hatását mind integráló, mind 
dezintegráló műveleteknél hasznosíthatjuk [8].
2.1. Emulgeálás és szuszpendálás ultrahanggal, szo-
nokémia
Az aktív ultrahang, emulzióképző berendezésben 
vagy szuszpenziók akusztikai ülepítésére alkal-
mas szeparáló készülékben és szonokémiai gene-
rátorban funkcionálhat a gyógyszerészet terüle-
tén. Az emulzióképzés elvi sémája alapján az ola-
jos és vizes fázis egymással szembe lép be a rend-
szerbe, majd a középvonalon, az addigi áramlás-
sal merőleges ultrahangsugárban képződik az 
emulzió. Több ultrahangos emulzió-előállító be-
rendezéssel szemben előnyt jelenthet, hogy az ult-
rahangsugár hosszabb távon érheti az anyagokat, 
így sokkal stabilabb emulziók készíthetőek [9]. To-
vábbi felhasználási lehetősége az ultrahangnak az 
emulziók és szuszpenziók ülepítésének gyorsítá-
sa. A technika lényege az, hogy speciálisan terve-
zett  akusztikai kamrában állóhullámot kialakítva 
történik meg az eltérő fi zikai tulajdonságú köze-
gek szétválasztása, a vivőközeghez képest sűrű-
ség, fajsúly, kompresszibilitásbeli különbség, alaki 
részecskejellemzők stb. alapján. Meghatározható, 
hogy milyen szemcsekoncentráció szükséges egy 
adott  intenzitás mellett , vagy milyen intenzitás 
szükséges egy adott  szemcsekoncentrációhoz az 
ultrahangtérben, hogy akusztikai állóhullám, 
vagy akusztikai kavitáció alakulhasson ki. 
Amennyiben a rendszerben állóhullám kerül ki-
alakításra, akkor a szeparáció és szedimentáció, 
amikor viszont kavitáció dominál a hangtérben, 
akkor a diszpergálás, az emulgeálás és a szusz-
pendálás valósítható meg az ultrahang segítségé-
vel [10]. A kémia speciális területe a szonokémia, 
melyben speciális reakciókat, új reakció utakat és 
reakciótermékeket nyerhetünk ultrahang hatásá-
ra, és az eljárásokat pedig szónikus reaktorokban 
folytatjuk. Az ultrahang fő kémiai szerepe a 
kavitációs buborékon kialakuló katalízis, vagyis a 
reakciók aktiválási energiájának csökkentése, 
szonoke mi káliák kialakítása, reakciók gyorsítása, 
reakciópartnerek diszpergálása, diﬀ úziós felület 
növelése és az enzimaktivitás szabályozása, 
preparatív termékek előállítása stb. [11]. 
2.2. Ultrahang alkalmazása a szemcsék habitusának 
változtatása céljából
Az ultrahangos homogenizálás egy mechanikai 
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folyamat, amely a részecskeméret csökkentésére, 
egyenletes méreteloszlás elérésére irányul, javítva 
ezáltal az egységességet és a stabilitást, növelve a 
részecskeszámot és a fajlagos felületet, csökkentve 
a részecskék között i átlagos távolságot. A részecs-
kék (diszpergált rész) lehetnek szilárd vagy folyé-
kony halmazállapotúak. További nagy előny, hogy 
a paraméterek (amplitúdó, pulzáció, idő, hőmér-
séklet) pontosan beállíthatók és ellenőrizhetők, az 
ultrahangos homogenizálás reprodukálható. Az 
ultrahangnak két fő része van, a szonotród és az 
áramlási cella, mindkett ő egyszerű geometriai fel-
építésű, nem rendelkeznek kicsi, rejtett  nyílások-
kal. Az ultrahangos homogenizálás egyik nagy 
előnye, hogy kevés a mozgó alkatrész, így megbíz-
hatóbb, kevésbé kopik és a tisztítási idő is rövidebb 
[12].
A méretcsökkentés, dezintegráció révén, a kavi-
táció eredménye. Az ultrahangos kavitáció nagy 
nyíróerőt generál, ami képes szétszakítani a ré-
szecske-aggregátumot, legyőzve a részecskék kö-
zött i vonzóerőket. Az ultrahangos kezelés által el-
érhető a részecskék homogén eloszlatása is. A ré-
szecskeméret akár 500 μm-ről 10 nm-re csökkent-
hető, ahol a nagy fajlagos felületű részecskék mé-
retének egységességét lehet elérni [13]. 
Az I. táblázat az ultrahang alkalmazásának le-
hetőségeit szemlélteti különböző hatóanyagok 
szemcseméret csökkentése céljából. 
3. Anyagok és eljárás
Felhasznált anyagok: meloxikám (MEL) – EGIS 
Gyógyszergyár (Budapest, Magyarország); Tween 
80 (Tween) – Hungaropharma (Budapest, Magyar-
ország); Poloxamer 188 (polox) (polietilén-polipro-
pilén glikol) – Fluka (Ljubljana, Szlovénia); Solutol 
HS 15 – BASF (Ludwigshafen, Németország); PVP 
K25 (PVP) (polivinilpirrolidon) – ISP Customer 
Service GmBH (Köln, Németország).
I. táblázat 
Az ultrahang szemcseméretre gyakorolt hatása
Anyagok Módszer Méret Eljárás jellemző paraméterei
Cefuroxim [14] Ultrahangos 
kristályosítás
80-130 nm 
(amorf)
Oldószer: aceton
Antiszolvens: izopropil-éter
T~5 °C; t = 1 perc
Kaolinit [15] Ultrahang 360 nm Diszpergálószer: ioncserélt víz
T: 20 °C; t = 20 h
20 kHz; 750 W
Glicin [16] Ultrahangos hűtéses 
kristályosítás
100 μm Diszpergálószer: ioncserélt víz
20 kHz
Dipiridamol [17] Szuperkritikus 
antiszolvens eljárás 
ultrahanggal 
kombinálva
300-600 nm Oldószer: metilén-klorid
T: 37 °C
Amplitúdó: 20-40%
Nitrendipin [18] Ultrahangos 
kristályosítás
209 nm Oldószer: PEG 200 + aceton (30 mg/ml 
nitrendipin konc.)
Antiszolvens: PVA + víz T: 3 °C alatt 
t= 15 perc; 400 W
Cellulóz [19] Hidrodinamikai 
kavitáció kombinálva 
ultrahanggal
301 nm (amorf 
és kristályos)
Diszpergálószer: ioncserélt víz
22 kHz
Nátrium-klorid [20] Szonokristályosítás 1,23 μm Diszpergálószer: ioncserélt víz
T: 5 °C alatt ; 20 kHz; 35 W
Ibuprofen [21] Olvadék-kristályosítás 13,01 μm Minta: ibuprofen olvadék + ionmentes víz
T: 25 °C; t = 2 perc; Amplitúdó: 80%
Meloxicam [22] Emulzió-diﬀ úzió 
módszer
165 nm Oldószer: benzil-alkohol + 3 perc ultrahang 
+ (Tween 80 + víz) + újabb 3perc ultrahang
Amplitúdó: 30%; 500 W
Gemfi brozil [23] Emulzió-diﬀ úzió 
módszer
2,89 μm Oldószer: etil-acetát, az oldat 0,5% PVP 
K-25 oldatba lett  csepegtetve
t = 7,5 perc; Amplitúdó: 30%
II. táblázat 
Szonikáció során változó paraméterek
Hőmérséklet (°C) szobahő, jeges hűtés
Amplitudó (%) 30, 50, 70
Idő (perc) 10, 20, 30
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Ultrahangos eljárás
Az eljárás során a mintákat (vizes szuszpenzió – 
300 mg hatóanyag / 30 ml víz) szobahőmérsékle-
ten (25 °C), illetve jeges hűtés (a mintát kezelés 
közben 18 °C-os jéggel hűtött  fürdőbe helyeztük) 
mellett  ultrahangoztuk (Hielscher 200 W 
Ultrasound system, Németország), az amplitúdót 
30 és 70% között  változtatt uk. A megjelölt paramé-
terekkel 10, 20, illetve 30 perces szonikációt végez-
tünk (II. táblázat).
4. Vizsgálati módszerek
4.1. Szemcseméret megoszlás, morfológia
A MEL szemcsék méretét és méreteloszlását Malvern 
Mastersizer 2000 készülékkel (Malvern Instru-
ments, Worcestershire, UK) határoztuk meg (Hydro 
2000 SM kis térfogatú diszpergáló egység). A ható-
anyag és szilárd minta morfológiai jellemzése pásztá-
zó elektronmikroszkóppal történt (Hitachi S4700, 
Hitachi Scientifi c Ltd., Japan). A minta töltődésének 
megakadályozása céljából arany-palládium bevonó 
anyagot használtunk 18 mA plazmaáram alkalma-
zásával. A felvételek 15 kV nagyfeszültség, 10 μA 
elektronáram és 0,1 Pa élővákuum beállításával ké-
szültek. A D 0,1, D 0,5, D 0,9 értékeket térfogat sze-
rinti méretanalízissel határoztuk meg. A D 0,1, D 
0,5, D 0,9 azok a méretek mikrométerben, amelyek-
nél a minta 10, 50 illetve 90%-a kisebb [24].
4.2. Szerkezeti jellemzők
A termékek termoanalitikai viselkedését Mett ler To-
ledo STAR® termoanalitikai készülékkel (Mett ler 
Inc., Schwerzenbach, Svájc) határoztuk meg. A 
DSC (diﬀ erenciál pásztázó kalorimetria) és TG 
(termogravimetria) méréseket argon gáz átáramolta-
tásával (10 l/óra) végeztük (2–5 mg-os minta, 25–
300 °C, 5 °C/perc fűtési sebesség).
A hatóanyag kristályos jellegét porröntgen 
diﬀ raktométerrel határoztuk meg (Minifl ex II 
Rigaku por-röntgen diﬀ raktométer, Rigaku Co. 
Tokyo, Japan). Mérési paraméterek: Cu (Kα = 
1,5405 Å), 30 kV, 15 mA.
5. Eredmények értékelése
5.1. Eljárási paraméterek és az összetétel optimalizálása
Munkánk során először az eljárás paramétereit 
vizsgáltuk, változtatva a hőmérsékletet, a szoni-
káció amplitúdóját, illetve az ultrahangozás idejét. 
Ezután segédanyagok alkalmazásával, a minta 
összetételét optimalizáltuk.
Az összetétel optimalizálásánál különböző sta-
bilizáló segédanyagokat használtunk, mint a PVP 
K-25 (kristályosodást gátló, stabilizáló szer), 
Poloxamer 188 (nemionos felületaktív anyag), 
Tween 80 (nemionos szolubilizáló szer), Solutol 
HS 15 (nemionos szolubilizáló szer), illetve tanul-
mányoztuk a ható- és segédanyagok koncentráció-
jának szemcseméretre gyakorolt hatását. A ható-
anyag koncentrációja 1 m/v %, a segédanyagé pe-
dig 0,5 illetve 0,25 m/v % volt. A III. táblázatban a 
MEL kiindulási méretmegoszlása látható, amelyre 
jellemző a heterodiszperzitás.
30%-os amplitúdóval 10 perces ultrahangozás 
után megállapított uk, hogy a szemcseméret a kiin-
dulásihoz képest a felére csökkent. 50%-os ampli-
túdó esetében a méret tovább csökkent, de az 
amplitúdó további növelése (70%) jelentős válto-
zást nem okozott , a D 0,5 érték körülbelül 26 μm 
maradt (2. ábra bal). A kezelés során a minta hő-
mérséklete kb. 85 °C-ra emelkedett , ami a ható-
anyag olvadáspontja (260 °C) alá esik, így az végig 
szilárd formában volt jelen.
Jéggel történő hűtéssel (Thűtővíz = 18 °C) és 30%-
os amplitudóval történő szonikációval ugyanazt a 
méretet értük el, amit szobahőmérsékleten az 50 
és 70%-os amplitúdóval sikerült megvalósítani (26 
μm). A minta kezelést követő hőmérséklete kb. 47 
°C volt, azaz felére csökkent a hűtés nélküli eljá-
ráshoz viszonyítva, ezzel segítve a kisebb méret 
elérését, mérsékelve a szemcsék között i kohézió 
nagyságát. A legjobb eredményt – mind a D 0,1, D 
0,5, D 0,9 értékek esetében – a 70%-os amplitúdó-
val történő kezelés biztosított a, a szemcsék átlago-
san 22 μm-esek lett ek (2. ábra jobb). 
A következőkben azt vizsgáltuk, hogy a kezelé-
si idő 20 illetve 30 percre növelése eredményez-e 
további szemcseméret csökkenést. 20 perces keze-
lést követően a méret 14 μm-re csökkenthető, a 30 
perces szonikáció azonban ezen jelentősen nem 
változtatott  (ábra nem látható).
Az eddigiek alapján tehát a következő eljárási 
paramétereket választott uk a további vizsgálatok-
hoz: jeges fürdőt (Thűtővíz = 18 °C), 70%-os amplitú-
dót és 20 perces kezelést. Az összetétel optimalizá-
lása céljából különböző segédanyagok hatását 
III. táblázat 
A MEL kiindulási D 0,1, D 0,5, D 0,9 értékei
D 0,1
(μm)
D 0,5
(μm)
D 0,9
(μm)
24,80 85,39 237,92
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vizsgáltuk a MEL szemcseméret megoszlására. A 
segédanyagokat, illetve azok koncentrációját ko-
rábbi tanulmányok alapján választott uk meg [14-
23]. Eredményeinket összevetve a segédanyag nél-
küli kísérletek eredményeivel (D 0,5: 14 μm), a leg-
kevésbé hatékonynak a Tween 80 bizonyult, ezt 
követt e a Poloxamer és a Solutol (IV. táblázat). A 
legkisebb szemcseméretet, átlagosan 5 μm-t PVP-
vel értük el. Ez az érték a PVP koncentrációjának 
csökkentésekor sem változott . Látható, hogy a 
PVP, mint stabilizáló és kristályosodást gátló 
anyag mindenképpen szükséges az összetételben. 
A PVP koncentráció csökkentésének jelentősége az 
esetleges toxicitási problémák megelőzésében rej-
lik, hiszen különböző beviteli kapuk (pulmonális, 
nazális) is előtérbe kerülhetnek a kis szemcsemé-
retű termék által, ahol az összetétel sejt toxicitásá-
ra is kiemelten fi gyelni kell. Tehát a vizsgált rend-
szerek közül a 0,25% PVP tartalmú MEL szemcse-
méret megoszlása bizonyult optimálisnak.
5.2. Szilárd fázisú termék jellemzése 
(SZ-MEL-UH)
Az előkísérletek alapján az eljárási paraméterek és 
összetételek optimalizálását követően a kapott 
szuszpenzióból (V. táblázat) 50 °C-on, nyugvó ré-
teges szárítóban távolított uk el a vizet (Memmert, 
Németország) abból a célból, hogy szilárd termé-
ket nyerjünk (SZ-MEL UH). A szárított  termék fi -
zikai-kémiai sajátságait az alábbiak szerint vizs-
gáltuk. Meg kívánjuk jegyezni, hogy a kezelt min-
ta hőmérséklete nem haladta meg a 46,2 °C-ot, te-
hát hő hatására bekövetkező bomlás nem történt.
DSC felvételek
A DSC görbén a MEL-nek 259,27 °C-on jól de-
fi niálható olvadáspontja van, amit bomlás követ. 
A PVP amorf sajátságú segédanyag, olva-
dásponttal nem rendelkezik (3. ábra). 
IV. táblázat 
Segédanyagok MEL szemcseméretére gyakorolt hatása
- 0,5% PVP 0,5% Tween 0,5% Polox. 0,5% Solutol 0,25% PVP
D 0,1 3,71 0,25 1,27 1,27 0,46 0,75
D 0,5 14,65 4,07 11,79 11,09 7,70 5,60
D 0,9 36,34 20,73 30,03 40,21 25,71 17,11
V. táblázat
Optimalizált paraméterekkel előállított  megfelelő összetételű minta
Szárítás
(°C)
Segédanyag Amp/T
(70%)/(°C)
T (Szuszp)
(°C)
Idő
(perc)
Konc.
(mg/30 ml)
Kiindulási 
méret 
D 0,5 (μm)
50 0,25% PVP Jeges fürdő, 18 46,20 20 300 5,60
2. ábra: MEL szemcseméret megoszlása hűtés nélkül (bal) és jegesfürdő (jobb) alkalmazásával
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A szilárd fázisú minta (SZ-MEL-UH) görbéjén 
is megfi gyelhető a hatóanyag kristályok olvadás-
pontja, amivel a MEL kezelés és szárítás utáni 
kristályos jellegét bizonyított uk. A mintában lát-
ható olvadáspont-csökkenés (244,10 °C) egyrészt 
annak köszönhető, hogy a kisebb kristályok meg-
olvadásához kevesebb energiára van szükség, 
másrészt pedig a PVP az üvegesedési hőmérsékle-
tén (Tg = 34 °C) meglágyul, ilyen körülmények 
közt a MEL olvadása alacsonyabb hőmérsékleten 
következik be. Referenciaként a termékkel azonos 
arányban fi zikai keveréket (MEL-PVP K25 FK) ké-
szített ünk, így összevetve a normalizált integrál 
értékeket az anyagok kristályossági indexét hatá-
roztuk meg. A fi zikai keverékben levő MEL kristá-
lyosságát 100%-nak véve a szilárd fázisú mintá-
ban jelen levő hatóanyag kristályossága kismér-
tékben csökkent (96%-ban kristályos frakciót de-
tektáltunk).
XRPD eredmények
A porröntgen-diﬀ rakciós vizsgálatok ugyancsak a 
minta kristályos jellegét bizonyítják, mert a karak-
terisztikus csúcsok a kiindulási anyagnál és a szi-
lárd fázisú termékben is megje-
lennek. A MEL-re jellemző csú-
csok 13,22, 15,06, 26,46 és 26,67 
2Θ értékeknél olvashatóak le 
(4. ábra). A PVP amorf sajátsá-
gát bizonyítja, hogy esetében a 
kristályos anyagra jellemző 
csúcsok nem jelennek meg a 
diﬀ raktogramon. Mivel a kiin-
dulási anyagok (MEL és PVP) 
és a termék (SZ-MEL UH) jel-
lemző csúcsai egybeesnek – 
azon kívül, hogy mintánk kris-
tályos maradt – az is megálla-
pítható, hogy polimorf módo-
sulat a kezelés hatására nem 
jött  létre.
3. ábra: A kiindulási anyagok és a termék DSC görbéi
4. ábra: A MEL, a PVP és a szilárd fázisú termék porröntgen felvételei
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Elektronmikroszkópos felvételek
Az elektronmikroszkópos képek alapján látható, 
hogy a kiindulási MEL kristályai nagy, hexagonális, 
sima felületű kristályok, míg a MEL-t, PVP-t tartal-
mazó ultrahanggal kezelt termék kristályai a kezelést 
követően szabálytalan alakúak, egyenetlen felszínű-
ek, a mérések alapján átlagosan 10 μm-esek (5. ábra). 
Szemcseméret megoszlás és specifi kus felület
A VI. táblázat összehasonlításban mutatja a kiin-
dulási MEL, a szuszpenzióban levő, már ultrahan-
gozott  (MEL UH) és az abból nyert szilárd fázisú 
termék (SZ-MEL UH) szemcseméret megoszlását 
és a részecskék specifi kus felületét. A szemcsemé-
retet egy nagyságrenddel csökkentett ük, ez jól lát-
ható a D 0,1, D 0,5 és D 0,9 értékek esetében is. A 
fajlagos felület vizes szuszpenzióban 21-szeresére 
növelhető. A MEL-nél szárítás hatására a stabili-
záló PVP alkalmazása mellett  is aggregáció követ-
kezett  be. A szilárd fázisú termék szemcsemérete 
ennek ellenére is kedvezőbb a kiindulási anyag-
hoz viszonyítva. Megállapítható, hogy a mikro-
szuszpenzió és a szilárd fázisú termék is alkalmas 
gyógyszerforma fejlesztéséhez.
6. Összegzés, jövőkép
Dolgozatunk összefoglalót adott  a kavitáció jelensé-
géről és csoportosításáról, az ultrahang fi zikai alap-
jairól és alkalmazásának lehetőségeiről a 
gyógyszerformulálás területén, elsősorban a kris-
tályméret megváltoztatása céljából. Munkánk so-
rán az eljárási paramétereket és az összetételt opti-
malizáltuk. Megállapított uk, hogy ultrahangozás-
sal a meloxikám kristályok mérete a mikrométer 
tartományba csökkenthető. A termékekben a ható-
anyag kristályosságát fi zikai-kémiai vizsgálatokkal 
bizonyított uk. Az eredmények azt igazolták, hogy 
a hatóanyag fi zikai-kémiai sajátsága, illetve az al-
kalmazott  segédanyagok befolyásolják mind a 
szemcseméret-csökkenést, mind a szárítás során az 
aggregáció mértékét. Az aggregáció gátlása céljából 
célszerűnek tartjuk hordozó segédanyag (pl. man-
nit) alkalmazását is. Terveink között  szerepel újabb 
modellanyagok vizsgálata, a kavitáció szemcsemé-
ret-csökkentő hatásának további tanulmányozása, 
paraméterek, összetételek optimalizálása. 
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